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	The	 neuronal	 ceroid	 lipofuscinoses	 (NCLs)	 are	 a	 group	 of	 up	 to	 14	 inherited	progressive	 neurodegenerative	 lysosomal	 storage	 disorders	 affecting	 children	and	 young	 adults.	 Together,	 they	 are	 the	 most	 common	 pediatric	neurodegenerative	storage	disorders.	Symptoms	include	loss	of	vision,	epileptic	seizures	 and	 the	 loss	 of	 cognitive	 and	motor	 function.	 A	 lack	 of	 any	 effective	therapies	means	that	all	forms	are	fatal.	CLN1	disease	or	Infantile	NCL	is	one	of	the	most	rapidly	progressing	forms	of	the	disease	and	is	caused	by	a	deficiency	of	 the	 lysosomal	 enzyme	 palmitoyl	 protein	 thioesterase	 –	 1	 (PPT1).	 Ppt1	deficient	 (Ppt1-/-)	 mice	 recapitulate	 features	 of	 the	 human	 disease	 and	 have	proved	to	be	a	useful	tool	in	characterizing	disease	progression	and	pathology	in	the	 brain.	 However,	 these	 pathological	 changes	 fail	 to	 fully	 explain	 the	sensorimotor	deficits	seen	in	this	mouse	model	as	well	as	in	human	CLN1	disease.	Along	with	the	limited	success	of	various	brain	directed	therapies,	this	led	us	to	analyze	 the	 spinal	 cord.	 Our	 analysis	 revealed	 unexpectedly	 profound	 and	rapidly	progressing	disease	pathology	in	the	spinal	cords	of	these	mice,	which	occurs	earlier	than	similar	events	in	the	brain.	This	included	regional	atrophy,	neuroinflammation,	and	significant	neuron	loss	at	all	levels	of	the	cord	as	well	as	novel	 phenotypes	 indicating	 a	 postnatal	 developmental	 delay	 and	 significant	white	 matter	 pathology.	 Automated	 gait	 analysis	 also	 showed	 novel	 early	phenotypes	in	these	mice	including	an	increased	dependence	on	the	forelimbs	for	locomotion.	Similar	spinal	cord	pathology	was	also	demonstrated	in	human	INCL	autopsy	samples	as	well	as	in	mouse	models	of	the	other	major	forms	of	NCL.	Targeting	the	spinal	cords	of	Ppt1-/-mice	with	enzyme	replacement	therapy	(ERT)	 and	 gene	 therapy	 significantly	 improved	 disease	 pathology,	 motor	function	 and	 lifespan	 in	 these	mice,	 demonstrating	 the	 clinical	 significance	 of	spinal	 cord	pathology	 in	 these	mice.	 Furthermore,	 combining	 intracranial	 and	intrathecal	 gene	 therapy	 showed	 a	 synergistic	 effect,	 showing	 the	 greatest	improvements	 for	 any	 CLN1	 disease	 therapy	 to	 date.	 Taken	 together,	 these	findings	highlight	the	spinal	cord	as	not	only	being	significantly	affected	in	CLN1	disease,	but	also	as	a	novel	and	effective	therapeutic	target.	
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The	neuronal	 ceroid	 lipofuscinoses	 (NCLs)	 are	 a	 group	of	 up	 to	 14	 lysosomal	storage	disorders	(LSDs)	that	mainly	affect	children	and	young	adults	(Bennett	&	Rakheja,	2013;	Mole	&	Cotman,	2015;	Santavuori,	1988).	Together,	 they	are	considered	 the	most	 common	 pediatric	 neurodegenerative	 storage	 disorders,	having	a	worldwide	incidence	of	approximately	1	in	100,000	live	births,	and	a	particularly	high	incidence	of	up	to	1	in	12,500	live	births	in	Scandinavia	(Goebel,	1995;	Haltia,	2006;	Jalanko	&	Braulke,	2009;	Schulz	et	al,	2013).	They	are	each	caused	by	monogenetic	recessive	mutations	in	their	respective	“CLN”	genes	that	impact	 the	 function	 of	 the	 endosomal-lysosomal	 system	 (Cotman	 et	 al,	 2013;	Mole	&	Cotman,	2015;	Schultz	et	al,	2011).			The	 NCLs	 are	 classified	 together	 based	 on	 shared	 clinical	 features	 including	visual	impairment	leading	to	blindness,	epileptic	seizures,	cognitive	impairment	and	 sensorimotor	 deficits	 (which	 is	 an	 umbrella	 term	 used	 here	 to	 describe	deficits	affecting	the	sensory	and	motor	systems)	(Dolisca	et	al,	2013;	Schulz	et	al,	2013;	Williams	et	al,	2006),	as	well	as	neuropathological	features	such	as	the	pathognomic	 accumulation	of	 autofluorescent	 storage	material,	 early	 glial	 cell	activation	and	the	progressive	and	widespread	loss	of	neurons	(Carcel-Trullols	et	al,	2015;	Cooper	et	al,	2015).	All	forms	of	NCLs	are	fatal	and	there	is	currently	no	effective	therapy	available	(Cotman	et	al,	2013;	Geraets	et	al,	2016).			Infantile	NCL	(INCL)	or	classic	CLN1	disease	is	one	of	the	most	severe	and	rapidly	progressing	forms	of	NCL	(Hawkins-Salsbury	et	al,	2013;	Santavuori	et	al,	1974).	It	is	caused	by	mutations	in	the	CLN1	gene	that	codes	for	the	lysosomal	enzyme	palmitoyl	protein	thioesterase-1	(PPT1)	(Vesa	et	al,	1995).	Children	affected	with	CLN1	disease	begin	to	show	symptoms	as	early	as	6-24	months	of	age	including	a	 rapid	 loss	 of	 motor	 function	 with	 hyperkinesias,	 loss	 of	 visual	 acuity	 and	cognitive	 abilities,	 and	a	 greatly	 reduced	 life	 expectancy	of	between	9	 and	13	years	(Dolisca	et	al,	2013;	Schulz	et	al,	2013;	Williams	et	al,	2006).	Ppt1	deficient	(Ppt1-/-)	mice	recapitulate	most	phenotypic	characteristics	of	the	human	disease	and	have	been	crucial	for	understanding	functional	deficits,	as	well	as	defining	the	pathology	present	in	the	forebrain	and	cerebellum	(Bible	et	al,	2004;	Griffey	et	al,	2006;	Gupta	et	al,	2001;	Kielar	et	al,	2007).	However,	these	findings	have	
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not	been	able	to	completely	explain	the	sensorimotor	deficits	seen	in	these	mice	(Dearborn	 et	 al,	 2015;	 Gupta	 et	 al,	 2001).	 Furthermore,	 various	 forebrain-directed	experimental	 therapies	have	only	met	with	 limited	success	 (Hu	et	al,	2012;	Macauley	 et	 al,	 2012;	Tamaki	 et	 al,	 2009;	Wei	 et	 al,	 2011).	While	most	studies	characterizing	the	pathology	in	CLN1	disease	focused	on	the	brain	and	cerebellum	(Bible	et	al,	2004;	Kielar	et	al,	2007;	Macauley	et	al,	2009),	 recent	studies	 have	 indicated	 the	 presence	 of	 pathology	 outside	 the	 central	 nervous	system	(Galvin	et	al,	2008),	and	the	original	study	of	human	pathology	in	INCL	briefly	mentioned	presence	of	pathology	in	the	spinal	cord	(Haltia	et	al,	1973a;	Santavuori	et	al,	1974).			The	 research	 presented	 in	 this	 thesis	 therefore	 aims	 to	 a)	 determine	 and	characterize	the	extent	and	nature	of	spinal	cord	pathology	in	murine	and	human	INCL,	b)	relate	abnormalities	 in	the	gait	of	Ppt1	deficient	(Ppt1-/-)	mice	to	this	pathology,	and	c)	whether	pathology	in	this	region	of	the	central	nervous	system	(CNS)	can	be	alleviated	with	experimental	therapies	targeted	to	the	spinal	cord.		
1.1	The	lysosome:	structure	and	function	
a)	Structure	The	lysosome	is	a	cellular	organelle	first	described	by	de	Duve	and	colleagues	in	1955	(Appelmans	&	De	Duve,	1955;	De	Duve	et	al,	1955).	They	are	bound	by	a	lipid	 bilayer	membrane	 and	 contain	 over	 60	 hydrolytic	 enzymes	 in	 an	 acidic	lumen	(pH	4.5-5.0).	The	lysosomal	membrane	contains	various	proteins	that	are	involved	with	transporting	molecules	across	this	membrane,	regulating	the	pH	of	 its	 lumen	and	 the	 fusion	of	 the	 lysosome	with	other	cellular	compartments	(Novikoff	 et	 al,	 1973;	 Parkinson-Lawrence	 et	 al,	 2010;	 Saftig	 &	 Klumperman,	2009;	Xu	&	Ren,	2015).			The	lysosome	is	formed	by	the	fusion	of	clathrin-coated	transport	vesicles	from	the	 trans-Golgi	 network	 (TGN)	 with	 late	 endosomes	 that	 form	 as	 a	 result	 of	endocytosis	(Luzio	et	al,	2007;	Luzio	et	al,	2000;	Saftig	&	Klumperman,	2009).	Many	different	soluble	hydrolase	enzymes	are	contained	in	the	lysosomal	lumen	including	 peptidases,	 sulphatases,	 glycosidases,	 phosphateses,	 nucleases	 and	
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lipases	that	help	to	degrade	a	wide	range	of	substrates	(Braulke	&	Bonifacino,	2009).	 After	 protein	 synthesis,	 hydrolases	 destined	 for	 the	 lysosome	undergo	post-translational	 modifications	 including	 being	 tagged	 with	 mannose	oligosaccharide	side	chains	and	linked	with	mannose-6-phosphate	residues	(M-6-P)	in	the	rough	endoplasmic	reticulum	(RER)	(Helenius	&	Aebi,	2001;	Kornfeld,	1992),	 as	 part	 of	 a	 highly	 regulated	 process.	 These	 hydrolases	 are	 then	transported	to	 the	Golgi	apparatus,	where	 they	are	recognized	by	mannose-6-phosphate/	 insulin-like	 growth	 factor	 II	 receptors	 (M6P/IGF	 IIr)	 or	 other	pathways,	 and	 this	 enzyme-receptor	 complex	 is	 coated	 with	 clathrin	 to	 be	transported	 across	 the	 TGN	 to	 the	 pre-lysosomal	 compartment	 or	 to	 the	endosome	(Braulke	&	Bonifacino,	2009;	Ghosh	et	al,	2003;	Saraste	&	Kuismanen,	1992).	 Fusion	with	 the	 late	 endosome	 results	 in	 lowering	 of	 the	 luminal	 pH,	which	in	turn	causes	the	enzymes	to	dissociate	from	the	M6P	receptors,	which	are	recycled	to	the	Golgi	apparatus	(Luzio	et	al,	2007;	Seaman,	2004).	Lysosomal	membrane	proteins	arrive	at	 the	endosome	 independent	of	 the	M6P	pathway,	either	directly	after	protein	synthesis	or	indirectly	after	being	transported	to	the	plasma	 membrane	 and	 being	 internalized	 during	 the	 formation	 of	 early	endosomes	(Braulke	&	Bonifacino,	2009;	Kornfeld	&	Mellman,	1989;	Luzio	et	al,	2000).			Molecules	 to	 be	 degraded	 in	 the	 lysosome	may	 reach	 the	 lysosome	 from	 the	extracellular	 or	 intracellular	 space	 (Zhang	 et	 al,	 2009).	 Molecules	 in	 the	extracellular	 space	 may	 be	 internalized	 by	 means	 of	 receptor-mediated	endocytosis	 (Doherty	 &	 McMahon,	 2009;	 Goldstein	 et	 al,	 1985)	 or	 by	phagocytosis	(Flannagan	et	al,	2012).	Intracellular	molecules	reach	the	lysosome	either	 as	 a	 result	 of	 autophagy,	 resulting	 in	 a	 double	 membrane	 bound	autophagosome	 (Levine	 &	 Klionsky,	 2004;	 Stromhaug	 &	 Klionsky,	 2001),	 or	directly	from	the	endoplasmic	reticulum	(Braakman	&	Bulleid,	2011).			
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b)	Function	The	 lysosome	 was	 initially	 thought	 to	 be	 solely	 concerned	 with	 the	 waste	disposal	 and	 recycling	 of	 endogenous	 and	 internalized	molecules	 (Kornfeld	&	Mellman,	1989).	This	role	as	being	the	terminal	degradative	compartment	in	a	cell	has	been	described	 in	great	detail	 (Boya,	2012;	Luzio	et	al,	2007;	Saftig	&	Klumperman,	 2009;	 Xu	 &	 Ren,	 2015).	 However,	 further	 studies	 of	 lysosomal	function	over	the	last	60	years	have	also	revealed	it	to	have	other	crucial	roles	to	play	 in	 cellular	homeostasis	and	repair,	 recycling	of	 cell	membrane	 receptors,	cholesterol	 homeostasis,	 antigen	 presentation,	 cell	 signaling,	 inactivation	 of	pathogens	and	mediating	cell	death	(Boya,	2012;	Saftig	&	Klumperman,	2009).			In	 the	 nervous	 system,	 lysosomes	 have	 been	 shown	 to	 be	 critical	 to	 the	development	 of	 neurons	 by	 regulating	 axon	 and	 dendrite	 growth,	 neurite	arborization	and	axon	pruning	(Sann	et	al,	2009;	Song	et	al,	2008).	They	also	help	regulate	synaptic	endocytosis	and	are	essential	for	normal	neuronal	functioning	and	cell	signaling	(Lasiecka	&	Winckler,	2011;	Murthy	&	Stevens,	1998;	Nixon	&	Cataldo,	 1995),	 as	 well	 as	 being	 involved	 in	 regulating	 neuronal	 cell	 death	(Terman	et	al,	2010;	Yamashima	&	Oikawa,	2009).			The	 complexity	of	 lysosomal	 cellular	 functions	as	well	 as	 the	highly	polarized	nature	 of	 neurons	 means	 that	 lysosomal	 dysfunction	 has	 a	 major	 impact	 on	neuronal	function	(Wong	&	Cuervo,	2010;	Zhang	et	al,	2009).	
1.2	Lysosomal	storage	disorders	(LSDs)	Following	the	discovery	of	the	lysosome	(Appelmans	&	De	Duve,	1955;	De	Duve	et	al,	1955),	Hers	and	colleagues	properly	developed	the	concept	of	 lysosomal	storage	diseases	with	the	identification	of	Pompe	disease	(Hers,	1965),	despite	the	 fact	 that	 many	 similar	 disorders	 had	 been	 described	 even	 before	 the	discovery	of	the	lysosome	itself	(Klein	&	Futerman,	2013).			LSDs	 are	 a	 group	 of	 around	 at	 least	 50	 heterogeneous	 diseases	 caused	 by	mutations	in	genes	that	code	either	for	lysosomal	proteins	or	proteins	involved	in	lysosomal	biogenesis	that	lead	to	reduced	or	nonexistent	functioning	of	these	
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proteins,	 and	 the	 characteristic	 accumulation	 of	 undegraded	 storage	material	(Ballabio	&	Gieselmann,	2009;	Cox	&	Cachon-Gonzalez,	2012;	Futerman	&	van	Meer,	2004;	Vitner	et	al,	2010;	Walkley,	2009).	LSDs	have	a	combined	incidence	of	 approximately	 1:5000-1:7000	 live	 births	 worldwide	 (Fuller	 et	 al,	 2006;	Kingma	et	al,	2015;	Klein	&	Futerman,	2013)	and	are	most	commonly	autosomal	recessively	inherited	(Winchester	et	al,	2000)	with	the	exception	of	Fabry	disease	(Desnick	et	al,	1989)	and	Hunter	syndrome	(Mucopolysaccharidosis	(MPS)	type	II)	(Hopwood	et	al,	1993),	which	are	X-linked,	as	well	as	the	inherited	adult	form	of	NCL	(CLN4),	which	shows	an	autosomal	dominant	inheritance	(Nijssen	et	al,	2003;	Noskova	et	al,	2011).			While	 most	 LSDs	 present	 clinically	 as	 diseases	 of	 childhood	 (Wraith,	 2002;	Wraith,	2004),	there	are	some	that	have	a	later	age	of	onset	(Nijssen	et	al,	2003;	Nixon	et	al,	2008;	Shapiro	et	al,	2008;	Spada	et	al,	2006).	Typically,	children	are	born	 healthy,	 with	 the	 exception	 of	 those	 diseases	 with	 storage	 material	deposition	 in	 the	 bone	 and	 cartilage	 (e.g.	 Mucopolysaccharidosis)	 (Klein	 &	Futerman,	 2013;	 Platt	 et	 al,	 2012;	 Wraith,	 2004).	 After	 initially	 meeting	developmental	 milestones,	 there	 is	 a	 period	 of	 decelerated	 development	 or	decline	(Beck,	2001;	Wenger	et	al,	2003;	Wraith,	2004).	While	some	LSDs	affect	non-neuronal	tissues,	such	as	macrophages	in	Type	1	Gaucher	disease	(Hollak	et	al,	1997;	van	Breemen	et	al,	2007),	the	vast	majority	of	LSDs	present	with	CNS	pathology	(Ballabio	&	Gieselmann,	2009;	Wraith,	2004).	This	neuropathology	is	typified	by	specific	temporal	and	spatial	patterns	of	glial	activation	and	neuron	loss,	and	the	accumulation	of	large	amounts	of	storage	material	within	different	cell	 types,	 although	 the	 links	 between	 these	 events	 is	 unclear	 and	 may	 vary	between	LSDs	(Platt	et	al,	2012;	Vitner	et	al,	2010).	Glial	cell	activation,	which	is	a	common	feature	in	LSDs,	may	potentially	have	a	negative	impact	upon	neuronal	function	and	therefore	contribute	 to	disease	progression	(Chen	et	al,	2007;	Di	Malta	et	al,	2012;	Ohmi	et	al,	2003;	Pressey	et	al,	2012;	Vitner	et	al,	2012).		While	the	primary	defects	in	LSDs	may	originate	in	the	proteins	of	the	lysosomal-endosomal	system	resulting	 in	 lysosomal	dysfunction	and	the	accumulation	of	undegraded	metabolites,	these	alone	do	not	necessarily	lead	to	cell	death	(Klein	
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&	 Futerman,	 2013;	 Vitner	 et	 al,	 2010;	Winchester	 et	 al,	 2000).	 Various	 other	cellular	pathogenic	mechanisms	have	been	shown	to	occur	in	most	LSDs,	such	as	altered	 calcium	homeostasis,	 oxidative	 stress,	 ER	 stress,	 increased	 autophagy,	autoimmune	 responses	 and	 inflammation	 that	 affect	other	 cell	 organelles	 and	therefore	exert	a	greater	deleterious	effect	upon	cell	function	(Platt	et	al,	2012;	Vitner	 et	 al,	 2010).	 Therefore,	 despite	 differing	 in	 the	 primary	 genetic	 defect,	LSDs	show	some	degree	of	overlap	in	their	pathological	 features,	although	the	nature	 and	 timing	 of	 these	 events	may	 differ	markedly.	 This	 has	 therapeutic	implications,	 as	 therapies	 that	 target	 shared	 pathological	 mechanisms	 can	theoretically	be	effective	in	multiple	LSDs	(Vitner	et	al,	2010;	Walkley,	2009),	but	this	 is	 likely	 limited	 to	 the	 downstream	 pathological	 cascade	 rather	 than	 the	primary	genetic	defect.		These	 potentially	 common	 pathogenic	 cascades	 may	 not	 only	 link	 lysosomal	dysfunction	and	its	cellular	sequelae	to	LSDs,	but	also	to	the	development	and/or	progression	 of	 various	 neurodegenerative	 disorders	 in	 which	 protein	aggregation	due	to	impaired	autophagy	is	observed,	such	as	Alzheimer	disease	(AD),	 Parkinson	 disease	 (PD),	 Huntington	 disease	 (HD),	 fronto-temporal	dementia	 (FTD)	 and	 amyotrophic	 lateral	 sclerosis	 (ALS)	 (Filimonenko	 et	 al,	2007;	Garcia-Arencibia	et	al,	2010;	Lee	et	al,	2007;	Nixon	&	Cataldo,	2006;	Nixon	&	 Yang,	 2011;	 Otomo	 et	 al,	 2012;	 Pan	 et	 al,	 2008;	 Wong	 &	 Cuervo,	 2010).	Therefore,	 despite	 different	 primary	 genetic	 causes,	 these	 more	 common	neurodegenerative	diseases	may	also	share	some	common	pathogenic	pathways	with	LSDs	that	are	downstream	of	 the	primary	defect,	and	therefore	may	also	potentially	be	amenable	to	some	therapies	targeting	these	downstream	effects.	
1.3	Neuronal	ceroid	lipofuscinoses	(NCLs)	or	Batten	disease.	
a)	History	and	classification	The	NCLs	are	a	group	of	up	 to	14	genetically	and	pathologically	distinct	LSDs	(Bennett	&	Rakheja,	2013;	Kohlschutter	&	Schulz,	2009;	Kollmann	et	al,	2013;	Mole	 &	 Cotman,	 2015).	 Together,	 they	 are	 the	 most	 common	 inherited	neurodegenerative	storage	disorders	of	childhood	(Goebel,	1995;	Haltia,	2006;	Schulz	et	al,	2013).		
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	While	first	described	by	Dr.	Otto	Stengel	in	a	small	Norwegian	mining	community	in	 1826	 (Brean,	 2004),	 this	 group	 of	 diseases	 was	 initially	 named	 after	 Dr.	Frederick	Batten	who	reported	cases	of	Juvenile	NCL	in	England	in	the	early	20th	century	(Batten,	1903;	Batten	&	Mayou,	1915;	Zeman	&	Dyken,	1969).	The	NCLs	were	 initially	 classified	 along	 with	 another	 LSD,	 Tay-Sachs	 disease	 (GM2-gangliosidosis	Type	A)	as	 “amaurotic	 familial	 idiocies”	due	 to	having	a	similar	clinical	 presentation	 of	 marked	 familial	 incidence,	 blindness	 and	 progressive	mental	 deterioration	 (Haltia	 &	 Goebel,	 2013).	 However,	 with	 time	 it	 became	evident	from	the	varying	age	of	onset	and	differing	biochemical	properties	that	these	 diseases	were	 a	 distinct	 group	 of	 LSDs,	 and	were	 named	 the	 “neuronal	ceroid	lipofuscinoses”	for	the	dense	storage	material	that	resembled	ceroid	and	lipofuscin	 that	accumulated	within	most	 cells	 in	 the	body	 (Seehafer	&	Pearce,	2006;	Zeman	&	Donahue,	1963;	Zeman	&	Dyken,	1969).		These	NCLs	were	initially	classified	based	on	their	age	of	onset:	infantile	(Haltia-Santavuori	 disease),	 late	 infantile	 (Jansky-Bielschowsky	 disease),	 juvenile	(Batten-Spielmeyer-Vogt	 disease),	 and	 adult	 (Kufs	 disease)	 (Getty	 &	 Pearce,	2011;	 Siintola	 et	 al,	 2006).	With	 the	 addition	 of	 congenital	 NCLs	 (Norman	 &	Wood,	1941;	Sandbank,	1968),	as	well	as	many	atypical	or	variant	forms	of	NCL,	this	classification	was	seen	to	be	insufficient	(Mole	et	al,	2011).	With	advances	in	molecular	genetics,	the	primary	genetic	defects	of	the	different	forms	of	NCL	have	been	identified,	allowing	for	the	NCLs	to	be	classified	based	on	their	affected	CLN	gene	and	age	of	onset	of	the	disease	(Kollmann	et	al,	2013;	Mole	&	Cotman,	2015;	Williams	&	Mole,	2012)	(Table	1.1).	The	NCLs	can	also	be	broadly	divided	based	on	the	gene	product	into	two	categories	–	those	that	code	for	lysosomal	enzymes	(e.g.	CLN1,	CLN2,	CLN10	etc.)	and	those	that	code	for	transmembrane	proteins	(e.g.	 CLN3,	 CLN6,	 CLN7,	 CLN8	 etc.)	 (Kollmann	 et	 al,	 2013).	 This	 is	 useful	 to	determine	which	therapeutic	approach	may	theoretically	be	applicable	in	each	form	of	NCL.	(Cooper	et	al,	2015)				
		 27	
Name Age of onset Gene affected Type of protein 
CLN1 Infantile NCL 
(INCL) 
CLN1/PPT1 Lysosomal hydrolase (Palmitoyl 
thioesterase) 
CLN2 Late Infantile 
NCL (LINCL) 
CLN2/TPP1 Lysosomal hydrolase (Serine 
Protease) 
CLN3 Juvenile NCL 
(JNCL) 
CLN3 Transmembrane lysosomal protein 
(modulation of vesicular trafficking and 
fusion) 




CLN4/DNAJC5 Cytoplasmic protein in cellular 
membranes (Hsc70 co-chaperone, 
involved in exocytosis and 
endocytosis) 
CLN5 Variant LINCL  
(vLINCL) 
CLN5 Soluble lysosomal protein 
CLN6 vLINCL or Adult 
Kufs type A 
CLN6 Transmembrane endoplasmic 
reticulum protein 




CLN8 Transmembrane endoplasmic 
reticulum protein 
CLN9 Juvenile NCL 
(Postulated) 
Not known Not known 
CLN10 Congenital NCL 
(CNCL) 
CLN10/CTSD Lysosomal hydrolase (aspartyl 
endopeptidase) 
CLN11 ANCL CLN11/GRN Unknown, resides in secretory 
pathway (roles in inflammation, 





CLN12/ATP13A2 Lysosomal transmembrane protein 
CLN13 Adult NCL (Kufs 
type B) 
CLN13/CTSF Lysosomal Hydrolase (Cysteine 
protease) 
CLN14 vINCL CLN14/KCTD7 Cytosolic protein, partially associated 
with membranes 
 
Table 1.1 – Classification of the neuronal ceroid lipofuscinoses (NCLs). 
Table describing the name, age of onset, gene defect and protein products of the 14 forms of 
NCL that have so far been identified. Adapted from (Kollmann et al, 2013; Mole & Cotman, 
2015; Williams & Mole, 2012) 		Despite	 the	 heterogeneity	 of	 genetic	 causes,	most	 forms	 of	 NCL	 present	with	common	 clinical	 symptoms	 of	 progressive	 visual	 loss	 due	 to	 retinopathy,	seizures	 of	 increasing	 severity	 and	 progressive	 decline	 of	 cognitive	 and	sensorimotor	function,	which	invariably	lead	to	premature	death	(Dolisca	et	al,	2013;	Williams	et	al,	2006;	Wisniewski	et	al,	2001).	
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b)	Pathology	in	the	NCLs	The	 hallmark	 of	 NCL	 pathology	 is	 the	 pathognomic	 accumulation	 of	autofluorescent	 lipopigment	 storage	 material	 inside	 cells	 (Zeman	 &	 Dyken,	1969),	which	was	shown	to	contain	subunit-C	of	mitochondrial	ATP	synthase,	Saposins	A	and	D,	as	well	as	β4	amyloid	and	Amyloid	Precursor	Protein	(APP)	in	varying	degrees	depending	on	the	type	of	NCL	(Palmer	et	al,	2002;	Wisniewski	et	al,	1993;	Wisniewski	et	al,	1990;	Zeman	&	Donahue,	1963).	 	However,	there	is	little	 evidence	 to	 suggest	 that	 this	 autofluorescent	 storage	 material	 is	 itself	pathogenic,	 as	 there	 is	 no	 direct	 correlation	 between	 its	 accumulation	 and	neuron	 loss	 (Cooper	 et	 al.,	 2006).	 This	 is	 evidenced	 by	 the	 fact	 that	 the	acummulation	 of	 storage	 material	 in	 the	 CNS	 is	 widespread,	 while	 other	pathological	markers	such	as	glial	activation	and	neuron	loss	correlate	with	one	another	and	show	far	greater	regional	specificity	(Cooper,	2010;	Weimer	et	al,	2002),	also	significantly	reducing	storage	burden	 in	 the	CNS	does	not	prevent	significant	neuronal	 loss	(Griffey	et	al,	2006)	and	inducing	neuronal	cells	with	storage	material	did	not	show	any	effect	on	cell	survival	(Ivy	et	al,	1984).		Apart	from	the	accumulation	of	autofluorescent	storage	material	in	cell,	the	NCLs	are	also	characterized	by	synaptic	pathology	(Cooper,	2010;	Cooper	et	al,	2015;	Kielar	 et	 al,	 2009;	 Partanen	 et	 al,	 2008),	 and	widespread	 neurodegeneration,	with	GABAergic	 interneurons,	 thalamic	 relay	 neurons	 and	 cerebellar	 Purkinje	cells	being	shown	to	be	more	vulnerable	(Cooper,	2010;	Cooper	et	al,	2006;	Kielar	et	al,	2007;	Oswald	et	al,	2005;	Pontikis	et	al,	2004;	Pontikis	et	al,	2005;	Sleat	et	al,	2004;	von	Schantz	et	al,	2009).	Even	the	loss	of	interneurons	is	graded,	with	calretinin	positive	interneurons	more	resistant	to	pathological	change	than	other	interneuron	populations	(Bible	et	al,	2004;	Mitchison	et	al,	2004).		This	 neuron	 loss	 also	 shows	pronounced	 regional	 specificity.	 Severe	 cerebral	and	 cerebellar	 atrophy	 was	 observed	 in	 most	 human	 post-mortem	 tissue	(Anderson	et	al,	2013),	along	with	the	loss	of	hippocampal	neurons	(Tyynelä	et	al,	 2004).	 Various	MRI	 studies	 have	 also	 consistently	 shown	decreased	 signal	intensity	from	the	thalamus	of	patients	(Autti	et	al,	2007;	Vanhanen	et	al,	2004).	These	findings	were	also	seen	in	various	animal	models	of	NCL,	with	thalamic	
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relay	 neurons	 being	 lost	 before	 any	 neurodegeneration	 in	 the	 corresponding	cortical	region	(Cooper	et	al,	2006).			This	selectivity	of	neuron	loss	is	similar	to	that	seen	in	other	LSDs	(Vitner	et	al,	2010),	but	is	unlikely	to	be	caused	by	the	accumulated	storage	material	(Cooper,	2010).	 Instead,	 the	 cause	 of	 neuronal	 death	 in	 NCLs	 has	 been	 attributed	 to	various	possible	mechanisms.	One	possibility	is	that	NCL	protein	defects	cause	defects	in	intracellular	trafficking,	which	are	more	damaging	in	highly	polarized	cells	like	neurons	(Jarvela	et	al,	1999;	Luiro	et	al,	2004;	Lyly	et	al,	2009;	Lyly	et	al,	2007).	Cells	with	higher	metabolic	rates	like	GABAergic	interneurons	may	also	be	more	vulnerable	to	these	disease	changes	(Walkley	&	March,	1993).	In	CLN3	disease,	antibodies	against	glutamic	acid	decarboxylase	(GAD65)	were	detected	(Chattopadhyay	 et	 al.,	 2002a;	 Chattopadhyay	 et	 al.,	 2002b).	 GAD65	 helps	 to	convert	 glutamate	 to	 GABA	 and	 this	 may	 help	 to	 further	 explain	 GABAergic	interneuron	 vulnerability	 in	 this	 disease	 (Chattopadhyay	 et	 al,	 2002a;	Chattopadhyay	 et	 al,	 2002b).	 There	were	 also	many	 antibodies	 against	 other	brain	proteins	detected	in	CLN3	disease	(Lim	et	al,	2007;	Lim	et	al,	2006),	which	may	potentially	also	contribute	to	neuron	loss.	Furthermore,	while	apoptosis	has	been	proposed	as	a	mechanism	by	which	cells	die	in	most	forms	of	NCL	(Cotman	et	al,	2002;	Koike	et	al,	2003;	Lane	et	al,	1996;	Seigel	et	al,	2002),	this	remains	unproven,	while	autophagy	has	also	been	implicated	(Bronson	et	al,	1998;	Larsen	&	Sulzer,	2002),	Excitotoxicity	has	also	been	implicated	to	play	a	role	in	cell	death,	given	 the	 synaptic	 pathology	 described	 in	 various	 animal	models	 (Finn	 et	 al,	2011;	Finn	et	al,	2012;	Kovacs	&	Pearce,	2008;	Kovacs	et	al,	2006).		Glial	activation,	represented	by	astrocytosis	and	microglial	activation,	has	been	observed	in	all	forms	of	human	NCL	at	autopsy	(Anderson	et	al,	2013;	Tyynelä	et	al,	 2004)	 as	 well	 as	 in	 various	 NCL	 animal	 models,	 where	 a	 pattern	 of	 glial	activation,	particularly	astrocytosis,	preceding	neuron	loss	is	evident	in	multiple	forms	of	NCL	(Bible	et	al,	2004;	Kielar	et	al,	2007;	Oswald	et	al,	2005;	Partanen	et	al,	2008;	Pontikis	et	al,	2004;	Pontikis	et	al,	2005).	Interactions	between	neurons	and	 glia	 (Belin	 &	 Hardin,	 1991;	 Burda	 &	 Sofroniew,	 2014;	 Fields	 &	 Stevens-Graham,	2002;	Salmina,	2009),	as	well	as	inter-glial	interactions	are	essential	for	
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neuronal	homeostasis	(Markiewicz	&	Lukomska,	2006;	Polazzi	&	Contestabile,	2002).	Glia	are	activated	in	response	to	brain	injury	or	immunological	stimuli	and	undergo	 pronounced	 changes	 in	morphology	with	 astrocytes	 becoming	more	hypertrophied	 with	 fewer	 thickened	 processes,	 while	 microglia	 go	 from	 a	ramified,	 ‘resting’	 morphology	 to	 a	 hypertrophied	 brain	 macrophage-like	morphology	(Nedergaard	et	al,	2003;	Nimmerjahn	et	al,	2005;	Ridet	et	al,	1997).	While	this	glial	activation	is	meant	to	be	protective,	over-activation	can	have	a	negative	impact	on	neurons	and	lead	to	cell	death	(O'Callaghan	&	Sriram,	2005;	Polazzi	&	Contestabile,	2002;	Shyng	&	Sands,	2014).	Furthermore,	given	the	role	that	 such	 glial	 activation	 plays	 in	 other	 neurodegenerative	 diseases	 such	 as	Alzheimer	disease,	Parkinson	disease	and	Huntington	disease	(Drew	et	al,	2006;	Hirsch	 et	 al,	 2003;	 Salmina,	 2009;	 Unger,	 1998),	 further	 research	 into	 the	possible	effects	of	glial	activation	on	neuronal	function	in	the	NCLs	is	warranted	and	is	currently	ongoing	(Cooper,	personal	communication).		From	the	broadly	similar	clinical	 symptoms	 in	NCLs,	most	of	 the	pathology	 in	these	diseases	has	been	ascribed	to	the	forebrain	and	cerebellum	(Cooper,	2003;	Cooper	 et	 al,	 2006;	 Jalanko	 &	 Braulke,	 2009).	 However,	 clinical	 studies	 have	consistently	noted	severe	sensorimotor	deficits	 in	patients	 that	do	not	always	correlate	with	brain	pathology	(Dolisca	et	al,	2013;	Schulz	et	al,	2013;	Williams	et	al,	2006).	Recent	studies	have	also	shown	the	accumulation	of	storage	material	in	 various	 tissues	 outside	 the	 CNS	 (Anderson	 et	 al,	 2013;	 Galvin	 et	 al,	 2008;	Staropoli	 et	 al,	 2012),	 which	 may	 help	 to	 better	 understand	 systemic	abnormalities	 in	 these	 diseases.	 Furthermore,	 there	 is	 evidence	 from	 human	post-mortem	 tissue	 (Anderson	 et	 al,	 2013;	 Santavuori	 et	 al,	 1974)	 for	 similar	autofluorescent	 storage	 material	 in	 the	 spinal	 cord.	 These	 data	 serve	 to	emphasize	 that	 NCL	 pathology	 is	 not	 confined	 solely	 to	 the	 brain	 and	characterizing	 these	additional	 sites	of	pathology	may	be	 crucial	 for	 targeting	future	experimental	therapies.	
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1.4	Infantile	NCL	or	Classic	CLN1	disease	
a)	Clinical	presentation		The	clinical	presentation	of	CLN1	disease	shows	a	general	genotype-phenotype	correlation	and	may	vary	from	a	devastating	disease	with	infantile	onset	to	an	adult	onset	form	(Kousi	et	al,	2012;	Mole	et	al,	2005).	Classically,	CLN1	disease	represents	a	very	severe	form	of	NCL	and	presents	at	6-24	months	of	age	with	a	rapid	 loss	 of	motor	 and	 cognitive	 abilities	 and	 the	 presence	 of	 hyperkinesias.	Often,	there	is	decelerated	head	growth	and	muscular	hypotonia	preceding	the	onset	of	these	symptoms.	Loss	of	vision,	hyperexcitability	and	restlessness	are	common	from	16-19	months	of	age.	Loss	of	vision	progresses	to	blindness	by	18-20	 months	 while	 the	 onset	 of	 epilepsy	 is	 usually	 around	 30	 months,	 with	myoclonic,	 tonic,	 clonic	 or	 hypomotor	 seizures	 common.	 As	 the	 child’s	 age	progresses,	there	is	increased	irritability	due	to	generalized	spasticity	and	pain.	The	child	loses	almost	all	cognitive	and	active	motor	skills	by	3	years	of	age	and	the	 usual	 life	 expectancy	 is	 between	 9	 and	 13	 years	 (Dolisca	 et	 al,	 2013;	Santavuori	 et	 al,	 1973;	 Williams	 et	 al,	 2006).	 MRI	 scans	 of	 patients	 show	decreased	 signal	 from	 the	 thalamus	 at	 an	 early	 age,	 followed	 by	 progressive	cerebral	 atrophy	 from	 around	 12	months	 of	 age,	which	 becomes	 very	 severe	around	4	years	(Vanhanen	et	al,	2004).	
b)	Genetics		Classic	CLN1	disease,	which	is	often	known	as	Infantile	NCL	(INCL)	(previously	known	as	Santavuori-Haltia	disease)	(Mole	et	al,	2011;	Santavuori	et	al,	1974)	is	caused	 by	 mutations	 in	 the	 CLN1/PPT1	 gene,	 located	 on	 chromosome	 1p32.		
CLN1/PPT1	 encodes	 the	 soluble	 lysosomal	 enzyme	 palmitoyl	 protein	thioesterase	1	(PPT1)	(Mole	&	Cotman,	2015;	Vesa	et	al,	1995).	Mouse	Ppt1	RNA	can	 be	 detected	 as	 early	 as	 embryonic	 day	 8	 (E8)	 throughout	 the	neuroepithelium,	with	increasingly	regionalized	expression	from	E11	onwards.	Furthermore,	 at	 post-natal	 day	 15	 (P15)	 the	 expression	 of	 Ppt1	wasPpt1was	generally	low	in	the	brain,	but	which	increased	by	P30,	especially	in	the	cerebral	cortex,	 hippocampus	and	hypothalamus	 (Isosomppi	 et	 al,	 1999;	 Salonen	et	 al,	1998).	In	rats,	the	cerebellum	exhibits	a	progessive	continuous	change	in	Ppt1	RNA	expression	until	P30.	In	contrast,	there	seems	to	be	little	change	in	Ppt1	RNA	
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expression	 in	 the	 spleen	 or	 liver	 during	 development	 (Suopanki	 et	 al,	 1999a;	Suopanki	et	al,	1999b).	Despite	extensive	work	to	study	the	expression	of	Ppt1	in	both	brain	and	non-neuronal	tissues	in	rodents	and	in	humans,	there	is	currently	no	data	on	its	expression	in	the	spinal	cord.	Indeed,	the	absence	of	data	for	Ppt1	expression	 in	 the	 spinal	 cord	 in	 the	 Allen	 brain	 atlas	 (http://www.brain-map.org)	is	very	conspicuous,	especially	given	that	similar	information	is	already	available	for	other	NCL	genes	including	Cln2,	Cln3,	Cln5,	Cln6	and	Cln8.					Up	 to	 64	 mutations	 have	 been	 described	 for	 the	 CLN1	 gene	 with	 the	 most	common	 mutation,	 a	 premature	 stop	 codon	 at	 arginine	 151	 (p.	 Arg151x),	accounting	for	40%	of	alleles	(Das	et	al,	1998;	Kousi	et	al,	2012;	Mink	et	al,	2013).	It	has	been	shown	that	mutations	in	CLN1/PPT1	that	leave	a	higher	residual	level	of	PPT1	activity	result	in	a	later	onset	and	slower	progression	of	the	disease.	This	suggests	that	the	loss	of	PPT1	activity	directly	affects	pathogenesis	(Bonsignore	et	al,	2006;	Kalviainen	et	al,	2007;	Mueller	&	Coovadia,	2010;	Perez-Poyato	et	al,	2011;	Simonati	et	al,	2009;	Van	Diggelen	et	al,	2001).	Structural	analysis	of	the	effects	of	mutations	on	PPT1	also	showed	that	larger	mutations	and	those	that	were	closer	to	the	core	of	the	enzyme,	reduced	enzymatic	activity	to	a	greater	degree	than	smaller	mutations,	or	those	near	the	surface	of	the	enzyme	(Ohno	et	al,	2010),	and	that	the	closer	the	mutation	is	to	the	active	site	of	the	enzyme,	the	more	 severe	 the	 disease	 (Hofmann	 et	 al,	 2001).	 Furthermore,	 Zhang	 and	colleagues	also	demonstrated	that	mutations	in	CLN1/PPT1	lead	to	a	mis-folding	of	the	protein	PPT1	(Zhang	et	al,	2006).	
c)	PPT1	function		PPT1	 is	 widely	 expressed	 in	 the	 CNS	 of	 mammals	 (Isosomppi	 et	 al,	 1999;	Suopanki	 et	 al,	 2002)	 and	murine	Ppt1	mRNA	 is	 expressed	 in	 various	 tissues	throughout	the	body	(Camp	&	Hofmann,	1993;	Camp	et	al,	1994;	Salonen	et	al,	1998).	PPT1	is	a	soluble	lysosomal	enzyme	that	removes	palmitate	groups	from	S-acylated	 proteins	 (Camp	 &	 Hofmann,	 1993).	 Many	 molecules	 undergo	palmitoylation	 and	 de-palmitoylation	 in	 the	 cell,	 and	 these	 changes	 influence	many	cellular	functions	including	subcellular	trafficking	and	vesicular	transport	(Aicart-Ramos	et	al,	2011).	PPT1	is	targeted	to	the	lysosome	via	the	mannose	6-
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phosphate	 receptor-mediated	 pathway,	 and	 this	 may	 be	 affected	 in	 disease	(Hellsten	et	al,	1996;	Lyly	et	al,	2007).			While	PPT1	is	a	lysosomal	enzyme,	there	is	growing	evidence	to	suggest	that	the	localization	and	 function	of	PPT1	 is	not	 confined	 to	 the	 lysosome.	PPT1	has	a	substrate-dependent	 neutral	 pH	 (7.0)	 for	 optimal	 enzyme	 activity,	 which	 is	unusual	for	lysosomal	enzymes	that	prefer	an	acidic	pH	(4.5-5.0)	(Cho	et	al,	2000)	suggesting	that	it	is	able	to	function	outside	the	milieu	of	the	lysosome.	PPT1	has	been	shown	to	associate	with	lipid	raft	domains	(Goswami	et	al,	2005)	and	has	been	found	in	vesicular	structures	in	axons,	soma	and	dendrites	(Ahtiainen	et	al,	2003;	Isosomppi	et	al,	1999;	Lehtovirta	et	al,	2001).	The	expression	of	PPT1	in	neurons	 parallels	 that	 of	 abundant	 presynaptic	marker	 proteins	 and	 cultured	PPT1	knock-out	neurons	show	altered	sensitivity	to	glutamate	(Finn	et	al,	2012)	and	there	is	evidence	of	PPT1	expression	in	pre-synaptic	vesicles	(Virmani	et	al,	2005).	Furthermore,	PPT1	seems	to	play	a	greater	role	than	previously	thought	in	 neurons	 than	 in	 other	 cell	 types,	 as	 evidenced	 by	 the	 difference	 in	 its	processing	and	trafficking	in	neurons	(Lyly	et	al,	2007).	PPT1	is	also	expressed	in	several	regions	of	human	and	rodent	brains	during	development,	and	has	been	shown	to	be	required	for	proper	neuronal	development,	including	axon	guidance,	synaptic	pruning	and	determining	cell	fates	(Chu-LaGraff	et	al,	2010;	Fabritius	et	al,	2014;	Isosomppi	et	al,	1999;	Minye	et	al,	2016).	Other	possible	functions	of	PPT1	 include	 roles	 in	 lysosomal	 protein	 sorting	 and	 pH	 regulation	 (Cho	 &	Hofmann,	2004),	involvement	in	caspase-mediated	apoptotic	pathways	(Cho	&	Dawson,	 2000),	 the	 negative	 mediation	 of	 tumor	 necrosis	 factor	 α	 (TNF-α)	(Tardy	et	al,	2009),	involvement	in	the	mitochondrial	respiratory	chain	(Meyer	et	 al,	 2016)	 and	 lipid	metabolism,	 calcium	homeostasis	 and	 thermoregulation	(Ahtiainen	 et	 al,	 2007;	 Khaibullina	 et	 al,	 2012;	 Lyly	 et	 al,	 2008).	 PPT1	 may	potentially	interact	with	other	NCL	proteins	such	as	CLN5	(Lyly	et	al,	2009)	and	Cathepsin	 D	 (CLN10/CTSD)	 (Scifo	 et	 al,	 2015b),	 although	 these	 data	 largely	depend	 on	 antibodies	 whose	 specificity	 is	 unclear.	 Proteomic	 or	 interactome	studies	of	PPT1	have	implicated	its	role	in	lipid	metabolism,	axonal	guidance,	the	myelin	proteome,	neuronal	migration	and	dopamine	receptor	mediated	signaling	(Scifo	et	al,	2015a;	Tikka	et	al,	2016).	
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1.5	The	Ppt1-/-	mouse.	Various	small	eukaryotic	 in	vivo	model	systems	have	been	used	to	study	CLN1	disease	(Phillips	et	al,	2006)	including	yeast	(Pearce,	2001),	C.	elegans	(Porter	et	al,	2005)	and	Drosophila	 (Chu-LaGraff	et	al,	2010;	Hickey	et	al,	2006;	Korey	&	MacDonald,	2003).	However,	the	most	powerful	tools	for	understanding	disease	pathology	as	well	as	for	testing	experimental	therapies	have	been	mouse	models	(Cooper	et	al,	2006).	Currently	there	are	four	mouse	models	for	CLN1	disease,	each	produced	by	a	different	targeting	strategy	to	produce		-	a)	a	null	mutant	by	replacing	exon	9	of	Cln1	with	a	premature	stop	codon	(Gupta	et	al,	2001),	b)	a	mouse	with	a	targeted	deletion	of	exon	4	of	Cln1	(Jalanko	et	al,	2005)	and	c)	mice	that	 recreate	 commonly	 occurring	mutations	 such	 as	 the	 c.451	C>T	nonsense	mutation	(Bouchelion	et	al,	2014),	or	the	pR151X	mutation	(Miller	et	al,	2015)	(Cln1R151X).	All	these	models	share	broadly	similar	phenotypes	of	deteriorating	motor	 performance	 with	 age,	 autofluorescent	 storage	 material	 buildup,	neuroinflammation,	significant	cortical	atrophy	and	premature	death.		By	 far,	 the	most	 commonly	 used	mouse	model	 for	 the	 study	 of	 CLN1	 disease	pathology	are	the	null-mutant	mice	(Ppt1-/-)	(Bible	et	al,	2004;	Kielar	et	al,	2009;	Kim	et	al,	2008;	Lyly	et	al,	2007;	Macauley	et	al,	2009).	These	mice	were	created	by	homologous	 recombination	 to	disrupt	 the	Ppt1	 gene,	whereby	a	portion	of	exon	9	of	the	Cln1	gene	was	replaced	by	a	premature	stop	codon,	resulting	in	a	truncated	mRNA	and	a	complete	loss	of	Ppt1	enzyme	activity	(Gupta	et	al,	2001).			These	Ppt1-/-	mice	exhibit	abnormal	clasping	behavior	in	the	tail-suspension	test,	myoclonus,	seizures	and	visual,	motor	and	cognitive	deficits.	They	also	exhibit	abnormal	gait	with	splayed	hindlimbs	and	lowering	of	the	pelvis	and	they	have	an	average	lifespan	of	8-8.5	months	(Gupta	et	al,	2001).	These	mice	also	show	severe	motor	deficits	such	as	a	significantly	decreased	latency	to	fall	starting	at	5	months	in	the	constant	speed	rotarod-testing	paradigm	(Macauley	et	al,	2009),	as	 well	 as	 significantly	 worse	 performance	 at	 in	 accelerating	 rotarod,	 pole-climbing	 and	 ambulation	 tests	 (Griffey	 et	 al,	 2006).	 A	 recent	 study	 of	 Ppt1-/-	mouse	behavior	revealed	further	subtle	motor	deficits	at	earlier	time	points	(1-3	months)	 in	walking	 initiation	and	walking	up	a	60°	 inclined	plane,	with	more	
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dramatic	 visual,	 cognitive	 and	 motor	 deficits	 observed	 at	 5-7	 months	 of	 age	including	differences	in	visual	acuity	tests,	the	Morris	water	maze,	conditioned	fear	 test,	 running	 wheel	 tests,	 inclined	 plane	 walking	 tests,	 and	 Actometer	readings	 (Dearborn	 et	 al,	 2015).	Ppt1-/-	mice	 also	 showed	 decreased	 learning	ability	in	a	light-cued	T-maze	(Wendt	et	al,	2005).	Furthermore,	despite	a	trend	towards	 lower	 body	 weights,	 Ppt1-/-	 mice	 did	 not	 show	 any	 statistically	significant	 difference	 in	 body	 weight	 when	 compared	 to	 their	 wildtype	counterparts	at	any	time	point	(Galvin	et	al,	2008).	Taken	together	 these	data	suggest	that	Ppt1-/-	mice	accurately	recapitulate	the	severe	visual,	cognitive	and	motor	deficits	seen	in	human	CLN1	disease	and	therefore	represent	a	good	model	of	the	disease.			Pathological	 analysis	 of	 Ppt1-/-	mice	 has	 shown	 that	 there	 is	 a	 deposition	 of	characteristic	autofluorescent	granular	osmiophillic	storage	material	in	the	CNS	and	visceral	organs	(Bible	et	al,	2004;	Galvin	et	al,	2008),	similar	to	human	CLN1	disease	 (Anderson	 et	 al,	 2013).	 	 Ppt1-/-	 mice	 demonstrate	 significant	 brain	atrophy	 with	 age	 starting	 at	 5	 months	 (Kühl	 et	 al,	 2013)	 along	 with	 region-specific	 glial	 activation	 and	 neurodegeneration,	 with	 astrocytosis	 preceding	microglial	activation	and	neuron	loss	in	the	brain	and	cerebellum	(Kielar	et	al,	2007;	Macauley	et	al,	2009).	Significant	astrocytosis	is	observed	in	the	thalamus	as	early	as	3	months	of	age,	while	neuron	loss	begins	at	5	months	(Bible	et	al,	2004;	Kielar	et	al,	2007).	Furthermore,	the	cerebellum	and	thalamus	are	affected	early	 in	 disease	 progression,	 with	 GABAergic	 interneurons	 and	 cerebellar	Purkinje	 cells	 particularly	 vulnerable	 (Bible	 et	 al,	 2004;	 Kielar	 et	 al,	 2007;	Macauley	 et	 al,	 2009).	 Towards	 the	 end	 of	 disease	 progression,	 there	 is	widespread	 gliosis	 and	 neuron	 loss	 in	 the	 brain	 and	 cerebellum,	 although	 it	remains	 most	 pronounced	 in	 the	 areas	 initially	 affected	 (Kielar	 et	 al,	 2007;	Macauley	et	al,	2009)		
Ppt1-/-	 mice	 display	 significant	 cerebral	 synaptic	 pathology	 early	 in	 disease	progression,	 with	 reduced	 levels	 of	 presynaptic	 proteins	 such	 as	 SNAP-25,	synaptophysin	and	the	aggregation	of	synaptobrevin	(VAMP2)	seen	as	early	as	3	months	 in	the	thalamus	(Kielar	et	al.,	2009).	These	changes	may	contribute	to	
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excitotoxicity	and	cell	death	(Kielar	et	al,	2009;	Kim	et	al,	2008).	There	was	also	a	 significant	 low-level	 infiltration	 of	 the	 brain	 parenchyma	 by	 peripheral	lymphocytes	indicating	an	adaptive	immune	response	in	addition	to	the	innate	glial	response	(Groh	et	al,	2013),	as	well	as	a	study	that	detailed	a	possible	change	in	the	integrity	of	the	blood-brain	barrier	(BBB)	in	these	mice	(Saha	et	al,	2012).	
Ppt1-/-	mice	also	show	abnormalities	in	the	ER,	altered	energy	metabolism	and	show	 activation	 of	 the	 unfolded	 protein	 response	 (UPR),	 possibly	 to	 reduce	oxidative	stress	(Wei	et	al,	2008;	Wei	et	al,	2011;	Zhang	et	al,	2006).					The	comprehensive	characterization	of	pathology	in	the	forebrain	of	Ppt1-/-	mice	has	helped	us	understand	CLN1	disease	pathology	in	some	detail,	but	still	cannot	explain	some	of	the	early	sensorimotor	deficits	seen	in	these	mice.	The	evidence	of	spinal	cord	pathology	from	human	CLN1	post-mortem	tissue	(Anderson	et	al,	2013;	Santavuori	et	al,	1974)	as	well	as	the	presence	of	pathology	in	the	viscera	of	 these	animals	 (Galvin	et	 al,	 2008),	 further	emphasizes	 the	need	 for	 a	more	comprehensive	study	of	sensorimotor	deficits	as	well	as	for	a	pathological	survey	of		the	CNS	outside	the	brain.		
1.6	Therapeutic	approaches	for	CLN1	Disease		The	availability	of	authentic	mouse	models	of	CLN1	disease	has	 facilitated	the	testing	of	a	range	of	experimental	 therapies	 for	this	disease.	However,	despite	numerous	 efforts,	 few	 of	 these	 therapies	 have	 provided	 both	 a	 significant	alleviation	of	 symptoms	and	extension	of	 lifespan.	Therefore	 either	 combined	therapeutic	approaches	or	targeting	regions	of	pathology	outside	the	brain	must	now	also	be	considered	(Hawkins-Salsbury	et	al,	2013).	
a)	Enzyme	replacement	therapy	(ERT)	As	 CLN1	 disease	 is	 a	 lysosomal	 enzyme	 deficiency,	 ERT	 utilizes	 “cross-correction”	 between	 cells,	 whereby	 lysosomal	 enzymes	 secreted	 into	 the	extracellular	space	can	be	take	up	by	neighboring	cells	by	means	of	the	mannose-6-phosphate	receptor	system.	Thus,	recombinant	post-translationally	modified	enzyme	can	be	endocytosed	by	cells	following	delivery	into	the	tissue	(Kornfeld,	1992;	Sands	&	Davidson,	2006).	This	approach	has	been	shown	to	be	successful	in	a	variety	of	enzyme-deficient	LSDs	including	Mucopolysaccharidosis	type	I	and	
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type	 IIIA,	 Niemann	 Pick-A	 disease	 and	 neuronopathic	 Gaucher	 disease	(Dierenfeld	 et	 al,	 2010;	 Dodge	 et	 al,	 2009;	 Hemsley	 et	 al,	 2009;	 Lonser	 et	 al,	2005).	Furthermore,	it	has	previously	been	shown	that	restoring	4-5%	of	PPT1	enzyme	 activity	 is	 sufficient	 to	 significantly	 reduce	 the	 neurodegenerative	phenotype	 in	Ppt1-/-	mice	 (Griffey	 et	 al,	 2006).	 This	 is	 similar	 to	 data	 from	 a	hypomorph	 mouse	 model	 of	 CLN2	 disease,	 where	 residual	 enzyme	 (TPP1)	activity	of	just	6%	of	the	normal	value	was	sufficient	to	significantly	ameliorate	disease	(Sleat	et	al,	2008).			Initial	high-dose	intravenous	delivery	of	recombinant	PPT1	enzyme	was	shown	to	distribute	well	and	reduce	storage	material	burden	 in	 the	visceral	 tissue	of	
Ppt1-/-	mice,	as	well	as	not	showing	any	overt	toxicity	(Hu	et	al,	2012;	Lu	et	al,	2010).	However,	very	little	of	the	enzyme	was	shown	to	cross	the	blood–brain	barrier	 (BBB)	 even	 at	 high	 doses,	 and	 therefore	 this	 approach	 had	 very	 little	effect	on	brain	pathology	(Hu	et	al,	2012;	Lu	et	al,	2010).	Nonetheless,	systemic	delivery	of	 recombinant	PPT1	enzyme	did	 result	 in	a	modest	 improvement	of	motor	function	as	well	as	an	increase	in	lifespan	of	these	mice	(Hu	et	al,	2012).	This	improvement	despite	the	lack	of	any	appreciable	effect	in	the	CNS	suggests	the	 presence	 of	 clinically	 significant	 pathology	 outside	 the	 CNS,	 and	 it	 may	therefore	 be	 possible	 to	 use	 systemic	 ERT	 in	 combination	 with	 other	 CNS	directed	therapies.			The	lack	of	effect	of	ERT	for	CLN1	disease	is	in	contrast	to	CLN2	disease,	which	is	also	 caused	 by	 a	 lysosomal	 enzyme	 deficiency	 (Mole	 &	 Cotman,	 2015).	Intrathecal	delivery	of	recombinant	TPP1,	the	enzyme	deficient	in	CLN2	disease,	resulted	in	significant	improvements	in	the	pathology	and	lifespan	in	these	mice	(Xu	et	al,	2011),	while	intra-ventricular	delivery	of	the	enzyme	in	a	canine	model	of	 the	 disease	 was	 also	 particularly	 effective	 in	 alleviating	 disease	 pathology	(Katz	 et	 al,	 2014)	 and	 this	 is	 now	 currently	 being	 tested	 in	 a	 clinical	 trial	(https://clinicaltrials.gov/show/NCT02678689).	 Thus,	 adopting	 similar	approaches	for	ERT	in	CLN1	disease	may	also	lead	to	better	outcomes.		
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b)	Anti-oxidant	drugs	Oxidative	and	ER	stress,	as	well	as	disrupted	adaptive	energy	metabolism,	have	been	suggested	to	have	a	role	 in	CLN1	disease,	and	appear	to	trigger	caspase-mediated	apoptosis	(Kim	et	al,	2006;	Wei	et	al,	2008;	Wei	et	al,	2011;	Zhang	et	al,	2006).	Resveratrol,	an	anti-oxidant	molecule	from	red	grape	skins,	was	shown	to	reduce	 apoptotic	 markers	 and	 improve	 the	 energy	 metabolism	 in	 CLN3	lymphoblast	cells	(Yoon	et	al,	2011)	and	the	administration	of	resveratrol	in	the	diet	of	Ppt1-/-	mice	resulted	a	modest	increase	in	lifespan,	as	well	as	a	reduction	of	 apoptotic	markers	 (Wei	 et	 al,	 2011).	 The	 increase	 in	 lifespan	was	 perhaps	surprising,	as	 this	drug	does	not	 target	 the	primary	enzyme	deficit	 (Wei	et	al,	2011).	 Further,	 the	 anti-inflammatory	 effect	 of	 resveratrol	 may	 also	 help	 to	reduce	the	BBB	defects	seen	in	these	mice	(Saha	et	al,	2012).		Therefore,	this	drug	that	can	be	easily	orally	administered	with	minimal	 side	effects	might	also	be	considered	 as	 a	 candidate	 for	 combination	 therapies	with	 other	 CNS-targeted	approaches.	
c)	PPT1	mimetic	drugs	Since	PPT1	cleaves	thioester	linkages	in	the	lysosome	(Camp	&	Hofmann,	1993),	it	 has	 been	 reasoned	 that	 other	 molecules	 that	 have	 a	 similar	 activity	 and	 a	lysosomal	localization	may	be	useful	in	treating	CLN1	disease	(Zhang	et	al,	2001).	Phosphocysteamine	and	N-	acetylcysteine	(NAC)	were	shown	to	be	able	to	cross	the	BBB,	localize	to	the	lysosome	and	have	thioesterase-like	function	(Bavarsad	Shahripour	 et	 al,	 2014;	 Zhang	 et	 al,	 2001).	While	 in	 vitro	 data	 suggested	 that	phosphocysteamine	did	not	 produce	 the	 same	 level	 of	 activity	 as	PPT1	 (Lu	&	Hofmann,	2006),	this	nevertheless	made	for	an	attractive	therapeutic	approach.	Phosphocysteamine	 therapy	 was	 shown	 to	 be	 effective	 in	 clearing	 storage	material	from	human	CLN1	disease	lymphoblasts	(Zhang	et	al,	2001),	but	showed	very	 little	 change	 in	pathology	or	 lifespan	when	administered	 alone	 to	Ppt1-/-	mice	 (Roberts	 et	 al,	 2012).	 This	 was	 mirrored	 in	 clinical	 trials	 where	phosphocysteamine	showed	little	clinical	benefit	either	given	alone	(Gavin	et	al,	2013),	or	in	combination	with	N-	acetylcysteine	(Levin	et	al,	2014).	
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d)	Stop	codon	read-	through	drugs	Many	 of	 the	 common	 mutations	 in	 CLN1	 disease	 result	 in	 the	 formation	 of	premature	termination	codons	(PTC)	as	a	result	of	base	substitutions,	insertions	or	deletions	in	introns	and	exons	of	the	CLN1	gene	which	cause	aberrant	splicing	and	 frame-shifts	 (Kousi	 et	 al,	 2012).	The	 resulting	mRNA	 from	 these	mutated	genes	are	prone	to	nonsense-mediated	decay	(NMD)	(Miller	et	al,	2013),	which	is	crucial	 for	post-translational	control	of	gene	expression	 in	mammalian	cells	(Chang	et	al,	2007;	Silva	&	Romao,	2009).	Therefore,	drugs	that	can	force	a	read-through	 of	 these	 PTCs	 or	 suppress	 the	 levels	 of	 NMD	 provide	 an	 attractive	therapeutic	option	in	LSDs	(Brooks	et	al,	2006;	Lee	&	Dougherty,	2012).		The	administration	of	the	stop	codon	read-through	drug	ataluran	(PTC124)	was	shown	to	decrease	storage	material,	increase	PPT1	enzyme	activity	and	reduce	apoptosis	in	human	CLN1	disease	lymphoblasts	(Sarkar	et	al,	2011).	The	recent	creation	 of	 two	 “knock-in”	 mouse	 models	 that	 recreate	 commonly	 occurring	point	 mutations	 in	 the	 Cln1	 gene	 has	 facilitated	 the	 testing	 of	 such	 drugs	(Bouchelion	et	al,	2014;	Miller	et	al,	2015).	Administration	of	ataluran	(PTC124)	was	shown	to	increase	PPT1	enzyme	activity	in	the	brain	and	liver	of	Cln1R151X	mice	 in	 a	 pilot	 study	 (Miller	 et	 al,	 2015),	 but	 a	more	 detailed	 study	 revealed	greater	variation	in	Cln1	gene	expression	and	PPT1	activity	(Thada	et	al,	2016).	Despite	 these	 moderate	 effects,	 these	 drugs	 still	 show	 promise	 in	 providing	clinical	therapies,	and	more	work	will	be	required	to	make	this	possible.		
e)	Bone	marrow	transplantation	(BMT)		Bone	marrow	transplantation	or	hematopoietic	stem	cell	transplantation	(HSCT)	has	been	found	to	have	varying	success	in	different	LSDs	depending	on	the	type	of	 LSD,	 the	 extent	 of	 brain	 pathology	 and	 the	 age	 that	 treatment	 is	 initiated	(Neufeld	&	 Fratantoni,	 1970).	 This	 therapy	 relies	 on	 “cross-correction”	 of	 the	enzyme	(Kornfeld,	1992;	Sands	&	Davidson,	2006)	with	a	small	number	of	donor	cells	 believed	 to	 migrate	 to	 the	 host	 brain	 to	 supply	 the	 missing	 enzyme	(Armitage,	1994;	Neufeld	&	Fratantoni,	1970).	Despite	a	number	of	trials	of	both	BMT	and	HSCT	in	the	enzyme	deficient	forms	of	NCL,	this	therapeutic	approach	has	proven	to	be	ineffective	(Deeg	et	al,	1990;	Lake	et	al,	1997;	Lonnqvist	et	al,	
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2001).	Indeed,	a	recent	trial	in	Ppt1-/-	mice	showed	almost	no	beneficial	effect	at	all	upon	of	BMT	by	itself	(Macauley	et	al,	2012).	
f)	Neuronal	stem	cells	The	culture,	banking	and	engraftment	of	Human-CNS	(Hu-CNS)	stem	cells	upon	intra-cerebral	delivery	was	shown	to	be	partially	successful	in	immunodeficient	mice	(Tamaki	et	al,	2002;	Uchida	et	al,	2000).	A	trial	of	similar	delivery	of	Hu-CNS	stem	 cells	 in	 Ppt1	 deficient	 mice	 on	 a	 similar	 immunodeficient	 background	showed	wide	distribution	of	these	cells	upon	delivery	and	an	increase	in	PPT1	levels	 that	significantly	reduced	 the	accumulation	of	storage	material,	delayed	the	loss	of	neurons	and	improved	motor	function	on	these	mice	(Tamaki	et	al,	2009).	This	relatively	promising	pre-clinical	data	led	to	a	phase	one	clinical	trial	of	 Hu-CNS	 stem	 cell	 therapy	 in	 CLN1	 and	 CLN2	 disease	(https://clinicaltrials.gov/ct2/show/NCT00337636).	 This	 was	 the	 first	 such	clinical	 trial	 for	 neural	 stem	 cell	 transplantation	 for	 any	 disease.	 This	 trial	provided	 no	 evidence	 of	 any	 deleterious	 effects	 of	 these	NSC	 transplants,	 but	equally	showed	no	positive	data	for	any	degree	of	efficacy.	While	not	as	effective	in	 clinical	 trials,	 stem	 cell	 therapy	 still	 remains	 another	 potential	 option	 for	delivering	PPT1	to	the	brain.		
g)	Gene	therapy	Of	 all	 the	 therapeutic	 approaches	 for	 CLN1	 disease,	 the	most	 promising	 pre-clinical	data	has	come	from	various	experimental	studies	involving	gene	therapy.	Intracranial	 (IC)	 injections	 of	 an	 adeno-associated	 virus	 (AAV)	 vector,	 AAV2	targeting	 the	 forebrain	 in	 Ppt1-/-	 mice	 showed	 significant	 improvements	 in	reducing	 the	 accumulation	 of	 autofluorescent	 storage	 material,	 as	 well	 as	increased	brain	mass	 and	 cortical	 thickness	 (Griffey	 et	 al,	 2004).	 Additionally	targeting	the	cerebellum	showed	more	pronounced	improvements	with	better	motor	function,	and	reduced	seizure	activity,	along	with	a	greater	effect	on	the	accumulation	of	autofluorescent	storage	material	and	neuron	loss	in	these	mice	(Griffey	et	al,	2006).	Retinal	gene	therapy	 in	Ppt1-/-	mice	not	only	reduced	the	retinal	 neurodegenerative	 phenotype,	 but	 also	 showed	 anterograde	 axonal	transport	of	PPT1	enzyme	to	the	connected	brain	regions	(Griffey	et	al,	2005),	demonstrating	 that	 this	 approach	 may	 be	 useful	 in	 combination	 with	 brain-
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directed	therapies.	Recently,	the	use	of	a	newer	AAV	vector	(AAV2/5)	has	been	shown	to	have	greater	distribution	and	efficacy	in	delivering	the	gene	product,	as	evidenced	by	further	improvements	in	brain	pathology	and	an	increased	lifespan	of	about	12	months	in	Ppt1-/-	mice	(Macauley	et	al,	2012;	Roberts	et	al,	2012).	However,	despite	significant	amelioration	of	brain	pathology	in	these	mice,	they	still	died	prematurely,	 implying	 that	 it	 is	 crucial	 to	additionally	 target	 sites	of	pathology	outside	the	brain	in	CLN1	disease	(Macauley	et	al,	2012).	Therefore,	gene	 therapy	 has	 considerable	 potential	 for	 treating	 brain	 pathology	 in	 pre-clinical	models	of	CLN1	disease.	It	is	likely	that	the	efficacy	of	this	approach	may	be	 enhanced	 by	 using	 newer	 AAV	 vectors	 that	 have	 better	 distribution	 and	neuronal	transduction	(Aschauer	et	al,	2013;	Cearley	&	Wolfe,	2006;	Gray	et	al,	2013;	Swain	et	al,	2014),	as	well	as	possibly	combining	this	method	with	other	therapeutic	approaches.		
h)	Combination	therapies	The	efficacy	of	AAV-mediated	brain-directed	gene	therapy	in	ameliorating	brain	pathology,	improving	the	behavioral	phenotype	as	well	as	improving	the	lifespan	of	Ppt1-/-	mice	(Macauley	et	al,	2012),	has	 led	to	this	approach	being	tested	 in	combination	 with	 other	 systemic	 approaches	 to	 determine	 if	 this	 combined	approach	would	improve	efficacy.			Combination	of	CNS-directed	gene	therapy	along	with	the	administration	of	the	PPT1	 mimetic	 drug	 phosphocysteamine	 (Zhang	 et	 al,	 2001)	 showed	 some	improvements	in	motor	function,	as	compared	to	the	gene	therapy	alone,	with	little	other	effect	 (Roberts	et	al,	2012).	Surprisingly,	bone	marrow	transplants	(BMT),	which	were	shown	to	have	little	effect	when	delivered	alone,	showed	a	great	 synergy	 with	 CNS-directed	 gene	 therapy	 with	 a	 significantly	 increased	lifespan,	 improved	 motor	 function	 and	 a	 reduction	 in	 almost	 all	 brain	pathological	 phenotypes,	 as	 compared	 to	 gene	 therapy	 alone	 (Macauley	 et	 al,	2012).			Given	the	significant	neuroinflammatory	phenotype	seen	in	the	brains	of	Ppt1-/-	mice	(Bible	et	al,	2004;	Kielar	et	al,	2007),	a	BBB-penetrant	anti-inflammatory	
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drug	 MW151	 was	 tested	 in	 combination	 with	 CNS-directed	 gene	 therapy.	Combination	therapy	treated	mice	showed	improved	the	lifespan,	motor	function	and	 reduced	 seizure	 activity,	 as	well	 as	 reduced	 neuroinflammation,	 cytokine	upregulation	and	brain	atrophy	(Macauley	et	al,	2014).		The	 improved	 efficacy	 of	 combining	 brain	 directed	 and	 systemic	 therapies,	compared	 to	 only	 brain-directed	 therapies	 not	 only	 hints	 at	 the	 presence	 of	clinically	 significant	 pathology	 outside	 the	 brain,	 but	 also	 that	 therapeutically	targeting	 such	pathology	 can	provide	 significant	 therapeutic	 benefits	 in	 CLN1	disease.		
1.7	The	spinal	cord	in	health	and	disease	The	spinal	cord	is	part	of	the	CNS,	extending	caudally	from	the	brainstem.	It	is	protected	by	the	structures	forming	the	vertebral	column.	It	serves	as	a	bridge	between	 the	 CNS	 and	 the	 periphery,	 allowing	 for	 the	 transmission	 and	modulation	of	information	between	them.	The	spinal	cord	is	linked	to	sensory,	autonomic	and	motor	control	and	is	therefore	crucial	to	CNS	function	(Nógrádi	&	Vrbová,	2006).		It	is	affected	in	injury	and	a	variety	of	diseases	including	infection,	neoplasms	and	neurodegenerative	diseases	(Cho,	2015).	
a)	Structure		In	 mammals,	 the	 spinal	 cord	 extends	 only	 for	 the	 upper	 two-thirds	 of	 the	vertebral	 canal.	 This	 is	 due	 to	 the	 differential	 growth	 of	 bony	 structures	compared	 to	 the	 cord	 during	 development.	 As	 with	 the	 rest	 of	 the	 CNS,	 it	 is	ensheathed	by	three	layers	of	meninges	–	the	dura,	arachnoid	and	pia	mater.	The	dura	 mater	 in	 the	 vertebral	 canal	 has	 two	 layers	 that	 are	 separated	 by	 the	epidural	space	while	cerebrospinal	 fluid	is	 located	between	the	arachnoid	and	pia	mater.	The	 spinal	 cord	 can	be	divided	 in	 to	 cervical,	 thoracic,	 lumbar	 and	sacral	segments	depending	on	the	position	within	the	canal	and	the	entry	or	exit	levels	of	nerve	roots,	and	the	cervical	and	lumbar	segments	can	be	distinguished	macroscopically	 as	 enlargements.	 The	 spinal	 cord	 gives	 rise	 to	 spinal	 nerves	throughout	 its	 length,	and	these	are	 formed	from	the	dorsal	and	ventral	roots	that	emerge	from	the	lateral	aspect	of	the	cord	on	either	side.	The	cord	is	also	bilaterally	 symmetrical	 and	 is	 divided	 by	 the	 anterior	 and	 posterior	 median	
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fissures	 into	 two	symmetrical	halves	along	the	median	sagittal	axis.	There	are	thirty	one	spinal	cord	segments	–	eight	cervical,	twelve	thoracic,	five	lumbar,	five	sacral,	and	one	coccygeal	(Cho,	2015;	Nógrádi	&	Vrbová,	2006).			In	 contrast	 to	 the	 brain,	 the	 gray	 matter	 of	 the	 spinal	 cord	 is	 completely	surrounded	by	white	matter.	The	gray	matter	 is	divided	 into	 the	dorsal	horn,	intermediate	gray,	the	ventral	horn	and	the	central	gray	matter,	while	the	white	matter	 is	 conventionally	 divided	 into	 various	 tracts	 or	 funiculi	 –	 dorsal,	dorsolateral,	lateral,	ventrolateral	and	ventral.	The	white	matter	gradually	ceases	in	the	caudal	region	of	the	cord,	when	the	gray	matter	forms	the	conus	terminalis,	which	then	divides	into	spinal	roots	forming	the	cauda	equina.	The	dorsal	horn	of	 the	spinal	cord	gives	rise	to	dorsal	roots,	which	 join	together	and	enter	the	dorsal	 root	 ganglion	 (DRG)	 in	 the	 intervertebral	 foramen,	where	 the	 primary	sensory	neurons	are	located	(Nógrádi	&	Vrbová,	2006;	Rexed,	1954).		The	gray	matter	of	the	spinal	cord	has	been	divided	into	various	laminae	based	on	the	topology	and	density	of	cells	(Brown,	1981;	Rexed,	1954)	(Fig	1.1).	The	characteristics	and	cell	types	that	are	present	in	each	lamina	are	detailed	in	table	1.2.		




Figure 1.1 – Laminar cytoarchitechture of the spinal cord. 
Schematic representation of the laminar organization of the gray matter of the spinal hemi-
cord at the level of L4, superimposed over a cresyl fast violet stained section to visualize 
neuronal cytoarchitechture. Adapted from (Nógrádi & Vrbová, 2006; Sengul, 2013). Red lines 
separate laminae I-X, while the gray matter is separated from the white matter by a black 
dotted line. Scale bar = 200μm.     
 Interneurons	 are	 the	most	 abundant	 and	 the	most	 important	modulating	 cell	type	 in	 the	 spinal	 cord.	 In	 the	 dorsal	 horn,	 they	 play	 a	 crucial	 role	 in	 the	transmission	of	 impulses	from	the	primary	sensory	neurons	in	the	DRG	to	the	ascending	 pathways	 that	 reach	 the	 centers	 in	 the	 brain	 and	 brainstem.	 They	perform	a	similar	role	in	the	flow	of	information	from	these	supra-spinal	centers	to	 the	 motor	 neurons	 in	 the	 ventral	 horn.	 Not	 only	 do	 they	 help	 in	 the	transmission	of	impulses,	but	also	help	to	modulate	them	by	means	of	functional	reorganization	of	the	complex	spinal	neural	networks	(Edgley,	2001;	Jankowska,	2001).			
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Apart	from	the	various	types	of	neurons,	the	spinal	cord	also	contains	many	glial	cells,	which	have	important	functions	including	astrocytes,	oligodendrocytes	and	microglial	 cells.	Astrocytes	are	 stellate	 cells	 that	have	 recently	been	 shown	 to	have	a	variety	of	functions,	in	addition	to	the	metabolic	and	trophic	support	of	neurons	including	CNS	energy	metabolism,	synaptogenesis	and	involvement	in	synaptic	 transmission	by	participating	 in	 the	 tripartite	 synapse	 (Araque	 et	 al,	1999;	 Kettenmann	 &	 Verkhratsky,	 2011;	 Kimelberg	 &	 Norenberg,	 1989;	Sofroniew	&	Vinters,	2010).	There	are	two	forms	of	astrocytes	in	the	spinal	cord	–	protoplasmic	and	fibrous	astrocytes.	 Protoplasmic	 astrocytes	 are	more	 common	 in	 the	 gray	matter	 and	have	 dense,	 thin	 processes	 and	 express	 lower	 levels	 of	 glial	 fibrillary	 acidic	protein	than	fibrous	astrocytes	that	are	predominantly	seen	in	the	white	matter	and	have	long,	thick,	fibrous	processes	with	high	levels	of	GFAP	expression.	The	former	are	more	commonly	associated	with	synapses,	while	the	later	are	present	at	 the	 nodes	 of	 Ranvier	 along	 axons,	 which	 are	 essential	 for	 proper	 impulse	propagation	(Kimelberg	&	Norenberg,	1989;	Molofsky	et	al,	2012).			Oligodendrocytes	are	glial	 cells	 that	produce	myelin	within	 the	CNS,	and	each	oligodendrocyte	 is	 able	 to	 myelinate	 several	 adjacent	 axons	 of	 neurons.	Wrapping	spiral	layers	of	oligodendrocyte	cell	membrane	around	the	axon	forms	myelin,	 with	 the	 inner	 surfaces	 of	 the	 cell	membranes	 eventually	 fusing.	 The	myelin	contains	various	special	 lipids	and	proteins,	 for	example	 the	glycolipid	galactocerebroside	and	myelin	basic	protein	(MBP).	Oligodendrocytes	also	play	a	role	in	supporting	the	integrity	of	myelinated	axons	(Simons	&	Nave,	2015).	The	spinal	cord,	like	the	rest	of	the	CNS	has	a	unique	set	of	immune	cells,	microglia.	Even	in	the	normal	brain,	these	cells	have	highly	motile	processes	by	which	they	can	“scan”	the	environment	for	any	noxious	substances.	They	also	communicate	with	both	neurons	and	 immune	cells	 through	a	variety	of	 signaling	pathways.	When	 activated,	 they	 proliferate,	 hypertrophy	 and	 can	 release	 a	 range	 of	substances	 that	 can	 either	 be	 beneficial	 or	 detrimental	 to	 surrounding	 cells	(Kettenmann	 et	 al,	 2011;	Kettenmann	&	Verkhratsky,	 2011;	Marin-Teva	 et	 al,	2011).		
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Lamina Characteristics 
Lamina I Dorsal-most lamina with typical Waldeyer cells (GABAergic inhibitory) and 
pyramidal cells with low neuronal density. 
Lamina II Densely packed neurons with two main types of cells - stalked cells and 
islet cells (inhibitory cells). 
Lamina III Lower neuron density than lamina II. Most cells are inhibitory, expressing 
GABA or glycine and have an antenna-like or radial appearance. 
Lamina IV Contain a variety of antenna-like cells as well as the so-called transverse 
cells. Axons of these cells mainly project to the spino-thalamic tract. 
Lamina V-VI Both these laminae have similar composition. The medial part has many 
triangular and fusiform cells while the lateral part is characterized as 
having many multipolar cells that correspond to the reticular formation.  
Lamina VII Occupies the intermediate zone of the gray matter. Between T1-L1, it 
contains the interomediolateral nucleus, which has autonomous and 
motor function. It also contains the dorsal nucleus of Clarke from T1-L2, 
the ascending projections of which form the spino-cerebellar tract.  
Lamina VIII Contains a variety of neurons with easily distinguishable dorso-ventral 
polarity. These neurons have finer Nissl bodies than motor neurons.  
Lamina IX This lamina contains motor neurons that are recognized by the 
abundance of Nissl bodies in their cytoplasm, their multipolar shape and 
their size. The α- motor neurons are larger than the γ-motor neurons. This 
lamina is divided into ventromedial, ventrolateral, dorsolateral and central 
columns, and the motor neurons in each column innervate a different 
group of muscles. 
Lamina X This lamina is also termed the substansia grisea centralis, and 
corresponds to the gray matter surrounding the central canal. It is a zone 
of actively dividing cells and the neurons here have a bipolar shape.  
 
Table 1.2 – Cellular characteristics of the spinal cord laminae.  
Adapted from (Brown, 1981; Nógrádi & Vrbová, 2006; Rexed, 1954; Romanes, 1964). 	
c)	Connections	of	the	spinal	cord	and	functions	The	spinal	cord	has	three	main	types	of	connections	or	pathways	–	ascending,	descending	 and	 intrinsic	 pathways.	 The	 ascending	 pathways	 facilitate	 the	movement	 of	 information	 from	 the	 periphery	 to	 the	 CNS.	 In	 humans,	 the	pseudounipolar	axons	of	the	primary	sensory	neurons	in	the	DRGs	send	fibers	to	the	dorsal	horn	of	the	spinal	cord,	where	they	synapse	and	second	order	neurons	then	cross	over	to	the	opposite	side	(anterior	to	the	central	canal)	to	ascend	via	white	matter	tracts	in	the	lateral	and	ventrolateral	funiculi	to	reach	the	ventral	posterior	 lateral	 (VPL)	nucleus	of	 the	 thalamus.	This	 forms	 the	 spinothalamic	tract	(Figure	1.2)	and	helps	convey	the	localization	of	thermal	and	pain	stimuli.			Alternatively,	DRG	fibers	that	may	enter	the	ipsilateral	dorsal	column	situated	in	the	dorsal	 funiculi	 ascend	 the	 entire	 length	of	 the	 spinal	 cord.	 This	 forms	 the	dorsal	tract	(Figure	1.3),	which	consists	of	the	medial	fasciculus	gracilis	and	the	lateral	fasciculus	cuneatus	and	becomes	thicker	rostrally	as	more	fibers	are		
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Figure 1.2 – The spinothalamic tract. 
Schematic representation of the paths of first, second and third orders of neurons involved in 
the human spinothalamic tract that helps convey information for localization of thermal and 
pain stimuli from the periphery. Ascending fibers either form the anterior or lateral 
spinothalamic tract. Adapted from (Nógrádi & Vrbová, 2006).  	
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Figure 1.3 – Dorsal column tract. 
Schematic representation of the paths of first, second and third orders of neurons involved in 
the human dorsal tract that helps convey information for discriminatory sensation, 
proprioception and skin pressure. First order neurons from the lower limbs synapse at the 
nucleus gracilis (not shown) while those from the upper limbs synapse at the nucleus 
cuneatus. Adapted from (Nógrádi & Vrbová, 2006).  	
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added	to	the	tract,	before	synapsing	in	the	nucleus	gracilis	and	nucleus	cuneatus	in	 the	medulla	respectively.	The	second	order	neurons	 from	these	nuclei	 then	cross	the	midline	before	reaching	the	contralateral	medial	lemniscus	and	then	to	the	VPL	nucleus	of	the	thalamus.	This	tract	carries	information	for	discriminatory	sensation,	 proprioception	 and	 skin	 pressure.	 Apart	 from	 these	 major	 spino-cortical	 pathways,	 there	 are	 also	 spino-reticular,	 spino-hypothalamic	 tract,	spino-mesencephalic	 tract	and	spino-cerebellar	 tracts	 that	control	a	variety	of	sensory	information	(Cho,	2015;	Nógrádi	&	Vrbová,	2006).			In	humans,	descending	tracts	carry	information	from	the	CNS	to	the	periphery.	The	cortico-spinal	 (pyramidal)	 tract	 (Figure	1.4)	 forms	the	major	pathway	 for	motor	control	and	is	formed	by	fibers	originating	in	the	precentral	gyrus	of	the	motor	cortex.	These	fibers	either	cross	over	to	the	opposite	side	at	the	level	of	the	medulla	to	form	the	lateral	cortico-spinal	tract,	or	some	remain	on	the	same	side	 to	 form	the	anterior	cortico-spinal	 tract,	which	crosses	at	 the	 level	of	 the	synapse	to	the	anterior	horn	cells	on	the	contralateral	side.	The	arrangement	of	fibers	 in	 the	 lateral	 cortico-spinal	 tract	 is	 such	 that	 the	medial	 fibers	 synapse	more	rostrally	while	the	lateral	fibers	synapse	caudally.	Apart	from	the	cortico-spinal	tract,	other	descending	pathways	include	the	rubro-spinal,	reticulo-spinal,	vestibule-spinal	and	tecto-spinal	tracts	that	all	help	with	balance,	posture,	gait	and	the	co-ordination	of	movement.	Additionally,	descending	autonomic	tracts	from	 the	 hypothalamus,	 limbic	 system	 and	 brainstem	 centers	 help	 to	 exert	autonomic	control	on	various	organs	and	tissues	 in	 the	periphery	(Cho,	2015;	Nógrádi	&	Vrbová,	2006).		Apart	from	the	ascending	and	descending	pathways,	there	exist	several	intrinsic	pathways	 within	 the	 spinal	 cord	 that	 help	 modulate	 the	 impulses	 of	 the	ascending	and	descending	tracts,	as	well	as	to	mediate	reflexes.	These	include	the	Lissauer	tract	between	the	dorsal	roots	and	lamina	I,	the	comma	tract	between	fasciculus	 gracilis	 and	 fasciculus	 cuneatus	 in	 the	 dorsal	 column,	 the	septomarginal	tract	in	the	dorsal	white	mater,	the	cornucommissural	tract	along	the	dorsal	commissure	and	the	lateral	and	anterior	ground	bundles	(Nógrádi	&	Vrbová,	2006).	
		 50	
	While	the	anatomy	of	the	human	spinal	cord	described	here	is	largely	similar	to	that	 seen	 in	 the	mouse,	 there	 are	 some	 crucial	 differences.	 As	 a	 general	 rule,	larger	animals	have	a	greater	proportion	of	white	matter	when	viewing	the	spinal	cord	 in	 cross	 section.	 Accordingly,	 the	 human	 spinal	 cord	 has	 a	 greater	proportion	of	white	matter,	relative	to	gray	matter.	This	is	especially	the	case	in	the	dorsal	funiculus	which	is	much	larger	in	human	spinal	cords	than	it	is	in	mice.	Furthermore,	in	mice,	the	corticospinal	tract	occupies	a	smaller	proportion	of	the	white	matter	and	lies	in	the	dorsal	column,	while	it	is	larger	and	lies	in	the	lateral	column	in	humans.	The	rubrospinal	tract,	which	is	involved	in	locomotion	and	maintaining	posture	is	larger	in	mice	than	it	is	in	humans.	Finally,	mice	are	more	reliant	on	the	autonomic	motor	pattern	generators	for	quadrupedal	locomotion.	These	 pattern	 generators	 can	 even	 function	 in	 the	 absence	 of	 sensory	 input.	Comparatively,	 human	 bipedal	 locomotion	 is	 less	 reliant	 on	 this	 reflexive	automaticity	and	more	on	the	integration	of	sensory	signals	withinwith	higher	control	centers	(Sengul,	2013;	Treuting	et	al,	2012).	




Figure 1.4 – Corticospinal (pyramidal) tract. 
Schematic representation of the paths of upper and lower motor neurons in the human 
corticospinal tract, showing the decussation of fibers at the level of the medulla that divides 
the fibers into the lateral (crossed over) corticospinal tract or the anterior corticospinal tract, 
whose fibers cross over at the level of the spinal cord. Adapted from (Nógrádi & Vrbová, 2006). 	  
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diseases	such	as	Alzheimer	disease	(AD)	(Wirths	et	al,	2010),	Parkinson	disease	(PD)	(Vivacqua	et	al,	2011)	and	Huntington	Disease	(HD)	(Muhlau	et	al,	2014).		With	 the	 extent	 of	 neurodegeneration	 observed	 in	 most	 LSDs,	 it	 is	 easy	 to	conceive	 that	 this	pathology	may	extend	 in	 to	 the	spinal	cord.	 Indeed,	various	reports	indicate	the	presence	of	storage	material	deposition	as	well	as	pathology	in	the	spinal	cord	in	human	and	experimental	models	of	LSDs	especially	in	GM1	gangliosidosis	(Hahn	et	al,	1997),	GM2	gangliosidosis	(Tay-Sachs	and	Sandhoff	diseases)	 (Jellinger	et	al,	1982;	 Jeyakumar	et	al,	2003;	Yokoyama	et	al,	2014),	Niemann	Pick	type	A	(Marmiroli	et	al,	2009)	and	Niemann-Pick	type	C	(Yan	et	al,	2011).	Therefore,	there	seems	to	be	a	potentially	considerable	overlap	of	clinical	and	 pathological	 features	 between	 GM2	 gangliosidosis,	 Niemann-Pick	 type	 C	disease	and	the	motor	neuron	diseases	(Dardis	et	al,	2016;	Shapiro	et	al,	2008).		In	 the	 NCLs,	 the	 evidence	 for	 spinal	 cord	 pathology	 comes	 from	 the	 study	 of	human	post-mortem	tissue,	where	studies	of	 Infantile,	 Juvenile	and	Adult	NCL	
post-mortem	 tissue	 have	 revealed	 the	 deposition	 of	 autofluorescent	 storage	material	as	well	as	atrophy	of	the	spinal	cord	in	this	region	(Anderson	et	al,	2013;	Bruun	et	al,	1991;	Santavuori	et	al,	1974).	The	mnd	mouse	model	that	was	later	shown	to	be	a	model	of	Cln8	(Cln8mnd)	 (Ranta	et	al,	1999)	was	shown	to	have	marked	neuroinflammation	and	neuron	loss	in	the	spinal	cord	(Fujita	et	al,	1998;	Plummer	et	al,	1995),	indicating	that	this	may	be	the	case	in	other	forms	of	NCLs	as	well.			In	 CLN1	 disease,	 the	 presence	 of	 profound	 sensorimotor	 deficits	 that	 are	 not	entirely	explained	by	brain	pathology	and	the	limited	success	of	brain-directed	therapies,	makes	the	spinal	cord	a	possible	site	of	pathology	that	may	be	clinically	significant	and	hence,	must	be	investigated.		
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1.8	Hypothesis	and	aims	CLN1	 disease	 is	 a	 rapidly	 progressing	 and	 devastating	 childhood	neurodegenerative	disease.	Despite	detailed	characterization	of	the	progression	of	brain	and	cerebellum	pathology	in	mouse	models,	 the	sensorimotor	deficits	seen	in	human	and	murine	disease	cannot	be	fully	reconciled.	Further,	there	has	been	very	little	success	with	various	systemic	and	brain-directed	therapies	for	CLN1	 disease.	We	 therefore	 hypothesized	 the	 presence	 of	 pathology	 in	 other	regions	of	the	CNS	that	are	not	affected	by	these	therapeutic	approaches,	focusing	on	 the	 spinal	 cord	 due	 to	 its	 significant	 involvement	 in	 the	 sensorimotor	pathways.			The	aims	of	this	thesis	are	threefold	–		a)	To	characterize	the	nature,	extent	and	progression	of	pathology	in	the	spinal	cords	of	Ppt1	deficient		(Ppt1-/-)	mice,	studying	the	known	pathological	features	from	the	brains	of	these	mice,	as	well	as	exploring	any	novel	phenotypes.	We	then	wished	to	determine	if	this	region	of	the	CNS	is	affected	in	the	human	disease,	as	well	as	to	analyze	the	spinal	cords	of	mouse	models	of	CLN2	and	CLN3	disease	to	investigate	whether	there	is	any	spinal	cord	pathology	in	these	other	major	forms	of	NCL.		b)	To	detail	the	occurrence	and	progression	of	any	gait	abnormalities	in	Ppt1-/-	mice	 utilizing	 the	 CatWalk	 XT	 automated	 gait	 analysis	 system	 (Noldus	












a)	Ppt1-/-	mice	A	 Ppt1	 deficient	 mouse	 (Ppt1-/-)	 model	 of	 Cln1	 disease	 was	 created	 by	 gene	disruption,	 whereby	 a	 portion	 of	 exon	 9	 of	 the	 Cln1	 gene	 was	 replaced	 by	 a	premature	stop	codon,	resulting	in	a	truncated	mRNA	and	a	complete	loss	of	Ppt1	enzyme	activity	(Gupta	et	al,	2001).			
Ppt1-/-	mice	were	backcrossed	for	at	least	10	generations	onto	a	C57BL/6	mouse	background	 (https://www.jax.org/strain/000664)	 and	 maintained	 as	homozygous	breeding	stocks	at	 the	Washington	University	School	of	Medicine	(St.	Louis,	MO),	the	University	of	Texas	Southwestern	Medical	Centre	(Dallas,	TX)	and	 the	 Institute	 of	 Psychiatry,	 Psychology	 and	 Neuroscience,	 King’s	 College	London	 (London,	UK).	 All	 procedures	were	 carried	 out	 under	NIH	 guidelines,	Institutional	 Animal	 Care	 and	 Use	 Committee	 (IACUC)	 guidelines	 at	 the	respective	institutions	(U.S.A)	and	the	Animals	(Scientific)	Procedures	Act,	1986	(UK).	
b)	Thy1-YFP/Ppt1-/-	mice	The	Thy1-YFP/Ppt1-/-	mouse	model	was	created	by	crossing	Thy1-YFP	reporter	mice	(Tg	(Thy1-YFP)	16Jrs,	The	Jackson	Lab,	Bar	Harbor,	ME,	USA)	(Feng	et	al,	2000)	with	Ppt1-/-	mice.	The	reporter	mice	were	maintained	as	a	homozygous	breeding	 stock	 of	 Thy1-YFP+/-/Ppt1-/-	 mice	 and	 Thy1-YFP	 reporter	 mice	 were	used	 as	 controls.	 All	 procedures	 were	 performed	 in	 accordance	 with	 NIH	guidelines,	approved	by	the	IACUC	at	Washington	University	School	of	Medicine.	




Figure 2.1 – Disease progression in Ppt1-/- mice. 
Schematic representation summarizing the progression of major behavioral changes and 
brain pathology observed in Ppt1-/- mice with increasing age. AFSM denotes Autofluorescent 
Storage Materia. Incorporates data from (Bible et al, 2004; Dearborn et al, 2015; Gupta et al, 
2001; Kielar et al, 2007). 
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2.2	Human	tissue Paraffin	wax-embedded	spinal	cord	tissue	of	a	single	INCL	patient	was	obtained	from	 the	 archives	 of	 the	 Department	 of	 Pathology,	 University	 of	 Helsinki.	Similarly,	a	single	spinal	cord	tissue	sample	from	a	neurologically	normal	control	was	 obtained	 from	 the	 Department	 of	 Pathology,	 University	 of	 Washington,	School	 of	 Medicine,	 St.	 Louis,	 MO.	 These	 samples	 were	 collected	 at	 routine	autopsies	of	the	individuals	with	informed,	written	consent	of	their	families.	The	work	was	 done	 under	 the	 approval	 of	 the	 Ethical	 Research	 Committee	 at	 the	Institute	of	Psychiatry,	Psychology	and	Neuroscience,	King’s	College	London,	UK	(Approval	numbers:	223/00	and	181/02).	
2.3	Quantitative	Gait	Analysis	Various	motor	deficits	have	been	described	in	Ppt1-/-	mice	including	an	abnormal	clasping	behavior	and	a	progressive	gait	abnormality	with	splaying	of	hindlimbs	and	lowering	of	the	pelvis,	eventually	resulting	in	hind	limb	paralysis	(Gupta	et	al,	2001).	A	more	comprehensive	study	showed	that	Ppt1-/-	mice	as	young	as	2-3	months	 showed	 subtle	 deficits	 on	 walking	 initiation	 tests	 and	 a	 60°	 inclined	screen	test	(Dearborn	et	al,	2015).	Collectively	these	data	imply	that	some	of	the	earliest	functional	deficits	in	this	mouse	model	affect	the	sensorimotor	system.		To	further	detail	these	gait	abnormalities,	we	used	the	CatWalk	XT	gait	analysis	system	 (Noldus	 Information	 Technology	 bv,	 Wagenigen,	 Netherlands.).	 The	




Figure 2.2 – CatWalk XT data acquisition. 
(A to C) Images of the CatWalk XT system showing the components of the walkway including 
the roof (Red), walkway floor (green) and bounding walls (A, B) as well as the digital camera 
used to capture videos (C). (D) Images showing a frame of the captured video from a single 
run. Each paw print appears as a fluorescent green mark. These are then classified as	Right 
Front (RF), Left Front (LF), Right Hind (RH) or Left Hind (LH). The Schematics below show 
placement of these classified paw prints over the duration of the run, with coloured bars 
indicating the periods when each foot was in contact with the glass floor of the apparatus.  	For	this	gait	analysis	study	we	used	12	age-matched	mice	per	group	(n=12)	for	
Ppt1-/-	mice	and	WT	mice.	Mice	were	initially	trained	starting	at	3	wks	of	age	to	walk	 the	 Catwalk	 XT	 system.	Monthly	 recordings	were	 collected	 between	1-7	months	 of	 age.	 Each	 recording	 day	 was	 preceded	 by	 a	 training	 session	 to	condition	 the	 mice.	 Experimental	 settings	 were	 chosen	 to	 allow	 for	 accurate	detection	of	walks		-	Camera	gain	20	dB,	green	intensity	threshold	0.10,	red	 	
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Figure 2.3 – CatWalk XT run visualizations. 
(A, B) Representative images showing 2D (A) and 3D (B) visualizations of paw contact 
intensities. Maximum intensities (A) are represented by the red line, while the coloured blocks 
represent mean intensities. (C) Representative image sowing the footfall patterns for a single 
run. 
 ceiling	 light	17.7	 volts	 and	 green	walkway	 light	16.5	 volts.	 Each	mouse	had	 a	minimum	of	3	‘compliant’	runs	measured	with	the	run	duration	ranging	from	a	minimum	of	1	second	to	a	maximum	of	5	seconds	to	be	considered	compliant.			The	Catwalk	XT	software	was	then	used	to	analyze	over	28	different	parameters	associated	with	gait	 including	paw	print	 areas,	 print	 intensities,	 stride	 length,	base	 of	 support,	 swing	 duration	 and	 measures	 of	 interlimb	 co-ordination	(Summarized	in	Table	1)	(Figure	2.2,	2.3).	These	data	were	then	exported	into	an	MS	Excel	 spreadsheet	 (Microsoft,	 Seattle)	 for	 further	 statistical	 analysis	 as	detailed	in	section	10.	
	From	an	initial	study	of	7-month-old	Ppt1-/-	and	wildtype	mice	(n=5),	a	maximum	speed	variation	of	80%	was	selected	to	allow	for	compliance	of	runs	at	the	end-stage	of	disease.			
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2.4	Tissue	processing	Mice	were	anesthetized	with	Euthatal	(200mg	sodium	pentobarbital/ml,	Merial	Animal	 Health	 Ltd.,	 UK),	 and	 injected	 intra-ventricularly	 with	 0.1ml	 of	 anti-coagulant	 heparin	 sodium	 (1000	 IU/ml)	 (Wockhardt,	 Wrexham,	 UK)	 and	transcardially	perfused	with	Phosphate	Buffered	Saline	(PBS:	50mM	Phosphate	Buffered	Saline	with	MgCl2	and	CaCl2,	pH	7.4,	Sigma,	Gillingham,	Dorset,	UK.)	and	4%	paraformaldehyde	in	0.1	M	Sodium	Phosphate	buffer,	pH	7.4	(PFA).					
 
 
Figure 2.4 – CatWalk XT step-fall patterns. 
Schematic representations of the different types of step fall patterns classified by the CatWalk 
XT system – which can be cruciate anti-clockwise (CA), cruciate clockwise (CB), alternate 
anti-clockwise (AA), alternate clockwise (AB), rotary anti-clockwise (RA) or rotary clockwise 
(RB). Adapted from (Hamers et al, 2006). 	 	
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I. Measures of run speed   
a. Body speed Average speed (cm/s) of the distance covered to 
time in a step cycle. 
b. Cadence The number of steps per second (frequency of 
steps). 
c. Run speed variation Average and maximum variation (%) of speed 
during a given run.  
II. Step cycle measures  
a. Step cycle Duration (s) between two consecutive initial 
contacts of the same paw. 
b. Stand  Duration in seconds (s) of contact of paw with 
glass plate. 
c. Swing Duration (s) of no contact of a given paw with 
glass plate. 
d. Duty cycle Stand expressed as a percentage (%) of step 
cycle 
e. Swing speed  Ratio of stride length/swing (cm/s). 
f. Stand Index Measure of the speed at which the paw loses 
contact with the glass plate. 
III. Paw Measures Duration (s) between two consecutive initial 
contacts of the same paw. 
a. Print Width Length and area Sum of all contact lengths (cm), widths (cm) and 
areas (cm2) of a given paw in a run (in the 
direction of walking). 
b. Max Contact Area Maximum area of the paw that comes in contact 
with glass plate (cm2). 
c. Stride length Length (cm) between successive placements of 
each paw. 
d. Min., Max. and mean intensities The minimum, maximum and mean intensities of 
a paw coming into contact with the glass plate 
(Ranges from 0-255). 
e. Max intensity to stand Maximum intensity relative to stand duration (%) 
IV. Stance and Support  
a. Stance Duration (s) of contact of single, dual paws. 
b. Base of Support (BOS) Average width between the front paws or hind 
paws. 
c. Support The fraction of the run (%) spent on one, two, 
three or four limbs 
V. Measures of coordination  
a. Print positions Relative placement of hind paws to the ipsilateral 
forepaws (-2 to +2) 
b. Normal step sequences Step sequences that fall within normal footfall 
patterns  (Figure 2.3). 
c. Regularity Index Ratio of the number of normal step sequences to 
the total number of paw placements (%). 
d. Phase dispersions Describes the temporal relationship between the 
placements of any two paws within a step cycle. 
	
Table 2.1 – CatWalk Parameters. 
Table detailing the various parameters measured on CatWalk XT system in the current study. 
Adapted from (Coulthard et al, 2002; Coulthard et al, 2003; Kloos et al, 2005). 	
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Whole	intact	mice	were	then	immersion	fixed	in	4%	PFA	for	at	 least	48	hours	before	being	transferred	to	a	50mM	Tris	Buffered	Saline	(TBS:	50	mM	Tris	(VWR,	Leicestershire,	UK),	pH	7.6,	150mM	NaCl	(VWR)).		To	harvest	the	brain	and	spinal	cord,	an	initial	incision	was	made	from	the	snout	to	tail	on	the	dorsal	aspect	of	the	mouse	and	skin	was	opened.	The	muscle	and	fatty	tissue	in	the	cervical	region	of	the	spinal	cord	were	cleared	with	Rongeur	forceps	(Fine	Science	Tools,	Heidelberg,	Germany).	The	head	of	the	mouse	was	then	flexed	with	one	hand	to	expose	the	C1	segment	of	the	spinal	cord	between	the	foramen	magnum	at	the	base	of	the	skull	and	the	C1	vertebra	(atlas).	From	the	dorsal	aspect,	a	clean	incision	was	made	to	the	spinal	cord,	using	a	size-11	scalpel	 (Swann-Morton,	 Sheffield,	 UK)	 to	 separate	 it	 from	 the	 brainstem.	 The	head	was	 then	 separated	 from	 the	 body	with	 scissors	 and	 the	 brain	 carefully	dissected	out	of	the	skull.	The	spinal	column	was	dissected	out	intact	by	from	the	rest	of	the	body	and	all	extraneous	muscle	and	connective	tissue	was	removed	using	 a	 Rongeur	 forceps	 to	 expose	 the	 vertebrae.	 The	 spinal	 cord	 was	 then	dissected	 out	 from	 the	 column	 by	 initial	 dorsal	 laminectomies,	 followed	 by	separation	 and	 removal	 of	 individual	 vertebrae	 (Figure	 2.4).	 The	 brain	 and	spinal	cords	were	 then	placed	 in	a	cryoprotectant	solution	 for	24	hours	(30%	sucrose	 solution	 in	 TBS	 with	 0.05%	 Sodium	 Azide	 (VWR,	 UK)).	 Dorsal	 Root	Ganglia	(DRGs)	were	dissected	out	from	the	spinal	nerve	roots	at	the	lumbar	level	for	 separate	 analysis	 (see	 below).	 Brain	 hemispheres	 for	 sectioning	 were	obtained	by	separating	the	cerebellum	and	brainstem	from	the	forebrain	using	a	single	edged	razorblade	(VWR)	to	make	a	coronal	cut.	An	additional	sagittal	cut	was	made	along	the	midline	to	separate	the	two	hemispheres	of	the	brain.	Spinal	cords	were	separated	into	cervical,	thoracic	and	lumbo-sacral	regions	via	coronal	cuts	with	a	razorblade	(Figure	2.4).		Each	hemisphere	of	the	brain,	and	each	spinal	cord	region	were	mounted	on	their	long	 axis	 to	 the	 stage	 of	 a	 freezing	microtome	 (Microm	HM	 430,	Wallendorf,	Germany),	 coated	 with	 Shandon	 M-1	 embedding	 matrix	 (ThermoFisher	Scientific,	Waltham,	MA,	USA)	and	40μm	coronal	sections	were	cut	and	stored	sequentially	in	96	well	plates	containing	an	anti-freeze	cryoprotectant	solution	
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(TBSAF:	TBS,	30%	Ethylene	Glycol	(VWR),	15%	Sucrose	and	0.05%	Sodium	azide	(VWR)).		
 The	 DRGs	 of	 7-month-old	 mice,	 and	 spinal	 cords	 from	 Thy1-YFP	 and	 Thy1-
YFP/Ppt1-/-	mice	 (n=3)	were	 embedded	 in	OCT	 (VWR),	 frozen	 on	 dry	 ice	 and	sectioned	 using	 a	 Leica	 CM1850	 cryostat	 (Leica	 microsystems,	 Wetzlar,	Germany)	 to	obtain	8μm	and	32μm	sections,	 respectively,	 that	were	 collected	directly	 onto	 Superfrost	 Plus	 slides	 (ThermoFisher	 Scientific).	 Paraffin	 wax-embedded	tissue	was	sectioned	into	5μm	coronal	sections	by	initially	trimming	the	paraffin	blocks	with	a	single	edged	razor	blade	and	sectioned	using	a	Leica	SM2400	base	 sledge	microtome	 (Leica	microsystems,	Wetzlar,	Germany).	The	sections	 were	 then	 floated	 out	 in	 a	 warm	 water	 bath	 and	 mounted	 on	 to	Superfrost	Plus	slides	(ThermoFisher	Scientific)	and	dried	on	a	warming	plate.			For	 toluidine	 blue	 staining,	 cervical	 and	 lumbo-sacral	 regions	 of	 7-month-old	spinal	cords	were	embedded	in	epoxy	resin	and	1	μm	semi-thin	sections	were	cut	using	an	ultramicrotome	at	the	laboratory	of	Dr.	Peter	Gann,	University	of	Illinois,	College	of	Medicine,	IL.		
2.5	Tinctorial	staining	





Figure 2.5 – Dissection of the spinal cord. 
(A) Representative dorsal and lateral views of spinal columns dissected out of perfused mice 
(left) and spinal cords after dorsal laminectomies followed by removal of vertebrae. (B) 
Schematic representation of the levels at which the spinal cords were separated into the 
cervical, thoracic and lumbosacral segments. 	being	cleared	in	Xylene	(VWR)	and	coverslipped	with	DPX	(VWR),	a	xylene-based	mountant	(Figure	2.5).	
b)	Luxol	Fast	Blue	Luxol	fast	blue	was	used	to	visualize	the	myelin	in	the	white	matter	of	spinal	cord	sections	 (Kluver	 &	 Barrera,	 1953).	 Selected	 40μm	 sections	 from	 the	 cervical,	thoracic	and	lumbo-sacral	spinal	cord	were	mounted	on	to	chrome-		
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Figure 2.6 – Cresyl fast violet staining. 
Representative images of Nissl stained sections of spinal cord aligned with level matched 
schematic images to allow for visualization of neuronal architecture.  Schematic images 
adapted from (Sengul, 2013). 
 gelatin	 coated	 glass	 slides	 and	 left	 to	 air-dry	 overnight.	 The	 slides	were	 then	incubated	in	a	0.1%	luxol	fast	blue	solution	(VWR)	with	0.05%	acetic	acid	(VWR)	at	 56°C	 overnight	 before	 being	 differentiated	 by	 passing	 the	 slides	 through	 a	0.05%	 aqueous	 solution	 lithium	 carbonate	 and	 a	 70%	 IMS	 solution	 before	clearing	the	sections	in	xylene	(VWR)	and	coverslipping	with	DPX	(VWR).	




a)	Immunohistochemistry	Each	 immunohistochemical	 staining	 experiment	 was	 performed	 with	 an	appropriate	 secondary-only	control,	keeping	all	other	parameters	 the	same	 in	order	to	check	the	specificity	of	staining.		Free-floating	sections	were	stained	as	previously	described	(Bible	et	al,	2004).	Either	a	1	in	48	series,	or	selected	40μm	mouse	spinal	cord	sections	and	a	1	in	6	series	 of	 brain	 sections	 were	 immunostained	 free-floating	 for	 markers	 of	interneurons,	 microglia,	 astrocytes,	 peripheral	 lymphocytes,	 white	 matter	proteins	and	pre-	or	post-synaptic	proteins	(Table	2.2).	Endogenous	peroxidase	activity	was	quenched	with	1%	H2O2	in	TBS	with	0.3%	Triton-X100	(TBS-T)	for	spinal	cord	sections,	and	with	1%	H2O2	in	TBS	for	brain	tissue,	washed	and	then	blocked	in	15%	normal	serum	(Vector	Laboratories,	Peterborough,	UK)	diluted	in	TBS-T.	The	species	of	normal	serum	was	directed	against	the	host	species	of	the	secondary	antibody.	After	blocking,	sections	were	incubated	overnight	at	4°C	in	primary	antibody	in	10%	normal	serum	in	TBS-T.	Sections	were	then	washed	and	incubated	at	room	temperature	in	biotinylated	secondary	antibody	at	1:1000	dilution	 for	 2	 hours	 (Table	 2.2)	 followed	 by	 washing	 and	 incubation	 in	Vectastain	 Elite	 ABC	 kit	 (1+1:1000,	 Vector	 Laboratories)	 for	 2	 hours	 before	visualization	 by	 incubation	 with	 0.05%	 3,3’-diaminobenzidine	tetrahydrochloride	(DAB)	(Sigma)	containing	0.001%	H2O2.	Sections	were	then	mounted	 on	 to	 chrome-gelatin	 coated	 slides,	 air-dried	 overnight,	 cleared	 in	xylene	(VWR)	and	coverslipped	in	DPX	(VWR).	Paraffin	wax-embedded	human	spinal	cord	tissue	sections	were	also	stained	as	previously	 described	 (Tyynelä	 et	 al,	 2004).	 Sections	 that	 were	 collected	 on	Superfrost	Plus	(ThermoFisher	Scientific)	slides	were	de-waxed	in	xylene,	and	endogenous	peroxidase	activity	quenched	by	incubating	the	sections	in	methanol	containing	1%	H2O2	for	30	minutes.	Sections	were	rinsed	in	de-ionized	water	and	antigen	retrieval	performed	by	boiling	for	20	minutes	in	0.01M	sodium	citrate	buffer,	pH=6.00.	All	sections	were	subsequently	rinsed	in	TBS	and	blocked	in	
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Primary Antibody Dilution Secondary 
Antibody 
I. Interneuron Markers   
a. Rabbit anti-Calbindin  
(Swant, CB38a) 
1:10,000 (SC) Swine anti- Rabbit 
1:1000, Dako 
b. Rabbit anti-Calretinin 
(Swant, 769914) 
1:5000 (SC) Swine anti- Rabbit 
1:1000, Dako 
II. Motor neurons   
a. Rat anti- CD71 
(AbD Serotec, MCA2474EL) 
1:200 (SC) Rabbit anti-Rat 
1:1000, Vector 
b. Goat anti-ChAT 
(Chemicon, AB144P) 
1:100 (SC) Rabbit anti-goat 
1:1000, Vector 
III. Astrocytes   
a. Rabbit anti- GFAP 
(Dako, Z0334) 
1:8000 (SC, Br) 
1: 3000 (Hu, DRG) 
Swine anti- Rabbit 
1:1000 (SC, Br), 
1:200 (Hu, DRG) Dako 
IV. Microglia   
a. Rat anti- mouse CD68 
(AbD Serotec, MCA1957) 
  




- Immunofluorescence 1:200 (SC) Goat anti-Rat 
1:1000, AlexaFluor 633 
ThermoFisher Scientific 
b. Mouse anti-CD68 
(Dako, clone PG-M1) 
1:800 (Hu, DRG) Goat anti- mouse, 
1:200, Vector 
V. Peripheral Lymphocytes    
a. Rat anti-CD4 
(AbD Serotec, MCA1767) 




b. Rat anti-CD8 
(AbD Serotec, MCA609G) 
1:100 (SC, DRG) Rabbit anti-Rat 
1:1000, Vector 
VI. Synaptic Markers   
a. Mouse anti- Synaptophysin 
(Upstate, ADI-VAM-SV011) 
1:100 (SC) Goat anti- mouse, 
1:1000, Vector 
b. Rabbit anti-SNAP25 
(Abcam AB5666) 
1: 1000 (SC) Goat anti-Rabbit, 
1:1000, Vector 
c. Chicken anti-mouse VAMP2 
(Chemicon, AB5625) 
1:400 (SC) Goat anti- chicken, 
1:1000, vector 
d. Mouse anti-PSD95  
(Neuromab) 
1:1000 (SC) Goat anti- mouse, 
1:1000, Vector 
VII. White matter    
a. Chicken anti-Neurofilament H 
(Acris, AP31813PU-N) 
1:16,000 (SC) Goat anti- chicken, 
1:1000, vector 
b. Rat anti-Myelin Basic Protein  
(MBP) 
(Merck Millipore, MAB386) 




Table 2.2 – Primary and secondary antibodies used for immunohistochemistry (IHC) 
and immunofluorescence (IF). 
SC= Spinal cord sections, Br= Brain sections, Hu= Human sections and DRG= Dorsal root 
ganglia sections. 
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15%	 normal	 serum,	 as	 before,	 in	 TBS-T	 for	 30	 minutes,	 before	 overnight	incubation	 at	 4°C	 with	 primary	 antiserum	 diluted	 in	 TBS-T	 containing	 10%	normal	 serum	 (Table	 2.2).	 Sections	were	 rinsed	 and	 incubated	 in	 secondary	antibody	(Table	2.2),	and	followed	as	above	by	treatment	with	Vectastain	Elite	
ABC	kit	(1:200;	Vector	Laboratories),	and	visualization	with	DAB	(Sigma).	
b)	Immunofluorescence	40μm	mouse	 spinal	 cord	 sections	 from	 the	 cervical,	 thoracic	 and	 lumbosacral	cord	were	stained	to	visualize	staining	of	CD68-positive	microglia	in	relation	to	the	accumulation	of	autofluorescent	storage	material.	Sections	from	the	cervical,	thoracic	and	lumbo-sacral	spinal	cord	were	blocked	in	a	15%	normal	goat	serum	(Vector)	solution	in	TBS-T	for	2	hours	and	incubated	overnight	at	4°C	in	primary	antibody	(Table	2.2)	diluted	in	10%	normal	serum	in	TBS-T.	Sections	were	then	washed	and	incubated	at	room	temperature	in	biotinylated	secondary	antibody	at	a	1:1000	dilution	for	2	hours	(Table	2.2).	Sections	were	washed	with	TBS	and	mounted	on	to	slides	and	coverslipped	with	Fluoromount-G	mounting	medium	(Southern	Biotech,	Birmingham,	AL).		
2.7	Stereology	Stereology	allows	for	the	rapid,	efficient	and	unbiased	quantitative	measurement	of	3D	parameters	of	an	object	using	2D	sections.	Design-based	stereology	enables	the	 accurate	 measurement	 of	 regional	 volumes	 and	 cell	 counts,	 as	 well	 as	measurements	of	thickness,	area	and	density	(reviewed	in	(Schmitz	&	Hof,	2005).	Design-based	 stereology	 is	 done	 by	 first	 designing	 a	 random	 and	 systematic	sampling	 scheme	such	 that	 the	objects	measured	are	 sampled	 independent	of	size,	shape,	spatial	orientation	and	distribution	(West,	2002).	This	is	important,	as	the	measurements	of	objects	will	therefore	be	unbiased	to	any	differences	in	the	morphology	and	 size	of	 any	brain	or	 spinal	 cord	 regions	being	 compared.	Furthermore,	this	assumption	of	three-dimensional	spatial	independence	allows	for	the	reduction	of	systemic	errors	in	counting,	as	compared	to	other	counting	methods	(Gundersen	&	Jensen,	1987;	West,	1993).				To	 perform	 design-based	 stereological	 measurements	 for	 brains	 and	 spinal	cords,	sections	of	known	thickness	are	collected	at	a	consistent	periodicity.	 In	
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this	study,	we	have	used	40μm	brain	sections	at	a	1	in	6	interval	and	40μm	spinal	cord	 sections	 at	 a	 1	 in	 48	 interval.	 These	 sections	 were	 stained	 for	 specific	markers	of	interest,	such	as	cresyl	fast	violet	to	view	neuronal	cytoarchitechture	or	for	markers	for	interneurons.	These	sections	are	then	compared	to	a	reference	atlas	 (Paxinos,	 2001;	 Sengul,	 2013),	 so	 as	 to	 accurately	 draw	 anatomical	boundaries	of	the	regions	of	interest	in	which	parameters	will	be	assessed.	Such	repeated	 comparisons	 of	 anatomical	 boundaries	 allows	 for	 an	 accurate	representation	 of	 the	 region.	 All	 stereological	 measures	 in	 this	 study	 were	carried	out	using	Stereoinvestigator	software	(MBF	Bioscience)	connected	to	a	Zeiss	Axioskop	2	MOT	(Zeiss)	with	a	DAGE-MTI	CCD-100	camera	(DAGE-MTI).		
a)	Measurements	of	cell	area	An	 increase	 in	 cell	 size	 of	 both	 Nissl-stained	 neurons	 and	 interneurons	 has	previously	been	documented	in	the	brains	of	Ppt1-/-	mice,	presumably	as	a	result	of	storage	material	accumulation	(Bible	et	al,	2004;	Haltia	et	al,	1973a).		Cell	areas	in	μm2	were	measured	for	Nissl-stained	motor	neurons	based	on	their	location	and	 morphology	 (Rexed,	 1954;	 Sengul,	 2013),	 as	 well	 as	 of	 calbindin	 and	calretinin	positive	interneurons	by	drawing	contours	around	their	cell	bodies	for	a	100	cells	per	region	of	spinal	cord,	per	mouse.		






Figure 2.7 – Measuring regional spinal cord volumes. 
(A) Representative images of a thoracic spinal cord sections stained for Nissl with contours 
(red) showing the contours drawn to measure total and gray matter volumes respectively. (B-
C) Representative images of thoracic spinal cord with contours for total volume and gray 
matter superimposed with a 125x125μm grid (B) and the gray matter contour filled with 
markers for the Cavalieri estimator (C).    
c)	Neuron	counts	of	Nissl	sections.	Cell	counts	were	performed	using	an	optical	fractionator	technique	(West,	2002).	This	combines	an	optical	dissector,	which	is	a	method	used	to	count	nuclei	in	a	three	dimensional	context	with	a	fractionator,	which	is	a	method	for	systematic	and	 uniform	 sampling	 of	 a	 two-dimensional	 area	 (West,	 2002).	 	 The	 optical	
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dissector	includes	the	optical	section	planes	by	moving	the	focal	plane	along	the	z-axis,	and	estimates	cell	numbers	without	any	bias	towards	their	size	or	shape.	The	fractionator	(Gundersen	&	Jensen,	1987),	applies	systematic	sampling	sites,	thus	reducing	the	total	number	of	cells	counted,	as	well	as	removing	any	sampling	bias.				To	count	cells	using	the	optical	fractionator,	first,	data	regarding	the	thickness	of	the	sections	and	periodicity	 is	 recorded.	The	region	of	 interest	 is	 identified	 in	each	section,	as	with	regional	volume	measurements	(see	above),	and	a	contour	is	drawn	around	 it	at	a	 low	magnification.	An	appropriately	sized	grid	 is	 then	superimposed	 onto	 the	 drawn	 contour	 to	 provide	 a	 succession	 of	 systematic	sampling	sites.			The	grid	sizes	used	for	different	brain	regions	are	given	in	table	2.3.	A	counting	frame	 is	 then	 defined	 at	 a	 high	 magnification	 such	 that	 there	 is	 a	 uniform	distribution	of	counting	frames	for	every	sampling	site	defined	by	the	grid.	We	used	70x40μm	for	the	frame	size.	Cells	are	then	counted	at	each	sampling	site,	to	include	those	within	the	defined	counting	frame	and	those	that	lie	in	contact	with	the	upper	and	right	borders	of	the	frame	(coloured	green),	while	excluding	those	outside	the	counting	frame	or	in	contact	with	the	left	and	upper	borders	of	the	counting	frame	(coloured	red)	(Figure	2.7). Counts	 obtained	 by	 the	 optical	 fractionator	 were	 within	 the	 limits	 of	 the	Gundersen	mean	co-efficient	of	error	(COE)	of	0.05-0.1.	
d)	Interneuron	and	motor	Neuron	counts	Because	of	 the	 relatively	 low	numbers	 of	 interneurons,	 stereological	methods	prove	 inefficient	 for	 counting	 them	 (Cooper	 et	 al,	 1999).	 Therefore,	 counts	 of	interneurons	in	Laminae	IV-IX,	stained	for	calbindin	and	calretinin	were	carried	out	 manually	 in	 hemi-cords	 within	 a	 1	 in	 48	 series	 of	 sections	 at	 a	 10x	magnification	for	each	section.	Total	estimates	were	obtained	as	the	product	of	the	counted	cells,	periodicity	and	the	number	of	intervals.	
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Figure 2.8 – Optical fractionator cell counts. 
 (A-C) Example of defining the counting frame (A) and grid size (B) for the optical fractionator 
probes, showing the distribution of sampling sites over a given contour (C). (D) Sample image 
demonstrating the counting of cells within the borders. Cells within the frame and in contact 
with the green borders (upper, right) are counted (represented by blue dots) while cells either 
outside the frame or in contact with red borders (lower, left) are not counted (pink cross) 
e)	Measurement	of	axon	density	For	semi-thin	sections	stained	 for	 toluidine	blue,	axon	density	measures	were	obtained	 in	 the	 dorsal	 and	 ventral	 funiculi	 by	 means	 of	 line	 sampling	 using	
Stereoinvestigator	 software	 (MBF	Bioscience)	connected	 to	a	Zeiss	Axioskop	2	MOT	(Zeiss)	with	a	DAGE-MTI	CCD-100	camera	(DAGE-MTI),	whereby	a	vector	is	drawn	across	a	region	to	be	measured	and	regularly	distributed	sampling	sites	are	obtained.	The	counting	frame	was	25x25	μm	in	size.	The	numbers	of	axons	were	 then	 counted	 in	 each	 sampling	 site,	 using	 the	 same	 counting	 rules	 for	counting	frames	when	making	the	optical	fractionator	estimates.	Measures	were	obtained	 for	 a	 minimum	 of	 4	 sections	 per	 region	 of	 each	 spinal	 cord,	 and	expressed	as	the	number	of	axons	per	100	μm	sampled.		
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Table 2.3 – Grid sizes for optical fractionator counts in different regions. 
 
2.8	Thresholding	Image	Analysis.	If	 a	 protein	 or	 marker	 is	 densely	 distributed	 in	 a	 region,	 the	 intensity	 of	immunostaining	can	make	it	difficult	to	accurately	discriminate	individual	cells.	For	 example,	 GFAP	 staining	 for	 fibrous	 astrocytes	 within	 any	 given	 region.	Therefore,	 attempts	 to	quantify	 such	 staining	by	 the	use	of	 counting	methods	proved	difficult.	In	such	cases,	semi-automated	thresholding	image	analysis	was	employed	to	obtain	a	measure	of	 the	amount	of	staining	per	microscope	 field,	which	 can	 be	 compared	 across	 samples	 (Bible	 et	 al,	 2004;	 Kielar	 et	 al,	 2007;	Pontikis	et	al,	2004).		This	technique	was	employed	in	the	current	study	to	analyze	the	levels	of	glial	activation	 for	 astrocytes	 (GFAP)	and	microglia	 (CD68),	 lamiae	 I-III	 of	 sections	stained	 for	 interneuron	 markers	 (calbindin	 and	 calretinin)	 and	 for	 the	accumulation	of	autofluorescent	storage	material	(AFSM).	To	visualize	the	AFSM,	unstained	 sections	 were	 de-waxed	 in	 xylene	 (VWR)	 where	 required,	 and	mounted	on	slides.	These	were	then	coverslipped	with	Fluoromount-G	(Southern	Biotech)	mounting	medium.			Whether	for	quantifying	AFSM	or	an	immunoperoxidase	stained	marker	a	similar	sampling	method	was	used.	In	this	a	set	number	of	images	were	obtained	for	each	region	measured	–	30	non-overlapping	images	over	3	sections	per	region	using	
Region Grid Size (μm x μm) 
I. Brain  
a. Primary motor (M1) Cortex 225x225 
b. Primary somatosensory Barrel-field 
(S1BF) Cortex 
225x225 
c. Medial and Lateral Ventral Posterior 
Thalamic Nuclei (VPM/VPL)  
175x175 
d. Dorsal Lateral Geniculate Body of 
Thalamus (LGnD) 
125x125 
II. Spinal Cord (Dorsal and Ventral Horns) 150x150 
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a	40x	objective	(for	GFAP,	CD68	and	AFSM),	or	50	non-overlapping	images	from	5	sections	per	region	using	a	63x	objective.			Images	 for	 the	 CD68,	 GFAP,	 calbindin	 and	 calretinin	 stained	 sections	 were	obtained	using	a	Leica	DRMB	microscope	(Leica	Microscopy	&	GmBH,	Wetzlar,	Germany)	 with	 a	 Zeiss	 AxioCam	 HRc	 Rev	 2	 digital	 camera	 (Zeiss).	 Images	 of	autofluorescent	 storage	 material	 were	 obtained	 using	 a	 Leica	 SP5	 confocal	microscope	 (Leica	 Microsystems,	 Welwyn	 Garden	 City,	 UK).	 Images	 were	sampled	in	a	chosen	uniform	pattern,	so	as	to	sample	the	entire	region	of	interest,	while	not	sampling	adjacent	areas.	All	images	were	obtained	while	maintaining	consistent	parameters	of	 light	 intensity,	 camera	 setup	and	 calibrations.	 In	 the	case	 of	 confocal	 microscopy,	 a	 consistent	 relative	 relationship	 between	amplitude	offset	and	detector	gain	was	maintained	between	animals.			The	 obtained	 images	 were	 analyzed	 using	 Image	 Pro	 Plus	 software	 (Media	Cybernetics,	 Chicago,	 IL),	 to	 select	 appropriate	 thresholds	 for	 every	 region	(Figure2.8).	 Thresholds	 were	 chosen	 to	 best	 distinguish	 between	 specific	immunoreactivity	 for	 each	 antigen	 and	 the	 background.	 Results	 obtained	 for	each	region	and	each	antigen	was	expressed	as	%	immunoreactivity	per	image.	The	mean	percentage	immunoreactivity	per	region	per	animal	was	then	obtained	for	further	analysis.		For	the	analysis	of	Thy1-YFP	and	Thy1-YFP/Ppt1-/-	mouse	spinal	cords,	 images	were	captured	using	a	10x	objective	in	the	lumbar	regions	of	the	cords	using	a	confocal	microscope	similar	to	the	analysis	of	AFSM	(see	above).	 Images	were	analysed	using	ImageJ	(Schindelin	et	al,	2015;	Schneider	et	al,	2012)	to	calculate	relative	 fluorescence	 units	 by	 first	 converting	 images	 to	 black	 and	white	 and	expressing	 the	number	 of	white	 (fluorescent)	 pixels	 over	 the	 total	 number	 of	pixels.	 Three	 images	 were	 taken	 for	 each	 section	 and	 their	 values	 averaged.	Therefore,	the	average	relative	fluorescence	for	each	spinal	cord	was	obtained.	
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2.9	Qualitative	Analysis	Some	staining	was	able	to	provide	qualitative	information	about	the	distribution,	morphology	or	density	of	an	antigen,	without	the	need	for	quantification.	Images	were	 taken	 at	 required	magnifications	 using	 x5,	 x10,	 x20,	 x40,	 x63	 and	 x100	objectives	on	either	using	a	Leica	DRMB	microscope	(Leica	Microsystems)	with	a	Zeiss	AxioCam	HRc	Rev	2	digital	camera	(Zeiss)	for	bright	field	microscopy	or	a	Leica	SP5	confocal	microscope	(Leica	Microsystems)	for	confocal	images.	Images	were	then	carefully	examined	to	comment	on	the	nature	of	the	staining	in	these	sections.		
	 	
Figure 2.9 – Selecting thresholds for thresholding image analysis. 
Representative images showing positive GFAP (astrocyte) staining (left) and the selection of 
a threshold for red, green and blue channels so as to accurately discriminate positively 
immunostained cells from the background (right) using the Image Pro Plus software (Media 
Cybernetics).  









3.1	Introduction	In	CLN1	disease,	as	with	other	forms	of	NCL,	the	brain	has	been	considered	the	main	 locus	 of	 pathology	 (Cooper,	 2003;	 Haltia	 et	 al,	 1973a;	 Santavuori	 et	 al,	1973),	mainly	due	to	the	clinical	presentation	of	symptoms	(Dolisca	et	al,	2013).	The	extent	and	progression	of	pathological	 changes	occurring	 in	 the	brains	of	
Ppt1-/-	 mice	 has	 been	 described	 in	 detail,	 revealing	 extensive	 degenerative	changes	particularly	affecting	the	thalamocortical	system	and	cerebellum	(Bible	et	al,	2004;	Kielar	et	al,	2007;	Macauley	et	al,	2009).			While	 there	 have	 been	 a	 few	 reports	 that	 have	 briefly	mentioned	 spinal	 cord	pathology	in	the	NCLs	(Bruun	et	al,	1991;	Haltia	et	al,	1973a;	Haltia	et	al,	1973b),	there	has	been	no	detailed	analysis	of	pathology	in	this	region	of	the	CNS	in	any	form	of	these	diseases.	Furthermore,	the	characterization	of	brain	pathology	in	
Ppt1-/-	mice	so	far	has	not	fully	been	able	to	explain	the	sensorimotor	deficits	seen	in	 these	 mice	 (Dearborn	 et	 al,	 2015;	 Gupta	 et	 al,	 2001),	 and	 previous	experimental	 therapies	 targeting	 the	 brain	 have	 only	 had	 limited	 success	 for	CLN1	disease	(Lu	et	al,	2010;	Macauley	et	al,	2012;	Tamaki	et	al,	2009).		This	study	is	the	first	to	detail	the	nature,	extent	and	progression	of	pathological	changes	 occurring	 in	 the	 spinal	 cord	 in	 CLN1	 disease,	 utilizing	 histochemical	techniques	to	compare	spinal	cord	and	DRG	tissue	of	wildtype	control	(C57BL/6)	and	Ppt1-/-	mice,	as	well	as	post-mortem	 spinal	cord	samples	of	a	human	INCL	case	with	a	neurologically	normal	control.	
3.2	Altered	spinal	cord	volumes	in	Ppt1-/-	mice.	Progressive	 regional	 atrophy	of	 the	brain	has	previously	been	documented	 in	
Ppt1-/-	mice,	and	has	been	observed	as	early	as	5	months	of	age	(Kühl	et	al,	2013).	Therefore,	 to	 determine	whether	 the	 volume	 of	Ppt1-/-	 mouse	 spinal	 cords	 is	similarly	altered,	we	employed	a	Cavalieri	estimator	(Kühl	et	al,	2013;	Lucocq,	2007)	 to	 measure	 total	 volumes	 and	 gray	 matter	 volumes	 as	 previously	described	(Figure	2.5),	the	white	matter	volumes	were	calculated	as	a	subtractive	value	of	these	volumes.	As	already	mentioned	stated	in	chapter	1.5,	there	are	no	statistically	significant	difference	between	the	overall	body	weights	of	Ppt1-/-	and	
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wildtype	 control	mice	 at	 any	 age	 (Galvin	 et	 al,	 2008).	 As	 such,	 these	 volume	measurements	were	not	normalized	to	the	animals’	respective	body	weights.		The	 volume	 of	 the	 mouse	 spinal	 cord	 has	 been	 shown	 to	 increase	 during	development	 between	 1-3	 months	 of	 age,	 affecting	 both	 the	 white	 and	 gray	matter	 (Sakla,	 1959;	 Sakla,	 1962;	 Sakla,	 1969).	 A	 similar	 initial,	 significant	increase	was	 observed	 during	 these	 time-points	 in	 the	 total,	 gray	matter	 and	white	matter	volumes	of	the	wildtype	mouse	spinal	cords.	However,	the	regional	volumes	of	Ppt1-/-	mouse	spinal	cords	did	not	increase	to	the	same	extent	during	this	time.	This	may	suggest	a	possible	postnatal	developmental	delay	in	the	spinal	cords	of	these	mice	(Figure	3.1).			There	was	 a	 consistent,	 significant	 difference	 in	 all	 the	measured	 spinal	 cord	volumes	between	Ppt1-/-	and	control	mice	from	2	months	of	age.	This	difference	appeared	earlier	than	any	regional	volume	difference	seen	in	the	brain	(Kühl	et	al,	 2013).	 Furthermore,	 the	 difference	 observed	 in	 spinal	 cord	 white	 matter	volumes	was	a	novel	 finding,	 as	previous	 studies	of	brain	pathology	 in	Ppt1-/-	mice	had	not	 revealed	 any	 significant	 changes	 in	 brain	white	matter	 volumes	(Bible	et	al,	2004;	Kielar	et	al,	2007;	Kühl	et	al,	2013).			The	patterns	of	altered	spinal	cord	volumes	observed	in	the	cervical,	thoracic	and	lumbo-sacral	spinal	cord	segments	of	Ppt1-/-	mice	were	similar	to	those	for	whole	cord	volumes	(Figure	3.2),	suggesting	that	these	volumetric	changes	do	not	have	any	regional	specificity,	as	they	do	in	the	brain,	and	that	the	spinal	cord	as	a	whole	seems	to	be	affected	at	all	levels	at	the	same	time	in	these	mice.				
3.3	Profound	neuron	loss	in	Ppt1-/-	mouse	spinal	cords.	Being	 a	 severely	 neurodegenerative	 disease,	 a	 prominent	 feature	 of	 CLN1	pathology	 is	 the	 profound	 loss	 of	 neurons	with	 disease	 progression	 (Cooper,	2003;	Kohlschutter	&	Schulz,	2009).		Significant	neuron	loss	is	observed	in	the	brains	of	Ppt1-/-	mice	from	5	months	of	age,	with	the	thalamus	and	cerebellum	being	 affected	 first	 (Kielar	 et	 al,	 2007;	 Macauley	 et	 al,	 2009).	 To	 determine	whether	there	was	a	similar	pathology	present	in	the	spinal	cords	of	these	mice,	
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40μm	 spinal	 cord	 sections	 were	 Nissl	 stained	 to	 visualize	 neuronal	cytoarchitechture,	 in	 addition	 to	 markers	 for	 specific	 neuronal	 populations.	Unbiased	 stereological	 estimates	 as	 well	 as	 thresholding	 image	 analysis	 of	neuronal	numbers	were	then	obtained	from	these	stained	sections.	As	before,		in	the	 absence	 of	 significant	 differences	 in	 body	 weight	 between	 Ppt1-/-	 and	wildtype	control	mice	(Galvin	et	al,	2008),	these	stereological	counts	were	not	normalized	to	the	animals’	respective	body	weights.		
	
Figure 3.1 – Altered spinal cord volumes in Ppt1-/- mice. 
Decreased volumes of the whole spinal cord by Cavalieri estimates, were evident in Ppt1 
deficient (Ppt1-/-) mice, as compared to age-matched wildtype controls (WT) as early as 2 
months of age in total, gray matter and white matter volumes. **p<0.01, ***p<0.001, 
****p<0.0001, two-tailed unpaired parametric t-test. Values shown are non-continuous 
observations from each cohort at each time point as mean ± Standard Error of the Mean 






















































































































































































































































































a)	Early	loss	of	neurons	at	all	levels	of	Ppt1-/-	mouse	spinal	cords.			To	determine	if	there	was	any	loss	of	neurons	in	Ppt1-/-	mouse	spinal	cords,	a	1	in	48	series	of	spinal	cord	sections	 from	1,	2,	3,	5	and	7	month	old	Ppt1-/-	and	wildtype	mice	were	Nissl	stained	with	cresyl	fast	violet.	The	dorsal	and	ventral	horns	were	counted	separately	to	represent	the	sensory	and	motor	regions	of	the	spinal	gray	matter.	Neurons	in	both	of	these	regions	were	counted	in	the	cervical,	thoracic	and	 lumbo-sacral	 spinal	cord	segments	using	an	design-based	optical	fractionator	(West,	2002),	with	the	regions	delineated	according	to	landmarks	in	a	spinal	cord	atlas	(Sengul,	2013).			These	data	revealed	that	there	was	an	early	and	profound	loss	of	neurons	at	all	levels	of	the	Ppt1-/-	mouse	spinal	cord	(Figure	3.3).	Significant	neuron	loss	was	observed	 in	 both	 the	dorsal	 and	 ventral	 horns,	with	 some	 regions	 affected	 as	early	as	3	months,	namely	the	dorsal	horns	of	the	cervical	and	lumbosacral	region	and	the	ventral	horn	of	the	thoracic	region.	All	regions	of	the	spinal	cord	showed	significant	neuron	loss	from	5	months	onwards,	which	worsened	with	time.	This	loss	of	neurons	is	further	illustrated	in	Table	3.1,	which	shows	that	there	is	an	average	loss	of	14.89%	of	neurons	in	the	dorsal	horn	and	9.31%	in	the	ventral	horn	 of	 Ppt1-/-	 mice,	 compared	 to	 their	 wildtype	 counterparts	 as	 early	 as	 3	months	of	age.	These	values	then	significantly	progress	to	34.4%	and	28.61%	at	7	 months	 respectively.	 These	 data	 further	 emphasize	 the	 progressive	 and	profound	 nature	 of	 neuron	 loss	 in	 the	 spinal	 cord	 of	 these	mice.	 Indeed,	 the	severity	of	this	neuron	loss	is	comparable	to	that	seen	in	Cln8	(Cln8mnd)	(Fujita	et	al,	1998;	Plummer	et	al,	1995)	as	well	as	to	other	models	of	neurodegenerative	diseases	affecting	the	spinal	cord	such	as	ALS	(Dal	Canto	&	Gurney,	1997;	Ravits	et	al,	2007)and	SMA(Simone	et	al,	2016;	Sleigh	et	al,	2011),	Parkinson’s	disease	(Martin	et	al,	2006;	Vivacqua	et	al,	2011),	Alzheimer’s	disease	(Seo	et	al,	2010)	and	HD	(Valadao	et	al,	2016).		This	neuron	 loss	occurs	earlier	 than	 that	 seen	 in	 the	brain,	which	begins	at	5	months	of	age	(Kielar	et	al,	2007).	Furthermore,	as	with	the	volume	changes,	all	levels	of	the	cord	seem	to	be	affected	at	the	same	time,	with	little	rostro-caudal	variation.	This	is	in	marked	contrast	to	the	region-specific	pattern	of	neuron	loss	
		 83	
seen	in	the	brain	(Kielar	et	al,	2007).	The	early	onset	of	such	profound	neuron	loss	 in	the	spinal	cords	of	Ppt1-/-	mice	 is	 indicative	that	 this	region	 is	severely	affected	 by	 CLN1	 disease	 and	 raises	 the	 possibility	 that	 it	 may	 contribute	 to	disease	progression.	
b)	Loss	of	GABAergic	interneurons	in	Ppt1-/-	mouse	spinal	cords.		Interneuron	populations	are	severely	affected	early	in	disease	progression	in	the	brains	of	Ppt1-/-	mice	(Bible	et	al,	2004;	Kielar	et	al,	2007).	Interneurons	form	a	large	 subset	 of	 the	 neurons	 in	 the	 spinal	 cord	 and	 are	 critical	 to	 the	 normal	functioning	of	spinal	neural	networks	(Edgley,	2001;	Jankowska,	2001).	
 
Figure 3.3 – Early neuron loss in spinal cords of Ppt1-/- mice. 
Unbiased optical fractionator counts reveal the significant loss of Nissl (cresyl fast violet) 
stained neurons in the dorsal and ventral horn of the cervical, thoracic and lumbosacral cord 
of Ppt1 deficient (Ppt1-/-) mice beginning as early as 3 months of age, compared to age-
matched wildtype controls (WT). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, two-tailed, 
unpaired parametric t-test. Values shown are non-continuous observations from each cohort 
at each time point as  mean ± SEM. (n= 5 mice/group).	
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% Loss of neurons 
(Ppt1-/- : WT) 
Dorsal Horn Ventral Horn 
Cervical Thoracic Lumbo- 
Sacral 
Average Cervical Thoracic Lumbo- 
Sacral 
Average 
1 MO -0.55 0.63 2.22 0.76 0.38 2.66 5.59 2.88 
2 MO 3.16 3.19 4.31 3.55 -1.52 -0.50 9.06 2.34 
3 MO 11.17 5.08 28.42 14.89 3.47 12.33 12.15 9.31 
5 MO 35.36 15.64 30.65 27.22 16.25 28.95 30.62 25.27 
7 MO 41.20 25.82 36.19 34.40 29.65 25.09 31.10 28.61 	
Table 3.1 – Percentage loss of neurons in Nissl stained sections 
Table showing the percentage loss of neurons in Nissl stained sections of Ppt1deficient (Ppt1-
/-) mice to wildtype (WT) mice from the averaged neuron counts (n=5 mice/group) at each time 
point in the dorsal and vental horns. Negative (-) values indicte lower WT neuron counts than 
in Ppt1-/- mice. Average is the combined average of cervical, thoracic and lumbo-sacral values 
at each time point.				Staining	for	CB	and	CR	revealed	a	dense	band	of	interneurons	and	their	terminals	in	 laminae	 I-III	 of	 the	 gray	matter	with	 sparsely	 scattered	 interneurons,	with	intensely	stained	cell	bodies	in	the	remaining	gray	matter	of	spinal	cord	sections	(Rexed,	 1954)	 (Figure	 3.4A,	 3.5A).	 Our	 analysis	 therefore	 employed	 semi-automated	thresholding	 image	analysis	 for	the	neuron	dense	 laminae	I-III	and	stereological	 counts	of	neurons	 in	 laminae	 IV-IX	of	each	section.	Results	were	obtained	for	the	cervical,	thoracic	and	lumbo-sacral	spinal	cord	segments	at	all	ages.		These	 analyses	 of	 sections	 stained	 for	 calbindin	 (CB)	 revealed	 a	 significant	decrease	in	the	number	of	these	neurons	as	early	as	3	months	of	age	in	laminae	IV-IX	at	all	levels	of	the	cord	of	Ppt1-/-	mice	(Figure	3.4B).	There	was	also	a	similar	significant	decrease	in	laminae	I-III	of	the	cervical	cord	starting	at	3	months,	and	
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in	the	thoracic	and	lumbo-sacral	segments	at	5	months.	These	data	suggest	that	this	loss	of	CB	positive	interneurons	is	at	least	partly	responsible	for	the	loss	of	neurons	 observed	 in	 Nissl-stained	 sections	 in	 Ppt1-/-	 mice.	 The	 early	 loss	 of	calbindin	positive	interneurons	in	the	spinal	cord	is	similar	to	events	in	the	brain,	where	calbindin	positive	 interneurons	have	been	shown	 to	be	one	of	 the	 first	neuron	populations	to	be	lost	in	the	forebrain	of	Ppt1-/-	mice	(Kielar	et	al,	2007).			Similar	analysis	of	sections	stained	for	calretinin	(CR)	revealed	that	there	was	also	a	significant	loss	of	these	neuron	populations	in	Ppt1-/-	mice	(Figure	3.5B).	There	was	significant	loss	of	CR	positive	neurons	at	all	levels	at	5	months,	with	laminae	IV-IX	of	the	cervical	and	lumbo-sacral	segments	showing	significant	loss	as	early	as	3	months	of	age.	Again,	this	was	similar	to	events	in	the	brain,	where	the	loss	of	calretinin	positive	interneurons	seems	to	follow	the	loss	of	calbindin	positive	neurons	in	Ppt1-/-	mice	(Kielar	et	al,	2007).		These	data	show	that	similar	interneuron	populations	are	affected	in	the	Ppt1-/-	mouse	 spinal	 cord	 as	 they	 are	 in	 the	 brain,	 but	 at	 an	 earlier	 time	 point.	Furthermore,	unlike	the	brain,	there	was	no	regional	specificity	of	this	neuron	loss,	with	all	levels	of	the	cord	equally	affected.	These	data,	along	with	the	counts	of	Nissl	stained	sections,	provide	further	evidence	for	severe	neurodegenerative	pathology	 in	 the	 spinal	 cord	of	Ppt1-/-	mice.	 It	will	 therefore	be	 interesting	 to	study	whether	there	is	aberrant	Ca2+		homeostasis	in	the	spinal	cords	of	Ppt1-/-,	as	 is	 seen	 in	 JNCL	 (Fossale	 et	 al,	 2004;	 Luiro	 et	 al,	 2006)	 as	well	 as	 in	 other	lysosomal	storage	disorders	(Kiselyov	et	al,	2010).	
c)	Loss	of	motor	neurons	in	Ppt1-/-	mouse	spinal	cords.		Motor	 neurons	 play	 a	 critical	 role	 in	 relaying	 signals	 along	 motor	 pathways	(Romanes,	1964).	To	determine	whether	these	neuron	populations	are	lost	in	the	
Ppt1-/-	mouse	spinal	cord,	we	initially	immunostained	sections	for	two	markers	of	 motor	 neurons,	 choline	 acetyl	 transferase	 (ChAT)	 and	 the	 anti-transferrin	receptor	maker,	CD-71.			
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Sections	stained	for	both	ChAT	and	CD-71	showed	a	consistency	in	marking	pools	of	large	motor	neurons	with	varying	staining	intensities.	Counts	of	cells	marked	with	either	marker	were	compared	between	wildtype	and	Ppt1-/-	mouse	spinal	cord	 sections	 in	 the	 lumbosacral	 region	 at	 7	 months	 of	 age.	 	 This	 analysis	demonstrated	a	consistency	in	detecting	motor	neuron	populations	in	this	region	of	 the	 spinal	 cord,	with	 a	 significant	 loss	 of	motor	 neurons	 stained	 for	 either	marker	observed	in	the	Ppt1-/-	deficient	cords	(Figure	3.6	A).	Additional	counts	of	CD-71	stained	neurons	in	the	cervical,	thoracic	and	lumbosacral	segments	of	wildtype	and	Ppt1-/-	spinal	cords	showed	that	there	was	indeed	significant	loss	of	motor	neurons	at	5	months	of	age	at	all	levels	(Figure	3.6	C),	which	seemed	to	worsen	similarly	at	all	levels	of	the	cord	until	7	months.			This	 loss	 of	 motor	 neurons	 in	 Ppt1-/-	 mouse	 spinal	 cords	 is	 a	 previously	undocumented	phenotype,	and	may	help	to	better	explain	the	motor	deficits	seen	in	these	mice	(Chapter	4).	As	altered	homeostasis	of	iron	is	a	common	feature	in	neurodegenerative	states	in	motor	neurons	(Carri	et	al,	2003;	Yu	et	al,	2009)	as	well	 as	 in	 the	NCLs	 (Grubman	et	 al,	 2014),	 it	will	 also	be	 interesting	 to	 study	whether	the	expression	of	CD-71	is	altered	in	the	surviving	motor	neurons.		
3.4	Accumulation	of	autofluorescent	storage	material	in	Ppt1-/-	
mouse	spinal	cords.	The	 progressive	 accumulation	 of	 autofluorescent	 storage	material	 within	 cell	bodies	 is	 pathognomic	of	 the	NCLs	 (Cooper,	 2003;	Mole	 et	 al,	 2005).	 In	CLN1	disease,	 the	 intralysosomal	 accumulations	 of	 granular	 autofluorescent	osmiophillic	deposits	have	been	shown	to	be	present	in	the	CNS	(Tyynela	et	al,	1993),	as	well	as	visceral	tissue	(Galvin	et	al,	2008).	While	there	is	little	evidence	to	 suggest	 that	 this	 storage	material	 is	 directly	 causative	 of	 neuron	 loss,	 the	progressive	 accumulation	 is	 easily	 visualized	 via	 fluorescence	 or	 confocal	microscopy	and	therefore	makes	a	useful	readout	of	disease	burden.			
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Figure 3.4 – Loss of Calbindin positive interneurons in Ppt1-/- mouse spinal cords.  
(A) Representative images of a lumbo-sacral spinal cord section stained for calbindin at low 
magnification (left) showing Laminae I-III as a dense band of interneurons in the dorsal horn 
of the gray matter with sparsely scattered interneurons in the remaining laminae, and at higher 
magnification (right) showing neurons stained for calbindin. Scale bars = 200μm (left panel) 
and 25μm (right panel). (B) Thresholding image analysis (Laminae I-III) and stereological 
counts (Laminae IV-IX) show significant loss of calbindin positive neurons as early as 3 
months at all levels of the cord. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, two-tailed, 
unpaired parametric t-test. Values shown are non-continuous observations from each cohort 
at each time point as mean ± SEM. (n= 5 mice/group). 
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Figure 3.5 – Loss of Calretinin positive interneurons in Ppt1-/- mouse spinal cords.  
(A) Representative images of a lumbo-sacral spinal cord section stained for calretinin (left) at 
low magnification showing Laminae I-III as a dense band of interneurons in the dorsal horn of 
the gray matter with sparse interneurons in the remaining laminae, and at higher magnification 
(right) showing neuronal cells stained for calretinin. Scale bars = 200μm (left panel) and 25μm 
(right panel). (B) Thresholding image analysis (Laminae I-III) and stereological counts 
(Laminae IV-IX) show significant loss of calretinin positive neurons as early as 3 months in 
the cervical and lumbosacral laminae IV-IX. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, two-
tailed, unpaired parametric t-test. Values shown are non-continuous observations from each 





Figure 3.6 - Loss of motor neurons in Ppt1-/- mouse spinal cords.  
(A) Representative images of a lumbo-sacral spinal cord section stained for the anti-transferrin 
receptor marker, CD-71 showing pools of motor neurons in the ventral horn. CD-71 positive 
motor neurons show a varying degree of staining intensities (Insert). Scale bars = 200μm and 
25μm (insert).  (B) Stereological counts of ChAT and CD-71 positive cells in the lumbosacral 
region at 7 months revealed consistent counts with either marker, demonstrating a significant 
loss of motor neurons in Ppt1 deficient (Ppt1-/-) spinal cords. (C) Stereological counts of CD-
71 positive cells in the ventral horns of the cervical, thoracic and lumbosacral spinal cord 
showed a significant loss of motor neuron populations at all levels starting at 5 months in Ppt1 
deficient (Ppt1-/-) mice compared to wildtype (WT) controls. **p<0.01, ****p<0.0001, two-tailed, 
unpaired parametric t-test. Values shown are non-continuous observations from each cohort 
at each time point as mean ± SEM. (n= 5 mice/group). 
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A	confocal	microscopy	survey	of	Ppt1-/-	spinal	cord	sections	revealed	that	there	was	a	similar	accumulation	of	autofluorescent	storage	material	within	the	gray	matter	of	the	spinal	cord	at	all	levels,	starting	at	3	months	of	age	(Figure	3.7).	This	provides	further	evidence	of	a	disease	process	occurring	in	the	spinal	cord	at	this	early	 time	point.	 This	 storage	material	 initially	 seemed	 localized	 to	 cells	with	neuronal	morphology,	but	 increasingly	also	appeared	as	dense	clusters	within	smaller	cells	starting	at	5	months	of	age.			In	 light	 of	 previous	 evidence	 of	 re-distribution	 of	 the	 autofluorescent	 storage	material	 to	microglial	 cells	 in	 a	 sheep	model	 of	NCL	 (Oswald	 et	 al,	 2005),	we	hypothesized	 that	 a	 similar	 process	may	 occur	 in	Ppt1-/-	 mouse	 spinal	 cords.	Selected	sections	from	cervical	and	lumbosacral	spinal	cords	at	each	time	point	were	stained	with	CD68,	a	marker	for	microglia.	Confocal	microscopy	was	then	used	 to	 simultaneously	 visualize	 these	 stained	 microglia	 and	 the	 storage	material.		The	 staining	 revealed	 that	 some	 of	 the	 autofluorescent	 storage	 material	 was	indeed	localized	within	CD68	positive	activated	microglia	starting	at	5	months	of	age	(Figure	3.8).	This	re-distribution	may	be	effected	by	the	activated	microglia	phagocytizing	 degenerating	 neurons,	 providing	 further	 evidence	 of	 a	pathological	process	in	the	spinal	cord	before	that	which	appears	in	the	brain.		
3.5	Hypertrophy	of	neuronal	populations	in	Ppt1-/-	mouse	spinal	





























































































































































































































































Figure 3.8 - Re-distribution of autofluorescent storage material in Ppt1-/- mouse spinal 
cords. 
Representative confocal microscope images of the ventral horn of the lumbosacral spinal cord 
of Ppt1-/- mice stained for the microglial marker CD68 (red). From 5 months onwards 
progressively more of this storage material (488nm (green) and 633nm (red) channels) was 
also present within CD68 positive microglia (633nm, red), appearing yellow in the merged 
overlay (white arrows). Scale bar = 25μm.  	 	
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To	determine	if	such	a	phenotype	was	present	in	the	spinal	cords	of	7	month	old	
Ppt1-/-	mice,	we	measured	 the	 cross-sectional	 cell	 body	 area	 of	 calbindin	 and	calretinin	 positive	 interneurons,	 as	 well	 as	 Nissl	 stained	motor	 neurons.	 The	latter	were	identified	by	their	location	and	morphology	within	the	ventral	horn	of	the	spinal	cord	(Romanes,	1964;	Sengul,	2013).			Analysis	of	average	cell	areas	revealed	a	significant	increase	in	the	size	of	both	calbindin	and	calretinin	positive	interneurons,	as	well	as	that	of	motor	neurons,	at	all	 levels	of	 the	cord	 in	7	month	old	Ppt1-/-	mice	(Figure	3.9).	This	provides	further	evidence	for	similar	pathological	changes	in	spinal	cord	neurons	as	there	are	in	the	brain	(Bible	et	al,	2004;	Kielar	et	al,	2007).		
































































































































































































































































Figure 3.10 – Synaptic marker distribution in the spinal cord of Ppt1-/- mice. 
Representative images of the ventral horn of the cervical spinal cord of 7 month old Ppt1-/- 
mice stained for various synaptic markers showing slightly altered distribution of 
Synaptophysin and SNAP25, dense aggregates of VAMP2 within cell bodies and increased 
intensity of PSD-95 staining in Ppt1 deficient (Ppt1-/-) mouse spinal cord sections as compared 




Figure 3.11 – Dorsal Root Ganglion (DRG) pathology in Ppt1-/- mice. 
(A) Nissl stained neurons in the DRGs of 7 month old Ppt1-/- mice appear shrunken and more 
darkly stained with some pale neurons as compared to wildtype (WT) controls.  (B) 
Representative confocal images of unstained DRG sections show the characteristic 
accumulation of autofluorescent storage material in Ppt1-/- mouse DRGs at 7 months 
compared to age-matched WT controls. Scale bars = 100μm and 25μm (inserts). 	Nissl	staining	showed	Ppt1-/-	mouse	DRGs	to	have	neurons	with	generally	denser	cytoplasmic	 staining	 than	 the	wildtype	DRGs,	 along	with	 some	 palely	 stained	cells,	presumably	due	to	the	accumulation	of	storage	material	(Figure	3.11).	This	was	confirmed	by	confocal	microscopy,	where	cells	 in	 the	Ppt1-/-	mouse	DRGs	were	shown	to	contain	punctate	autofluorescent	storage	material.	
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These	data	show	there	to	be	similar	pathology	in	the	DRG,	as	there	is	in	the	spinal	cord	of	Ppt1-/-	mice.	However,	staining	these	tissues	for	GFAP	to	 label	satellite	cells,	as	well	as	a	combination	of	CD4	and	CD8	to	stain	peripheral	lymphocytes	(Hanani,	2005;	Scholz	&	Woolf,	2007),	did	not	show	any		positive	staining	for	any	of	these	antigens	(data	not	shown).	Therefore,	having	demonstrated	the	presence	of	pathology	at	7	months	in	the	lumbar	DRGs	of	Ppt1-/-	mice,	further	work	will	now	 be	 required	 to	 detail	 the	 progression	 and	 extent	 of	 this	 pathology.	 This	anysis	should	include	investigating	the	potential	presence	of	any	inflammatory	phenotype,	 within	 DRGs	 at	 various	 levels	 of	 the	 cord	 in	 order	 to	 provide	 a	comprehensive	understanding	of	when	and	how	these	primary	sensory	neurons	are	affected	in	these	mice.	 
3.8	 Early	 onset	 innate	 and	 adaptive	 immune	 response	 in	 the	
Ppt1-/-	mouse	spinal	cord.	Profound	astrocytosis	and	microglial	activation	are	a	prominent	feature	of	the	pathology	seen	in	Ppt1-/-	mouse	brains,	and	have	been	shown	to	occur	in	the	same	regions	 of	 the	 brains	 of	 Ppt1-/-	 mice	 as	 where	 neuron	 loss	 occurs,	 typically	preceding	neurodegeneration	(Bible	et	al,	2004;	Kielar	et	al,	2007).	To	determine	whether	a	similar	glial	response	occurs	in	the	spinal	cords	of	these	mice,	sections	from	the	cervical,	thoracic	and	lumbosacral	segments	of	the	spinal	cord	of	1,	2,	3,	5	 and	 7	 month	 old	 Ppt1-/-	 and	 wildtype	 mice	 were	 immunostained	 for	 Glial	Fibrillary	 Associated	 Protein	 (GFAP)	 to	 mark	 astrocytes	 and	 CD68	 to	 mark	microglia.	 The	 forebrain	 of	 Ppt1-/-	 mice	 is	 also	 progressively	 infiltrated	 by	peripheral	lymphocytes,	both	by	cytotoxic	and	helper	T	cells	(Groh	et	al,	2013).	Therefore,	 sections	 from	 1,	 3,	 5	 and	 7	month	 old	Ppt1-/-	and	wildtype	mouse	spinal	 cords	 were	 immunostained	 for	 CD4	 and	 CD8	 to	 mark	 peripheral	lymphocytes.		
a)	Astrocytosis	in	the	Ppt1-/-	mouse	spinal	cord.	In	the	brain,	there	are	fibrous	astrocytes	in	the	white	matter	and	protoplasmic	astrocytes	in	the	gray	matter.	Fibrous	astrocytes	show	intense	GFAP	staining	in	white	matter	in	the	brains	of	both	the	wildtype	and	Ppt1-/-	mice	(Bible	et	al,	2004;	Kielar	et	al,	2007).	Similarly,	in	the	spinal	cord,	GFAP	staining	revealed	intense	staining	 of	 fibrous	 astrocytes	 in	 the	 white	 matter.	 However,	 as	 compared	 to	
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wildtype	controls,	in	the	spinal	gray	matter	of	Ppt1-/-	mice	there	was	early	and	profound	astrocytosis.	Many	more	positively	stained	astrocytes	was	observed	in	the	dorsal	and	ventral	horns	at	all	levels	of	the	cord	of	Ppt1-/-	mice	as	early	as	3	months.	 These	 astrocytes	 were	 present	 throughout	 the	 gray	 matter	 with	 no	obvious	laminar	specificity.	At	5	and	7	months,	these	astrocytes	almost	covered	the	entirety	of	the	gray	matter	of	Ppt1-/-	mouse	spinal	cord	sections	(Figure	3.12	A).			Upon	 viewing	 these	 sections	 at	 higher	 magnification,	 wildtype	 spinal	 cords	showed	only	scarce	GFAP	positive	protoplasmic	astrocytes	 in	 the	gray	matter,	which	were	faintly	stained	with	small	cell	bodies	and	numerous	thin	processes.	A	similar	distribution	and	staining	of	astrocytes	was	present	at	all	ages	in	these	mice.	 In	contrast,	 from	3	months	of	age,	Ppt1-/-	mouse	spinal	cords	showed	an	increased	abundance	of	darkly	stained	reactive	astrocytes	with	relatively	fewer	thickened	processes.	There	was	an	increased	abundance	of	astrocytes	with	this	typically	activated	morphology	at	5	and	7	months	of	age	(Figure	3.12	B).		Thresholding	image	analysis	was	performed	to	quantify	these	observations	and	this	analysis	showed	that	there	was	a	significant	astrocytosis	at	all	levels	of	the	
Ppt1-/-	mouse	spinal	cord,	as	early	as	2	months,	which	was	seen	in	both	the	dorsal	and	ventral	horns,	and	further	increased	with	age	(Figure	3.12	C).	This	is	similar	to	events	in	the	forebrain	of	these	mice,	where	astrocytosis	precedes	neuron	loss.	However,	compared	to	the	brain,	there	was	significant	astrocytosis	in	the	cord	at	a	very	early	time	point	and	there	was	no	regional	specificity,	with	all	levels	of	the	
Ppt1-/-	 mouse	 spinal	 cord	 affected	 uniformly.	 This	 pattern	 of	 astrocytosis,	however,	is	very	similar	to	the	neuron	loss	described	above	(Chapter	3.3),	and	further	emphasizes	the	close	relationship	between	astrocytosis	and	neuron	loss.	
b)	Microglial	activation	in	Ppt1-/-	mouse	spinal	cords.	As	with	 astrocytosis,	 sections	 of	Ppt1-/-	mouse	 spinal	 cords	 showed	 increased	intensity	of	CD68	staining	in	the	gray	matter	as	early	as	3	months	of	age.	This	increased	immunoreactivity	was	observed	in	both	the	dorsal	and	ventral	horns,	with	 no	 laminar	 specificity,	 and	 was	 present	 at	 all	 levels	 of	 the	 cord.	 The	
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abundance	of	these	positively	stained	microglia	continued	to	increase	at	5	and	7	months	of	age	(Figure	3.13	A).	In	the	wildtype	spinal	cords,	CD68	staining	revealed	several	faintly	stained	cells,	with	small	cell	bodies	and	a	sometimes	“dotted”	or	punctate	appearance	typical	of	resting	or	quiescent	microglia.	This	appearance	of	microglia	did	not	seem	to	change	with	age	in	these	wildtype	mice.	At	3	months	of	age,	Ppt1-/-	mouse	spinal	cords	showed	microglia	that	stained	more	intensely	with	larger	cell	bodies	and	shortened	processes,	typical	of	activated	brain	macrophages.	The	abundance	and	intensity	of	staining	of	these	cells	continued	to	increase	with	age	in	these	mutant	mice	(Figure	3.13	B).		Quantification	 of	 these	 observations	 by	 thresholding	 image	 analysis	 showed	there	to	be	a	significant	increase	in	microglial	activation,	as	early	as	2	months	of	age	 in	Ppt1-/-	mouse	 spinal	 cords,	which	 further	 increased	with	 age.	This	was	observed	in	the	dorsal	and	ventral	horns	at	all	levels	of	the	cord	(Figure	3.13	C).	Therefore,	as	with	astrocytosis,	microglial	activation	seems	to	precede	neuron	loss	in	Ppt1-/-	mouse	spinal	cords,	occurring	earlier	than	in	the	brain	and	showing	no	regional	specificity	for	any	one	level	of	the	cord.			Furthermore,	examining	microglia	in	the	white	matter	of	7	month	old	Ppt1-/-	mice	revealed	a	similar	brain	macrophage-like	morphology	to	those	in	the	gray	matter.	Thresholding	image	analysis	was	therefore	additionally	performed	for	the	dorsal	and	 ventral	 funiculi	 of	 the	white	matter	 in	 cervical	 and	 lumbosacral	 cords	 of	wildtype	and	Ppt1-/-	mice.	This	analysis	revealed	significant	microglial	activation	within	these	white	matter	fiber	tracts	at	very	early	time	points	in	all	regions	in	




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.14 - Progressive microglial activation in the white matter of Ppt1-/- mouse 
spinal cords.  
Thresholding image analysis of CD68 stained sections reveals a significant increase in 
staining intensity as early as 1 month of age in the dorsal and ventral funiculi of Ppt1-/- mice, 
compared to WT controls, which increases with time, showing a drastic increase at 7 months. 
*p<0.05, ***p<0.001,****p<0.0001, two-tailed, unpaired parametric t-test. Values shown are 
non-continuous observations from each cohort at each time point as mean ± SEM. (n= 5 
mice/group). 
 pronounced	pathological	process	in	the	white	matter	of	the	Ppt1-/-	mouse	spinal	cord,	something	that	is	not	observed	in	the	brain.	
c)	Peripheral	lymphocyte	infiltration	of	Ppt1-/-	mouse	spinal	cords.	Selected	 sections	 from	 the	 cervical,	 thoracic	 and	 lumbosacral	 spinal	 cords	 of	wildtype	and	Ppt1-/-	mice	were	immunostained	with	a	combination	of	CD4	and	CD8	to	detect	the	presence	of	peripheral	lymphocytes.			Positively	stained	cells	were	not	seen	in	any	of	the	wildtype	spinal	cord	sections.	However,	as	early	as	three	months,	single	cells	and	small	clusters	of	CD4	and	CD8	positively	stained	cells	were	detected	in	the	gray	matter	of	Ppt1-/-	mouse	spinal	cords.	 This	 is	 consistent	 with	 infiltration	 from	 the	 vasculature	 of	 the	 central	canal.	However,	there	was	no	evidence	of	any	overt	perivascular	cuffing.	At	5	and	7	months,	there	was	an	increased	abundance	of	CD4	and	CD8	positive	cells	in	the	
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gray	 matter,	 with	 only	 the	 occasional	 lymphocyte	 seen	 in	 the	 white	 matter	(Figure	3.15).	Taken	together,	these	observations	suggest	that	there	is	an	early,	low-level	infiltration	of	peripheral	lymphocytes	in	the	spinal	cord,	similar	to	that	seen	in	the	brain.		
3.9	White	matter	pathology	in	Ppt1-/-	mouse	spinal	cords	While	there	was	no	appreciable	pathology	observed	in	the	white	matter	of	Ppt1-
/-	mice	brains	(Bible	et	al,	2004),	the	differences	in	white	matter	volumes	(Figures	3.1,	 3.2),	 as	well	 as	 progressive	microglial	 activation	within	 the	white	matter	(Figure	 3.14)	 of	 Ppt1-/-	 spinal	 cords	 suggested	 that	 there	 was	 previously	undocumented	pathology	in	the	spinal	white	matter	of	these	mice.			To	study	myelin	changes,	we	stained	selected	cervical	and	lumbo-sacral	sections	at	1,	3,	5	and	7	month	time	points	for	luxol	fast	blue,	a	marker	of	myelin	(Figure	3.16	A),	but	there	was	little	observable	difference	between	the	genotypes,	even	at	 end-stage	 time	 points.	 Staining	 for	 myelin	 basic	 protein	 (MBP)	 revealed		clusters	of	intense	MBP	immunoreactivity	starting	at	5	months	in	Ppt1-/-	mouse	cords	at	the	cervical	and	lumbosacral	levels,	with	a	general	disorganization	of	the	distribution	of	MBP	staining	(Figure	3.16	B).		In	 order	 to	 study	 axonal	 changes,	 we	 stained	 spinal	 cord	 sections	 with	 an	antibody	 against	 Neurofilament-H	 200kD,	 and	 this	 revealed	 a	 decrease	 in	staining	intensity	in	Ppt1-/-	mice	at	7	months,	with	patches	of	markedly	decreased	staining	 in	 the	 dorsal	 and	 ventral	 funiculi,	 compared	 to	 wildtype	 controls	(Figure3.16	C).	This	decrease	in	neurofilament-H	staining	intensity	is	consistent	with	axonal	loss	(Wujek	et	al,	2002).	To	further	investigate	this	apparent	axonal	loss,	semi-thin	sections	of	&	month	old	mice	were	stained	with	toluidine	blue-O.		This	revealed	similar	findings	to	that	seen	in	MBP	staining,	with	Ppt1-/-	mouse	cords	showing	a	general	vacuolar	disorganization	of	axon	bundles.	There	were	also	 many	 myelin	 dense	 bodies	 (MDB)	 scattered	 throughout	 the	 dorsal	 and	ventral	funiculi,	similar	to	the	axonal	spheroids		 	
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Figure 3.15 - Progressive lymphocyte infiltration activation of Ppt1-/- mouse spinal 
cords.  
Representative images of lumbosacral spinal cord sections showing an increased abundance 
of CD4/CD8 positive cells in the gray matter of Ppt1 deficient (Ppt1-/-) mice compared to 
















































































































































































































































































Figure 3.17 – Axon loss in the white matter of Ppt1-/- mouse spinal cords.  
(A) Representative images of the ventral funiculi of lumbosacral semi-thin spinal cord sections 
stained for Toluidine Blue showing general disorganization of axons (including apparent 
vacuolar degeneration, white spaces) along with Myelin Dense Bodies (Black arrows), scale 
bars = 20μm (Left). Line sampling of toluidine blue stained semi-thin sections showed a trend 
towards decreased axon density in the cervical and lumbosacral dorsal funiculi of Ppt1-/- mice, 
and a significant decrease in axon density in the corresponding ventral funiculi. *p<0.05, 
**p<0.01, two-tailed, unpaired parametric t-test (right). (B) Confocal images from the 
lumbosacral spinal cord of Thy1-YFP/Ppt1-/- mice reveal the marked loss of axons loss from 
the white matter of these mice compared to Thy1-YFP mice, in which many YFP-expressing 
axons were still present, scale bar = 100μm (left). Quantifying the amount of YFP signal 
present confirmed this loss to be significant. *p<0.053, two-tailed, unpaired parametric t-test. 
Scale bar = 100μm. 		 	
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observed	in	the	optic	nerve	of	these	mice	(Groh	et	al,	2013),which	are	a	hallmark	of	 axonal	 degeneration	 (Jeong	 et	 al,	 2011)(Figure	 3.17	 A).	 Quantitative	 line	sampling	 of	 these	 toluidine	 blue	 sections	 revealed	 a	 non-significant	 trend	towards	decreased	axon	density	 in	the	dorsal	 funiculi	of	both	the	cervical	and	lumbosacral	 cords	 of	 Ppt1-/-	 mice,	 but	 showed	 a	 significant	 decrease	 in	 axon	density	 in	 the	 ventral	 funiculi	 of	 these	 regions	 (Figure	 3.17	 A).	 Analysis	 of	longitudinal	sections	of	Thy1-YFP/Ppt1-/-	mouse	spinal	cords	(Castelvetri	et	al,	2011;	 Feng	 et	 al,	 2000)	 showed	 similar	 axonal	 blebs	 and	 gross	 axonal	degeneration	in	these	mice	at	7	months,	compared	to	the	Thy1-YFP	mice	(Figure	3.17	 B).	 Moreover,	 there	 was	 a	 significant	 (p<0.05)	 decrease	 in	 axonal	fluorescence	in	the	lumbar	spinal	cords	(Figure	3.17	B)		Taken	together	these	data,	indicate	the	presence	of	significant	pathology	in	the	white	matter	of	Ppt1-/-	mouse	spinal	 cords,	which	 is	a	phenotype	 that	has	not	been	reported	in	the	brain,	other	than	the	optic	nerve	(Groh	et	al.,	2013).	
3.10	Human	CLN1	spinal	cord	pathology.	In	an	early	study	of	human	CLN1	disease,	the	spinal	cord	was	described	as	not	being	as	severely	affected	as	the	brain	and	cerebellum	(Santavuori	et	al,	1974).	However,	histopathological	analysis	revealed	the	anterior	horn	cells	of	the	spinal	cord	 to	be	 “distended”	 in	appearance,	presumably	due	 to	 the	accumulation	of	storage	 material	 (Haltia	 et	 al,	 1973a;	 Santavuori	 et	 al,	 1974).	 To	 determine	whether	the	profound	histopathological	changes	seen	in	the	spinal	cords	of	Ppt1-
/-	mice	were	also	seen	in	human	CLN1	disease,	we	obtained	thoracic	spinal	cord	tissue	from	a	single	10-year	old	diseased	case	and	an	age-matched	neurologically	normal	spinal	cord.	The	tissues	were	sectioned	and	Nissl	stained	to	examine	their	cytoarchitectural	 organization,	 and	 immunostained	 for	 CD68	 to	 examine	microglial	 activation.	 Additionally,	 confocal	 microscopy	 images	 were	 also	obtained	 to	 look	 for	 the	 presence	 of	 autofluorescent	 storage	material	 (Figure	3.18).		
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Figure 3.18 – Human CLN1 Disease spinal cord pathology.  
Representative images of ventral horns of human thoracic spinal cord showing fewer, more 
darkly Nissl stained neurons of CLN1 disease tissue in Nissl stained sections (A). CD68 
stained sections showed increased abundance and hypertrophy of intensely immunoreactive 
microglia in CLN1 disease spinal cords (B). There was also pronounced accumulation of 
Autofluorescent Storage Material (AFSM) in persisting neurons in the gray matter of disease 
spinal cords (C). Scale bars = 100μm and 25μm (inserts).  
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Examination	of	the	human	CLN1	tissue	revealed	similar	end-stage	pathology	to	that	seen	in	Ppt1-/-	mouse	spinal	cords.	Nissl	stained	human	CLN1	disease	spinal	cord	sections	revealed	fewer	neurons	than	in	the	control	tissue.	The	neurons	that	were	present	displayed	a	range	of	morphologies	with	some	that	were	intensely	stained	 and	 shrunken,	 while	 others	 appeared	 distended	 and	 palely	 stained,	presumably	due	to	the	accumulation	of	storage	material	(Figure	3.18	A).	CD68	staining	 revealed	 an	 abundance	 of	 intensely	 stained,	 hypertrophied	microglia	that	were	often	found	in	clumps.	These	activated	microglia	were	largely	present	in	 the	 gray	matter	with	 a	 lesser	 number	 in	 the	white	matter	 (Figure	 3.18	B).	Lastly,	confocal	images	of	the	human	CLN1	disease	spinal	cords	revealed	intense	accumulation	of	autofluorescent	storage	material	in	cells	within	the	gray	matter	of	the	spinal	cord.	This	storage	material,	as	expected,	was	largely	present	in	cells	with	a	neuronal	morphology,	but	some	was	also	distributed	 in	clusters	within	smaller	 cells,	 as	 seen	 before	 in	 Ppt1-/-	 mouse	 spinal	 cords	 (Chapter	 3.11	 b).	Presumably,	 this	 is	 also	 due	 to	 the	 re-distribution	 of	 storage	 material	 to	phagocytizing	microglial	cells	(Figure	3.18	C).			These	 data	 indicate	 that	 there	 is	 indeed	 a	 pathological	 process	 occurring	 in	human	CLN1	disease	spinal	 cords,	 similar	 to	 that	 seen	 in	Ppt1-/-	mouse	spinal	cords.	This	is	significant	as	it	shows	that	the	spinal	cord	will	need	to	be	targeted	by	future	therapies	for	this	disease,	in	addition	to	the	brain.		
3.11	Spinal	cord	pathology	in	other	NCL	mouse	models.	The	 NCLs	 are	 a	 group	 of	 lysosomal	 storage	 disorders	 with	 similar	 clinical	presentations,	but	dissimilar	etiology	(Cooper,	2003;	Jalanko	&	Braulke,	2009).		Therefore,	having	observed	early	and	profound	pathology	in	the	spinal	cords	of	


























































































































































































































































































































































































































Tpp1-/-	and	Cln3-/-	mouse	spinal	cords	also	showed	lower	levels	of	astrocytosis	in	both	the	dorsal	and	ventral	horns,	compared	to	that	seen	in	Ppt1-/-	mice,	but	still	higher	than	the	wildtype	control	tissue.	Tpp1-/-	mouse	spinal	cords	did	not	show	any	microglial	activation,	similar	to	the	wildtype	control,	but	the	Cln3-/-	mouse	spinal	cords	displayed	an	increased	level	of	microglial	activation	compared	to	the	wildtype,	but	still	lower	than	that	seen	in	Ppt1-/-	mice	(Figure	3.19).		These	 observations	 provide	 the	 first	 evidence	 of	 the	 presence	 of	 spinal	 cord	pathology	in	mouse	models	of	NCL	other	than	that	for	CLN1	disease.	Although	the	nature,	extent	and	timing	of	pathology	may	differ	in	these	models,	these	data	show	that	the	spinal	cord	is	a	hitherto	unexplored	region	of	pathology,	not	just	in	CLN1	disease,	but	also	in	other	forms	of	NCL	and	may	be	critically	involved	in	disease	progression.	
3.12	Summary	Our	 analysis	 of	 Ppt1-/-	 mouse	 spinal	 cords	 has	 demonstrated	 a	 profound	pathological	 process	 in	 this	 region	 of	 the	 central	 nervous	 system	 (CNS).	 The	nature	of	this	pathology	is	largely	similar	to	that	seen	in	the	brains	of	these	mice	(Bible	 et	 al,	 2004;	 Kielar	 et	 al,	 2007;	 Macauley	 et	 al,	 2009),	 showing	 overall	atrophy	 (Figures	 3.1,	 3.2),	 severe	 neuronal	 loss	 (Figure	 3.3-3.6),	 progressive	accumulation	of	autofluorescent	storage	material	(Figure	3.7),	synaptic	changes	(Figure	3.10)	and	progressive	glial	activation	(Figure	3.12-3.15).	However,	 the	spinal	cord	pathology	observed	crucially	differs	 from	that	seen	 in	 the	brain	 in	
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4.1	Introduction	Cases	of	human	CLN1	disease	initially	present	with	muscle	hypotonia,	clumsiness	and	 ataxia	 along	 with	 decelerated	 head	 growth	 in	 the	 first	 year,	 this	 is	 then	followed	by	the	irritability,	visual	loss	and	the	development	of	epileptic	seizures,	together	with	the	abnormal	fine	motor	movements	or	hyperkinesias	that	are	also	characteristic	of	the	disease	(Dolisca	et	al,	2013;	Williams	et	al,	2006;	Wisniewski	et	al,	2001).	Collectively,	these	findings	suggest	that	the	sensorimotor	system	is	affected	early	in	CLN1	disease	progression.		Similarly,	Ppt1-/-	mice	display	a	 range	of	 sensorimotor	defects,	with	 the	 initial	study	describing	these	mice	demonstrating	an	abnormal	clasping	behavior	in	the	tail-suspension	 test	 as	 well	 as	 reporting	 the	 lowering	 of	 the	 pelvis,	 splayed	hindlimbs	 and	 an	 abnormal	wobbling	 gait	 towards	 the	 later	 stages	 of	 disease	progression	(Gupta	et	al,	2001).	In	view	of	demonstrable	cerebellar	pathology	in	these	mice,	constant	speed	rotarod	testing	in	these	mice	revealed	a	significant	decrease	 in	 the	 latency	of	 fall	 from	5	months	onwards	(Macauley	et	al,	2009).	Recently,	a	broader	behavioral	characterization	of	both	younger	(1-3	month	old)	and	 older	 (5-7	 month	 old)	 Ppt1-/-	 mice	 showed	 subtle	 changes	 in	 walking	initiation	and	walking	up	a	60°	inclined	plane	in	younger	mice,	while	older	mice	showed	a	wide	array	of	motor	deficits	that	affected	their	speed	of	movement	and	stride	 length	 as	 well	 demonstrating	 other	 cognitive	 deficits	 (Dearborn	 et	 al,	2015).			Having	characterised	early,	progressive	and	profound	spinal	cord	pathology	in	
Ppt1-/-	mice	(Chapter	I),	we	wished	to	detail	gait	deficits	in	these	mice	so	as	to	gain	 a	more	 comprehensive	 understanding	 of	 how	Cln1	 pathology	 affects	 the	sensorimotor	system	in	these	mice.	For	this,	we	employed	the	CatWalk	XT	gait	analysis	system	and	software	(Noldus,	Wageningen,	Netherlands).	As	previously	described,	this	system	allows	for	a	detailed	and	relatively	non-invasive	study	of	gait	 in	 rodents	 (Hamers	 et	 al,	 2006;	 Hamers	 et	 al,	 2001;	 Kloos	 et	 al,	 2005)	(Chapter	2.3).			
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For	this	 initial	study	of	gait,	we	chose	to	study	a	group	of	Ppt1-/-	and	wildtype	(C57BL/6)	control	mice	(n=12)	at	monthly	intervals	between	1	and	7	months	of	age.	 Runs	 of	 mice	 were	 then	 analyzed	 using	 the	 CatWalk	 XT	 10.5	 software	(Noldus)	 to	 classify	 each	 footfall	 and	produce	 results	 describing	 their	 gait.	 As	previously	stated	(Chapter	1.5),		there	was	no	statistically	significant	difference	in	the	overall	body	weights	of	Ppt1-/-	and	wildtype	control	mice	at	any	age(Galvin	et	al,	2008).	Therefore,	all	gait	analysis	parameters	are	reported	without	being	normalized	 to	 the	 animals’	 respective	 body	weights.	 showed	 that	Ppt1-/-	mice	have	a	progressive	motor	deficit	demonstrated	by	various	measures	of	their	gait	that	 is	 similar	 to	 previous	 studies	 of	 motor	 function	 in	 these	 mice,	 but	 adds	considerably	 more	 detail(Dearborn	 et	 al,	 2015;	 Macauley	 et	 al,	 2009).	Furthermore,	we	also	demonstrate	an	initial	period	when	these	mice	move	more	quickly	than	wildtype	controls,	demonstrate	a	progressive	lack	of	co-ordination	of	movement,	as	well	as	an	 increased	reliance	on	 fore-paws	 for	 locomotion	 in	
Ppt1-/-	mice	that	have	not	previously	been	documented.	
4.2	Decreased	run	speed	in	Ppt1-/-	mice.	Various	 measures	 describing	 the	 speed	 of	 mice	 moving	 along	 the	 CatWalk	(Noldus)	runway	demonstrated	differences	between	Ppt1-/-	and	wildtype	mice.	Measurements	of	cadence,	defined	as	the	number	of	steps	taken	by	a	mouse	per	second	 (Hamers	 et	 al,	 2001;	Neumann	et	 al,	 2009)	 (Table	2.1),	 as	well	 as	 the	average	speed	were	surprisingly	higher	in	Ppt1-/-	mice	than	wildtype	mice	at	2	months,	 but	 this	was	 followed	by	 lower	measures	 for	Ppt1-/-	mice	 from	 three	months	onwards,	 reaching	significance	at	5	months	 (Figure	3.20).	Conversely,	the	measures	of	the	maximum	speed	variation	in	each	run	showed	the	opposite	pattern	to	body	speed,	with	Ppt1-/-	mice	showing	lower	variation	at	2	months	and	higher	variation	at	4	months	onwards,	compared	to	their	wildtype	counterparts,	which	showed	a	trend	towards	decreased	in	variation	with	age		(Figure	4.1).				Similar	 measures	 to	 the	 average	 speed	 were	 observed	 in	 the	 body	 speed	measured	 for	 individual	 paws	 (Figure	 4.2	 A),	 while	 the	 speed	 variation	 for	individual	paws	showed	less	difference	between	Ppt1-/-	and	wildtype	mice	paws	
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at	 1,	 2	 and	 6	months,	 as	 compared	 to	 the	 other	 time	 points,	 as	 that	 seen	 for	maximum	variation	(Figure	4.2	B).		Taken	 together,	 these	 data	 suggest	 that	 at	 2	 months,	 Ppt1-/-	 mice	 move	 at	 a	significantly	faster	pace	with	much	less	variation	in	speed	than	wildtype	mice,	but	show	a	drastic	reduction	of	speed	and	an	increase	in	run	variation	from	3	moths	onwards,	with	a	 significant	difference	seen	as	early	as	4	months	 in	 the	latter	measure	(Figure	4.2).	This	demonstrates	that	these	mice	have	appreciable	difficulty	in	movement	as	early	as	3-4	months,	which	is	the	same	time	that	initial	neuron	loss	is	observed	in	the	spinal	cord	(Chapter	3.3).		
 
Figure 4.1 - Decreased speed and increased variation with advancing age in Ppt1-/- mice. 
CatWalk XT (Noldus) measures of cadence and average run speed showing Ppt1 deficient 
(Ppt1-/-) mice to have a higher rate of movement at 2 months, followed by decreased speeds 
from 3 months onwards, becoming significant at 5 months compared to age-matched wildtype 
(WT) mice. Maximum variation showed an opposite pattern with decreased values at 2 moths 
followed by significantly higher values starting at 4 months in Ppt1 deficient (Ppt1-/-) mice, 
compared to wildtype mice, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, two-tailed, unpaired 
parametric t-test. Values shown are continuous observations from each cohort at each time 








































































































































































































































































































































































































4.3	Measures	of	the	step	cycle.		Having	observed	significant	differences	in	the	body	speed	in	Ppt1-/-	mice,	we	then	analyzed	measures	 of	 the	 step	 cycle.	 The	 step	 cycle	 was	 defined	 as	 the	 time	between	 two	 successive	 initial	 contacts	 of	 a	 given	paw.	This	 consisted	of	 two	phases	–	a)	the	stand,	where	the	paw	remains	in	contact	with	the	plate,	and	b)	the	swing,	where	the	paw	is	lifted	off	or	is	not	in	contact	with	the	plate	(Hamers	et	al,	2006;	Hamers	et	al,	2001)	(Table	2.1).		Measures	comparing	the	step	cycle	and	duty	cycle	(Figure	4.3)	values	for	each	paw	 showed	 that	 while	 Ppt1-/-	 mice	 had	 shorter	 step	 cycles	 and	 duty	 cycles	consistent	with	their	increased	speed	at	2	months,	both	their	step	and	duty	cycles	showed	 higher	 values	 than	 wildtype	 mice	 from	 3	 months	 onwards,	 with	forelimbs	 and	 hindlimbs	 showing	 significantly	 higher	 values	 from	 5	 months	onwards	(Figure	4.3A).	These	data	show	that,	in	accordance	with	changes	in	their	speed,	Ppt1-/-	mice	were	successively	spending	less	time	at	2	months,	and	more	time	from	3	months	onwards	completing	each	step	cycle.	The	duty	cycle,	which	is	the	fraction	of	time	standing	in	each	step	cycle	(Table	2.1),	also	showed	that	this	change	in	step	cycle	duration	was	in	greater	part	due	to	the	amount	of	time	
















































































































































































































































































































































































































































































































































































































































































































































































































































These	data	confirmed	observations	in	the	duty	cycle,	in	that	Ppt1-/-	mice	spend	a	greater	amount	of	 time	during	a	step	cycle	with	 their	paw	in	contact	with	 the	ground	(or	plate)	after	3	months	of	age,	a	common	feature	in	spinal	cord	injury	and	disease	(Hamers	et	al,	2006;	Hamers	et	al,	2001).			Measures	 of	 the	 swing	 phase	 showed	 no	 significant	 difference	 between	genotypes	in	the	fore	paws	until	7	months,	where	Ppt1-/-	mice	had	lower	swing	times,	especially	in	the	left	front	(LF)	paws.	However,	the	hind	limbs,	showed	a	consistent	trend	of	longer	swing	times	from	3	months	onwards,	with	significantly	higher	 values	 from	 5	 months,	 as	 compared	 to	 wildtype	 mice	 (Figure	 4.5	 A).	Furthermore,	Ppt1-/-	mice	 had	 a	 significantly	 higher	 swing	 speed	 at	 2	months	followed	by	consistently	lower	speeds	from	3	months	onwards,	as	compared	to	wildtype	mice.	These	values	were	significantly	lower	from	5	months	onwards	in	the	hind	limbs	and	6	months	onwards	in	the	fore	limbs	(Figure	4.5	B).	These	data	suggest	that,	while	the	overall	movement	of	limbs	at	2	months	is	faster	in	Ppt1-/-	mice,	 they	 subsequently	 take	 more	 time	 to	 move	 their	 hindlimbs	 than	 their	forelimbs	from	3	months	onwards.	These	data,	along	with	the	stand	phase	data	show	that	Ppt1-/-	mice	may	support	themselves	more	with	their	forelimbs	than	their	hindlimbs	during	a	step	cycle	from	3	months	onwards.	
4.4	Individual	paw	measurements	We	next	analyzed	how	the	mice	of	both	genotypes	were	placing	their	paws	on	the	glass	 plate,	 by	 measuring	 the	 length,	 width	 and	 area	 of	 each	 footfall.		Measurements	 of	 print	 length	 showed	 an	 increase	 in	 Ppt1-/-	 mice	 at	 2	 and	 4	months	compared	to	the	wildtype	mice	in	the	fore	paws,	while	the	hind	paws	did	not	show	much	variation	between	genotypes	until	6-7	months,	when	Ppt1-/-	mice	showed	 a	 decreased	 print	 length,	 compared	 to	 wildtype	mice	 (Figure	 4.6	 A).	Measurements	of	print	width,	however,	showed	an	increase	in	the	width	of	fore	paw	prints	at	2,	6	and	7	months	in	Ppt1-/-	mice,	but	an	opposite	decrease	in	width	at	6	and	7	months	 in	their	hind	paws,	with	the	exception	of	 the	3	month	time	point	in	the	right	hind	paw,	which	showed	a	higher	print	width	(Figure	4.6	B).	Overall,	these	data	imply	that	Ppt1-/-	mice	have	wider	and	longer	forepaw	prints	at	 two	months,	when	 they	 also	 appear	 to	move	 faster,	while	 they	 continue	 to	
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Figure 4.8 - Altered stride length in Ppt1-/- mice. 
CatWalk XT (Noldus) measures of stride length showed that 2 month old Ppt1 deficient (Ppt1-
/-) mice had a longer stride length for all limbs, as compared to wildtype mice (WT), while 
having significantly shorter strides in all limbs as early as 5 months onwards. *p<0.05, 
**p<0.01, ****p<0.0001, two-tailed, unpaired parametric t-test. Values shown are continuous 



































































































































































































































































































































































































































































































































































4.5	Measures	of	stance	and	support	Having	shown	initial	evidence	that	Ppt1-/-	mice	seem	to	have	altered	values	for	placing	their	feet	in	contact	with	the	plate	in	a	step	cycle	(as	revealed	by	their	duty	cycle,	stand	and	stand	index	measures,	Figures	4.3,	4.4),	we	then	looked	at	measures	of	stance	and	support.	Stance,	describes	the	duration	of	contact	of	two	paws	in	a	step	cycle	(Table	2.1),	and	this	data	is	then	classified	as	either	–	a)	single	stance	-	where	a	single	paw	is	in	contact	with	the	plate,	b)	initial	dual	stance	–	where	both	fore	or	hind	paws	are	in	contact	with	the	plate	at	the	start	of	a	step	cycle,	or	c)	terminal	dual	stance	–	where	both	fore	or	hind	paws	are	in	contact	with	the	plate	at	the	end	of	a	step	cycle	(Coulthard	et	al,	2002;	Coulthard	et	al,	2003).		This	analysis	 revealed	 that	Ppt1-/-	mice	had	significantly	 less	single	and	 initial	dual	stance	durations	at	2	months	compared	to	wildtype	mice,	however,	 their	initial	 and	 terminal	 dual	 stance	 times	 significantly	 increased	 from	 5	 months	onwards,	compared	to	wildtype	mice	(Figure	4.11).	These	data	suggest	that	Ppt1-
















































































































































































































































































































Figure 4.12 - Increased base of support in Ppt1-/- mice. 
CatWalk XT (Noldus) measures of base of support (BOS) in fore and hind limbs shows an 
earlier, significant increase in forelimb BOS at 4 months, than hind limb BOS at 6 months in 
Ppt1 deficient (Ppt1-/-) mice as compared to wildtype (WT) mice. *p<0.05, two-tailed, unpaired 
parametric t-test. Values shown are continuous observations from each cohort at each time 
point as mean ± SEM. (n= 12 mice/group). 	Our	 analysis	 of	 stance	 and	 the	 base	 of	 support	 led	 us	 to	 analyze	 the	 overall	support,	which	is	the	relative	duration	of	simultaneous	contact	of	a	given	paw	(or	combination	of	paws)	for	a	given	run.	These	parameters	were	classified	as	shown	in	 table	 4.1.	 A	 majority	 of	 support	 is	 generally	 seen	 in	 as	 diagonal	 support	(Hamers	et	al,	2006),	and	this	was	seen	in	wildtype	mice	at	all	time	points	(Figure	4.13).	At	2	months,	Ppt1-/-	mice	also	showed	a	significantly	higher	percentage	of	diagonal	 support	 compared	 to	wildtype	mice,	 however,	 in	 addition,	 they	 also	showed	 an	 increased	 percentage	 of	 single	 and	 girdle	 support	 compared	 to	wildtype	mice	at	this	time	point	(Figure	4.13),	presumably	due	to	their	higher	speed	of	movement	(Figure	4.1).	From	5	months	onwards,	there	was	a	significant,	and	drastic	decrease	in	the	percentage	of	diagonal	support	in	Ppt1-/-	mice,	with	a	concurrent	increase	of	lateral,	three-limb	and	four-limb	support	in	these	mice,	as	compared	to	wildtype	mice	(Figure	4.13).	This	data	reveals	that	with	advancing	age,	Ppt1-/-	mice	show	less	stability	and	therefore	require	greater	support	from	other	limbs	to	move.	The	increase	of	lateral	support	at	6	and	7	months	is	similar	to	 the	 “lateral	wobbling”	gait	previously	observed	 in	Ppt1-/-	mice	 (Gupta	et	al,	2001).	This	increased	utilization	of	three	and	four-limb	support	in	Ppt1-/-	mice	
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would	also,	in	part	explain	the	increased	stand	durations	observed	in	these	mice	(Figure	4.4).			
Support Parameter Simultaneous paw contact (s) measured 
Zero No paw. 
Single Any one paw. 
Diagonal Contralateral fore-and hind paw. 
Girdle Contralateral set of either forepaws or hind paws.  
Lateral Ipsilateral fore- and hind paw. 
Three Any three paws. 
Four All four paws. 
 
Table 4.1 – Support parameters for CatWalk XT analysis. 









































































































































































































































































































































































Figure 4.14 - Ppt1-/- mice place hind paws closer to fore paws. 
CatWalk XT (Noldus) measures of print positions showing consistently lower values on both 
sides for Ppt1 deficient (Ppt1-/-) mice as compared to wildtype (WT) mice at nearly all time 
points, implying that these mice place their hind paws closer to fore paws during step cycles. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, two-tailed, unpaired parametric t-test. Values 
shown are continuous observations from each cohort at each time point as mean ± SEM. (n= 




Figure 4.15 - Ppt1-/- mice show altered but regular step-fall patterns  
CatWalk XT (Noldus) measures of step-fall patterns (A) show that Ppt1 deficient (Ppt1-/-) mice 
show an increasing shift towards an AA pattern with age, with an increase in RA pattern at 7 
months, compared to wildtype (WT) mice that showed a majority of the AB pattern with age. 
The regularity index for these patterns was almost identical between genotypes until 7 months 
when Ppt1-/- mice showed significantly lower regularity of step patterns. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001, two-tailed, unpaired parametric t-test. Values shown are continuous 
observations from each cohort at each time point as mean ± SEM. (n= 12 mice/group). A	 measure	 of	 the	 regularity	 of	 step	 sequences	 of	 step	 cycles	 within	 a	 run	remained	 consistent	 until	 7	 months,	 when	 Ppt1-/-	 mice	 showed	 a	 significant	
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decrease	in	regularity,	compared	to	wildtype	mice	(Figure	4.15	B).	This	shows	that,	while	Ppt1-/-	mice	show	altered	step	sequences	starting	at	3	months,	 the	regularity,	which	can	also	be	described	as	a	measure	of	the	number	of	missteps,	was	 the	same	as	 that	of	wildtype	mice	until	7	months,	when	this	regularity	of	steps	significantly	decreased.			Another	way	of	studying	co-ordination	between	limbs	is	to	analyze	the	temporal	relationship	 between	 any	 two	 limbs	 in	 a	 given	 step	 cycle.	 These	 phase	dispersions	describe	 the	duration	of	 contact	with	 the	 glass	of	 a	 target	paw	 in	relation	to	the	stand	of	the	first	or	“anchor”	paw	(Hamers	et	al,	2006).	Positive	values	indicate	that	the	target	paw	is	placed	after	the	anchor	paw.		Our	analysis	of	 the	 mean	 values	 of	 phase	 dispersions	 showed	 little	 difference	 between	genotypes	 for	 either	 diagonal	 or	 girdle	 limbs	 (Figure	 4.16),	 with	 the	 LH-RH	dispersion	showing	significantly	lower	values	at	2	and	7	months	for	Ppt1-/-	mice	compared	 to	 wildtype	 mice,	 and	 the	 LF-RH	 dispersion	 showing	 significantly	higher	 values	 for	 Ppt1-/-	 mice	 at	 7	 months,	 compared	 to	 wildtype	 mice.	 The	biggest	difference	was	 seen	between	 the	 ipsilateral	 limbs	 (LF-LH	and	RF-RH),	where	 there	 were	 significantly	 more	 positive	 values	 for	 Ppt1-/-	 mice	 from	 5	months,	and	this	seemed	to	increase	with	age	(Figure	4.16).	This	may	be	a	result	of	increased	step	cycle	durations	observed	at	these	time	points,	as	well	as	being	indicative	of	increasing	lateral	support	used	by	Ppt1-/-	mice	with	age.	
4.7	Summary	Overall,	the	analysis	of	gait	using	the	CatWalk	XT	system	(Noldus)	has	revealed	unexpectedly	early	and	significant	changes	in	Ppt1-/-	mice,	while	also	confirming	the	 extensive	 deterioration	 of	 their	 ambulatory	 ability	 with	 the	 further	progression	of	disease.		A	quick	survey	of	the	spatial	and	temporal	primary	run	visualizations	(previously	shown	in	Figure	2.2)	revealed	readily	observable	changes	in	measures	such	as	stride	length	(SL)	as	early	as	2	months	in	Ppt1-/-	mice	(Figure	4.17	and	4.18). 
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Figure 4.16 - Phase dispersions of Ppt1-/- show changes in ipsilateral limbs.  
CatWalk XT (Noldus) measures of mean phase dispersions showing generally more positive 
values for Ppt1 deficient (Ppt1-/-) mice in LF-RH dispersion at 7 months and ipsilateral limbs 
from 5-7 months compared to wildtype mice, while the opposite relationship was seen for hind 
limb dispersions at 2 and 7 months respectively. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, 
two-tailed, unpaired parametric t-test. Values shown are continuous observations from each 
cohort at each time point as mean ± SEM. (n= 12 mice/group). 
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A	noticeable	decline	 in	both	spatial	and	 temporal	readings	was	seen	 in	Ppt1-/-	mice	compared	to	wildtype	mice	from	5	months	onwards	(Figure	4.17	and	4.18).	These	readily	observable	differences	serve	to	further	demonstrate	the	extent	of	the	changes	seen	in	the	gait	of	Ppt1-/-	mice	compared	to	wildtype	mice	and	are	reinforced	by	 the	statistical	analysis	of	data	produced	by	 the	CatWalk	XT	10.5	software	(Noldus).		This	CatWalk	XT	analysis	has	shown	that	at	an	early	time	point	of	2	months,	Ppt1-
/-	 mice	 unexpectedly	 seemed	 to	 perform	 better	 than	 wildtype	 mice,	 as	 they	moved	with	greater	speed,	 larger	strides	and	shorter	step	cycles	compared	 to	wildtype	mice	(Figures	4.1,	4.3,	4.8).	This	is	a	surprising	finding,	as	no	previous	study	 of	 these	 mice	 has	 suggested	 either	 hyperactivity	 or	 improved	 motor	performance	 at	 any	 age.	However,	 this	 apparent	 improved	 function	may	 be	 a	result	 of	 various	 other	 factors	 including	 variations	 in	 weight	 gain,	 learning	ability.	 This	 may	 also	 be	 caused	 by	 the	 possible	 effect	 of	 the	 postnatal	developmental	delay	(Chapter	3.2)	or	the	significant	inflammation	(Chapter	3.8)	that	have	been	documented	in	the	spinal	cords	of	these	mice	at	this	age	(Beh	et	al,	2013;	Eilam,	1997;	Hausmann,	2003).		From	3	months	of	age,	Ppt1-/-	mice	appeared	to	move	more	slowly,	with	smaller	strides,	increased	step	cycles,	stand	and	phase	dispersions	as	well	as	showing	a	trend	to	decreased	paw	intensities	(Figures	4.1	–	4.10,	4.16).	These	data	are	very	similar	 to	 previous	 more	 qualitative	 studies	 of	 motor	 function	 in	 these	 mice	(Dearborn	et	al,	2015;	Gupta	et	al,	2001;	Macauley	et	al,	2009).	However,	these	studies	only	provided	evidence	of	these	deficits	from	5	months	of	age	onwards.	Therefore,	this	current	study	provides	further	evidence	for	early	sensorimotor	defects	in	these	mice.		

































































































































































































































































































































































































































































































































































































































































































	walking	as	evidenced	by	increases	in	dual	stance,	as	well	as	three	and	four-limb	support	 (Figure	 4.11.	 and	 4.13).	 Lastly,	 measures	 of	 co-ordination	 showed	 a	switching	of	step	sequence	preference	that	is	often	seen	in	spinal	injury	(Bem	et	al,	1995),	that	was	seen	as	early	as	4	months	(Figure	4.15).	Changes	seen	between	3-5	months	in	Ppt1-/-	mice	are	more	readily	explainable	as	being	significantly	due	to	spinal	pathology,	while	changes	after	5	months	are	possibly	a	result	of	multiple	loci	of	pathology	including	the	thalamocortical	region	and	the	cerebellum	(Bible	et	al,	2004;	Kielar	et	al,	2007;	Macauley	et	al,	2009).		The	 findings	of	 increased	early	 reliance	on	 forepaws	 for	 locomotion	 in	Ppt1-/-	mice	 are	 a	novel	 finding,	 and	 further	 elucidate	 early	 sensorimotor	 changes	 in	











5.1	Introduction		CLN	1	 disease	 or	 Infantile	NCL	 (INCL)	 is	 one	 of	 the	most	 rapidly	 progressing	forms	 of	 NCL	 (Dolisca	 et	 al,	 2013;	 Mole	 et	 al,	 2005;	 Santavuori	 et	 al,	 1974).	Despite	many	advances	in	our	understanding	of	CLN1	disease	pathology,	there	is	currently	 no	 effective	 curative	 therapy	 available	 for	 this	 disease	 (Hawkins-Salsbury	et	al,	2013).		The	Ppt1-/-	mouse	model	for	CLN1	disease	has	proved	to	be	a	powerful	tool,	not	just	 as	 a	 means	 of	 studying	 disease	 pathology	 and	 progression,	 but	 also	 for	testing	 various	 experimental	 therapies	 (Hawkins-Salsbury	 et	 al,	 2013).	 Until	now,	the	brain	has	been	considered	the	main	locus	of	pathology	in	CLN1	disease,	as	had	previously	been	demonstrated	in	Ppt1-/-	mice	(Bible	et	al,	2004;	Kielar	et	al,	2007;	Macauley	et	al,	2009).	Therefore,	almost	all	experimental	therapies	for	CLN1	 disease	 have	 been	 targeted	 to	 the	 brains	 of	 these	 mice.	 The	 various	experimental	therapeutic	approaches	have	so	far	included	the	administration	of	anti-oxidants	 such	 as	 Resveratrol	 (Wei	 et	 al,	 2011),	 Human	 CNS	 stem-cell	neurosphere	 (HuCNS-SCns)	 implants	 in	 the	brain	 (Tamaki	 et	 al,	 2009),	 brain-directed	Enzyme	Replacement	Therapy	(ERT)	(Hu	et	al,	2012;	Lu	et	al,	2010)	and	brain-directed	gene	therapy	(Griffey	et	al,	2004;	Griffey	et	al,	2006;	Macauley	et	al,	 2012).	 However,	 all	 these	 therapies	 have	 only	 been	 partially	 successful	 in	treating	CLN1	disease.		A	previous	study	had	shown	that	intrathecal	(IT)	administration	of	a	large	dose	of	 human	 recombinant	 enzyme	 in	 a	 mouse	 model	 of	 CLN2	 disease	 or	 late-infantile	NCL	(LINCL)	increased	survival	and	positively	affected	brain	pathology	(Xu	 et	 al,	 2011).	 These	 intrathecal	 injections	were	 administered	 into	 the	 sub-arachnoid	 space,	 between	 the	 L5	 and	 L6	 spinal	 cord	 vertebrae.	 Having	demonstrated	early	and	profound	pathology	in	the	spinal	cords	of	Ppt1-/-	mice	(Chapter	 3),	 we	 hypothesized	 that	 the	 limited	 success	 of	 forebrain-directed	therapies	 in	 these	mice	was	 in	part	because	 they	had	 little	or	no	effect	on	the	pathology	 in	 the	 spinal	 cords	 of	 these	mice.	 Therefore,	 similar	 IT	 delivery	 of	therapeutic	 agents	may	have	 a	 significant	 beneficial	 effect	 on	 spinal	 cord	 and	brain	pathology	in	these	mice.		
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5.2	Intrathecal	(IT)	administration	of	human	recombinant	PPT1	
Enzyme	in	Ppt1-/-	mice.		Based	on	the	encouraging	results	seen	from	delivering	intrathecal	recombinant	human	TPP1	enzyme	in	a	mouse	model	of	CLN2	(Xu	et	al,	2011),	as	well	as	the	partial	 efficacy	 of	 human	 recombinant	 PPT1	 enzyme	 in	 alleviating	 brain	pathology	(Hu	et	al,	2012),	we	undertook	a	pilot	study	to	investigate	the	effect	of	IT	administration	of	human	recombinant	PPT1	(hPPT1)	enzyme	in	Ppt1-/-	mice.			For	this	study,	4	groups	of	16-20	Ppt1-/-	mice	were	administered	with	increasing	titers	of	 the	human	 recombinant	 enzyme	at	6	weeks	of	 age,	when	 there	 is	no	detectable	brain	or	spinal	cord	pathology.	Mice	were	initially	anesthetized	with	isoflurane,	and	then	injected	using	a	30-gauge	needle	placed	between	L5	and	L6	lumbar	vertebrae	on	three	consecutive	days.	The	groups	of	treated	mice	received	either	0	(Vehicle),	2.6,	5.3	or	10.6	mg/ml	doses	of	hPPT1.	They	were	then	tested	for	motor	performance	at	3,	5,	7,	8	and	9	months,	and	compared	to	untreated	




Figure 5.1 - Investigating the effects of intrathecal (IT) administration of human 
recombinant PPT1 enzyme – study design and biodistribution of PPT1 enzyme. 
(A) Four groups of Ppt1 deficient (Ppt1-/-) mice were randomized and received three 
consecutive daily lumbar spinal infusions of 80μl human recombinant PPT1 (hPPT1) at 
concentrations of 0, 2.6, 5.3 or 10.6 mg/ml at six weeks of age. Rotarod testing was performed 
at successive monthly time points with age-matched untreated Ppt1-/- and wildtype mice. Mice 
from each group (n=3) were sacrificed at 7.5 months for pathological examination. (B) PPT1 
activity in whole brain homogenates following intrathecal injection of 80μl of 10.6 μg/μ hPPT1 
at 6 weeks showing persistent enzyme activity (n=4,3,3,3 at 1,3,5,9 days respectively and n=1 
at later time points). Adapted from (Lu et al, 2015). 
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of	wildtype	(WT)	enzyme	levels	was	observed,	and	5-9%	of	PPT1	activity	was	present	as	late	as	248	days	post-injection	(Figure	5.1	B).	This	demonstrated	that	IT	injections	of	hPPT1	distributed	the	enzyme	sufficiently	to	result	in	brain	PPT1	activity	 that	 persisted	 for	 a	 long	 period.	 The	 mechanisms	 underlying	 this	unexpectedly	prolonged	persistence	of	PPT1	activity	remain	unclear.	However,	it	 is	 considered	 that	 low	 levels	of	enzyme	activity	are	sufficient	 to	correct	 the	disease	phenotype	in	LSDs	(Donsante	et	al,	2007;	Neufeld	&	Fratantoni,	1970).	This	may	help	explain	the	significant	improvements	in	motor	performance	and	increase	in	lifespan	observed	in	these	mice	(Lu	et	al,	2015).						To	 further	explore	 this,	a	subset	of	mice	 from	the	same	cohort	of	mice	as	 this	study	were	sacrificed	at	7.5	months	for	histological	analysis	(Figure	5.1A),	so	as	to	include	mice	from	each	of	the	treatment	groups,	as	well	as		Ppt1-/-	and	wildtype	controls	 (n=3)	 (Lu	et	al,	2015).	With	 the	administration	of	 recombinant	PPT1	enzyme	 into	 the	 sub-arachnoid	 cerebrospinal	 fluid	 (CSF),	 a	 greater	 effect	was	predicted	in	the	superficial	areas	of	the	brain	and	spinal	cord	compared	to	deeper	structures	(Hu	et	al,	2012;	Xu	et	al,	2011).	Therefore	to	provide	a	comprehensive	view	of	the	effect	of	IT	ERT	on	pathology	in	Ppt1-/-	mice	from	our	study,	we	chose	to	 examine	 established	markers	 of	 disease	 progression	 in	 both	 the	 brain	 and	spinal	cords	of	these	mice	(Bible	et	al,	2004;	Kielar	et	al,	2007;	Macauley	et	al,	2009).			We	first	immunostained	for	markers	of	glial	activation	-	GFAP	for	astrocytes	and	CD68	for	microglia.		Both	microglia	and	astrocytes	are	activated	early	in	disease	progression	in	the	brain	(Kielar	et	al,	2007)	and	the	spinal	cord	(Chapter	3.8),	and	levels	of	glial	activation	were	quantified	using	semi-automated	thresholding	image	analysis	(Chapter	2.8).	Similar	methods	were	used	for	assessing	the	levels	of	 accumulated	 autofluorescent	 storage	 material	 within	 cells	 (Chapter	 2.8).	Lastly,	stereological	estimates	of	neuron	number	were	obtained	to	determine	if	the	therapy	had	any	neuroprotective	effect	(Chapter	2.7).			Regions	of	the	brain	that	have	been	shown	to	be	significantly	affected	by	disease	pathology	in	Ppt1-/-	mice	were	analyzed,	including	the	medial	and	lateral	ventral	
		 148	
posterior	 thalamic	 nuclei	 (VPM/VPL),	 the	 dorsal	 lateral	 geniculate	 nucleus	(LGnD)	and	the	primary	somatosensory	barrel-field	of	the	cortex	(S1BF)	(Bible	et	al,	2004;	Kielar	et	al,	2007).		The	cervical	and	lumbar	regions	of	the	spinal	cord	were	similarly	analyzed	to	study	the	proximal	and	distal	effects	of	lumbar	IT	ERT	administration.		
a)	Effect	of	IT	human	recombinant	ERT	on	glial	activation	in	Ppt1-/-	mice.	Both	microglia	and	astrocytes	are	activated	early	in	disease	progression	in	the	brains	(Kielar	et	al,	2007)	and	spinal	cords	(Chapter	3)	of	Ppt1-/-	mice,	typically	before	the	occurrence	of	neuron	 loss.	There	 is	a	growing	body	of	evidence	for	glial	cells	playing	a	significant	role	in	disease	progression	of	CLN1	disease	(Shyng	&	 Sands,	 2014)	 (Lange,	 PhD	 Thesis).	 Therefore,	 we	 investigated	 whether	 IT	administration	 of	 human	 recombinant	 PPT1	 had	 any	 effect	 on	 this	 glial	activation.			A	survey	of	various	regions	of	the	brain	and	spinal	cord	stained	for	the	microglial	marker	 revealed	 a	 clearly	 visible	 dose-dependent	 reduction	 of	 microglial	activation	in	the	somatosensory	cortex	and	spinal	cord	of	treated	compared	to	untreated	Ppt1-/-	mice,	while	 lesser	 effects	were	 seen	 in	 their	 thalamic	nuclei.	This	was	a	result	of	not	only	a	decreased	density	of	activated	microglia,	but	also	due	 to	 fewer	microglial	 cells	 showing	 the	hypertrophic	morphology	 typical	 of	activated	microglia.	However,	these	levels	of	microglial	activation	in	treated	Ppt1-
/-	mice	were	 still	 higher	 than	 that	 seen	 in	 the	wildtype	 controls	 (Figure	 5.2).	Quantitative	 thresholding	 image	 analysis	 confirmed	 a	 greater	 effect	 of	 the	 IT	human	recombinant	ERT	in	more	superficial	structures	of	the	brain	and	spinal	cord,	with	a	significant	reduction	of	microglial	activation	seen	in	the	S1BF	as	well	as	both	the	dorsal	and	ventral	horns	of	the	cervical	and	lumbar	cord.		While	there	was	a	trend	towards	reduced	microglial	activation	in	the	LGnD	with	increased	dosage	 of	 the	 recombinant	 enzyme,	 this	 did	 not	 reach	 statistical	 significance.	Similarly,	 the	VPM/VPL	 showed	 a	 reduced	 level	 of	 CD68	 immunoreactivity	 in	treated	Ppt1-/-	mice,	but	again,	this	was	not	statistically	significant	(Figure	5.3).			
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Analysis	of	sections	 from	treated	Ppt1-/-	mice	stained	 for	GFAP	showed	a	 low-level	astrocyte	response	to	the	human	recombinant	PPT1,	especially	in	the	Ppt1-










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Ppt1-/-	mice	treated	with	IT	human	recombinant	ERT.		There	 is	 a	 characteristic	 progressive	 accumulation	 of	 autofluorescent	 storage	material	(AFSM)	within	the	cells	of	the	brain	(Bible	et	al,	2004;	Kielar	et	al,	2007)	and	spinal	cord	(Chapter	3)	in	Ppt1-/-	mice.	While	there	is	no	evidence	for	this	storage	material	being	directly	 involved	 in	causing	neuron	 loss,	a	reduction	 in	storage	material	burden	in	these	tissues	would	be	indicative	of	either	a	reduction	or	reversal	of	the	disease	process.	Furthermore,	the	use	of	AFSM	as	a	prognostic	measure	 of	 therapeutic	 efficacy	 has	 been	 well	 established	 (Hu	 et	 al,	 2012;	Macauley	et	al,	2012;	Tamaki	et	al,	2009),	and	such	analysis	would	allow	us	to	compare	the	efficacy	of	IT	human	recombinant	ERT	with	previous	experimental	therapies.			Upon	observing	sections	of	Ppt1-/-	mice	treated	with	IT	human	recombinant	ERT	via	confocal	microscopy,	a	clear	dose-dependent	reduction	of	storage	material	was	observed	 in	 the	S1BF	and	 lumbar	SC,	with	a	 lesser	effect	observed	 in	 the	VPM/VPL,	compared	to	untreated	Ppt1-/-	mice	(Figure	5.6).	Thresholding	image	analysis	 of	 confocal	 microscopy	 images	 revealed	 that	 there	 was	 a	 significant	reduction	in	AFSM	in	the	cervical	spinal	cord	of	Ppt1-/-	mice	that	received	either	a	2.6mg/ml	or	10.6mg/ml	dose	of	recombinant	enzyme,	and	in	the	lumbar	spinal	cord	of	Ppt1-/-	mice	that	received	a	10.6mg/ml	dose	of	recombinant	enzyme,	as	compared	 to	 their	 untreated	 counterparts.	 Other	 regions	 including	 the	 S1BF,	VPM/VPL	 and	 the	 LGnD	 showed	 a	 decrease	 of	 AFSM	 accumulation	 for	 all	treatment	 groups,	 compared	 to	 untreated	Ppt1-/-	mice,	 but	 this	 did	 not	 reach	significance	(Figure	5.7).				Overall,	the	reduction	of	AFSM	levels	in	the	cord	and	the	brain	indicate	the	partial	efficacy	of	IT	human	recombinant	ERT.	The	fact	that	this	was	significant	in	the	spinal	cord,	but	not	the	brain,	is	presumably	due	to	a	reducing	effect	of	ERT	with	greater	 distance	 from	 the	 site	 of	 administration.	 The	 reduction	 of	 AFSM	anywhere	was	particularly	surprising,	given	that	these	tissues	were	analyzed	6	months	 after	 ERT	 administration,	 and	 suggests	 that	 there	 might	 be	 either	 a	
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lasting	therapeutic	effect	with	early	therapeutic	intervention	or	a	pool	of	PPT1	enzyme	that	persists	much	longer	than	expected.	










































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5.9 – Combined intracranial (IC) and intrathecal (IT) treated mice show greatest 
improvements in motor function and lifespan. 
 
(A) Constant speed rotarod test for motor function revealed that untreated Ppt1 deficient (Ppt1-
/-) mice (blue) were unable to stay on the rotarod past 7 months, IT treated mice (red) showed 
motor deficits at 7 months and could not stay on the rotarod past 11 months, IC treated mice 
(green) showed deficits at 9 months and could not stay on the rotarod past 13 months, and 
IC/IT treated mice (purple) showed deficits at 15 months and could not stay on the rotarod 
past 19 months. Significance is compared to wildtype mice. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001, two-way repeated measure ANOVA. Values shown are continuous 
observations from each cohort at each time point as  mean ± SEM. (n= 10 mice/group). (B)	
Kaplan-Meier survival curve showing the median lifespan for Ppt1-/- mice (blue) was 8.4 
months, IT treated mice (red) had an extension in lifespan of 11.3 months (+3 months), IC 
treated mice (green) had an extension in lifespan of 13.7 months (+5.3 months) and 
combination IC/IT treated mice (purple) had an extension in lifespan of 19.3 months (+11.5 
months). Analysis by log-rank test for trend was significant for overall survival (p<0.0001). 
Individual comparisons between curves, using Bonferroni correction were each significant 
(p<0.002). n= 10 mice/group. 
 All	treatment	groups	showed	a	significant	increase	in	median	lifespan,	compared	to	untreated	Ppt1-/-	mice,	which	had	a	median	lifespan	of	8.4	months.	IC/IT	mice	had	the	longest	median	lifespan	of	19.3	months,	with	the	longest-lived	mouse	at	22	 months,	 compared	 to	 IT	 mice	 (11.8	 months)	 or	 IC	 mice	 (13.6	 months).	
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However,	these	were	still	short	of	the	median	wildtype	mouse	lifespan,	of	which	all	 but	 one	 mouse	 remained	 alive	 at	 24	 months.	 Similarly,	 rotarod	 testing	revealed	that	IC/IT	mice	performed	better,	and	showed	a	later	decline	in	motor	function	 as	 compared	 to	 either	 IC	 or	 IT	mice	 (Figure	 5.9)	 (Shyng	 et	 al.	 2016,	submitted	for	publication).			The	brains	and	spinal	cords	of	mice	from	all	treatment	groups	collected	at	3,	5,	7	and	9	months	for	histological	analysis	were	sectioned	and	analyzed	for	the	same	disease	markers	 as	 those	 for	 the	 IT	human	 recombinant	ERT	 study,	 including	CD68	 for	microglial	 activation,	 GFAP	 for	 astrocytosis,	 autofluorescent	 storage	material	 (AFSM)	and	neuron	 counts.	These	measures	were	 collected	 from	 the	primary	(M1)	motor	cortex,	where	the	IC	gene	therapy	had	been	targeted,	 the	ventral	posterior	medial	and	lateral	thalamic	nuclei	(VPM/VPL)	and	the	lumbar	spinal	cord.		
 
a)	Combination	therapy	reduces	glial	activation	in	brain	and	spinal	cord	of	
Ppt1-/-	mice.		Microglial	 activation	 and	 astrocytosis	 have	 been	 shown	 to	 typically	 precede	neuron	 loss	 in	 the	 brains	 and	 spinal	 cords	 of	Ppt1-/-	mice	 (Kielar	 et	 al,	 2007)	(Chapter	3.8).	Therefore,	we	stained	sections	for	CD68,	a	marker	for	microglia.	This	 staining	 revealed	 that,	 at	 the	 7-month	 time	 point,	 there	 was	 a	 clearly	observable	increase	of	CD68	staining	in	all	regions	of	untreated	Ppt1-/-	mice	as	compared	to	wildtype	controls.	There	was	a	decrease	in	CD68	staining	in	the	M1	cortex	 of	 IC	 and	 IC/IT	 mice	 (Figure	 5.10),	 and	 a	 slight	 decrease	 in	 IT	 mice	compared	to	untreated	Ppt1-/-	mice.	There	was	also	significant	decrease	in	CD68	staining	 in	 the	 lumbar	 spinal	 cords	 of	 IT	 and	 IC/IT	mice,	with	 no	 observable	difference	in	the	lumbar	spinal	cords	of	IC	mice	compared	to	untreated	Ppt1-/-	mice	(Figure	5.10).	Furthermore,	IC/IT	mice	showed	a	greater	reduction	of	CD68	staining	in	the	VPM/VPL	than	either	IC	or	IT	mice,	compared	to	untreated	Ppt1-/-	mice	(Figure	5.10).	Less	pronounced	reductions	in	CD68	staining	were	observed	as	a	result	of	decreased	microglial	density,	as	well	as	fewer	microglia	having	the	hypertrophied	 and	 intensely	 stained	 soma	 typical	 of	 activated	 macrophages.	Indeed,	 microglia	 in	 the	 lumbar	 spinal	 cords	 of	 IC/IT	 and	 IT	 mice	 showed	 a	
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Taken	together,	 these	data	show	that	IC	therapy	alone	has	very	 little	effect	on	gliosis	in	the	spinal	cord	despite	significant	effects	in	the	brain	regions	analyzed.	Moreover,	 while	 IT	 therapy	 alone	 is	 effective	 at	 treating	 the	 spinal	 cord	pathology,	it	does	have	a	mild	beneficial	effect	on	the	superficial	brain	structures,	but	not	to	the	same	extent	as	IC-delivered	gene	therapy.	Combined	IC/IT	therapy	appears	 to	have	a	greater	effect	 in	reducing	 the	glial	activation	 in	Ppt1-/-	mice	than	 either	 IC	 or	 IT	 therapy	 alone,	 with	 combination	 therapy	 treated	 mice	showing	a	greater	effect	on	the	thalamus	than	the	other	treatment	groups.		
b)	 IC	 and	 IT	 delivery	 of	 gene	 therapy	 differentially	 reduce	 ASFM	 in	 the	










































































































































































































































































































































































































































































































































































































































































Ppt1-/-	mice.	Furthermore,	at	9	months,	only	IT	and	IC	mice	showed	a	significantly	higher	 level	 of	 AFSM	 compared	 to	 the	wildtype	 in	 the	M1	 cortex	 and	 lumbar	spinal	cord	respectively	(Figure	5.15).				These	 data	 are	 consistent	 the	 analysis	 of	 glial	markers	with	 IC	 therapy	 alone	having	little	to	no	effect	on	the	accumulation	of	AFSM	in	the	spinal	cord.	On	the	other	hand,	IT	therapy	had	some	early	effect	in	reducing	AFSM	accumulation	in	the	cortex	while	effectively	treating	the	spinal	cord.	However,	IC/IT	mice	show	the	greatest	overall	 reduction	of	pathology	 than	either	 IC	or	 IT	 therapy	alone.	Furthermore,	this	combination	IC/IT	therapy	seems	to	have	an	additional	effect	on	reducing	pathology	in	the	thalamus,	which	is	not	readily	observed	in	either	of	the	single	therapies.	
c)	Delayed	neurodegeneration	in	combination	IC/IT	treated	Ppt1-/-	mice.		Profound	and	progressive	neuron	loss	is	observed	in	the	brains	and	spinal	cords	of	Ppt1-/-	mice	(Bible	et	al,	2004;	Kielar	et	al,	2007;	Macauley	et	al,	2009)(Chapter	3.3).	Therefore,	to	assess	any	neuroprotective	effect	afforded	by	either	the	single	IC	 or	 IT	 therapies	 or	 the	 combination	 IC/IT	 therapy;	 unbiased	 stereological	neuron	counts	were	obtained	from	a	series	of	Nissl	stained	sections	in	the	M1	cortex,	 the	 VPM/VPL	 and	 the	 ventral	 horn	 (VH)	 of	 the	 lumbar	 spinal	 cord	(Chapter	2.7).		In	the	M1	cortex,	all	treatment	groups	showed	a	neuroprotective	effect	from	3	to	7	 months,	 with	 significant	 neuron	 loss	 only	 seen	 in	 untreated	 Ppt1-/-	 mice	compared	to	wildtype	controls.	At	9	months,	however,	all	treatment	groups		showed	 a	 significant	 reduction	 in	 estimated	 neuron	 number	 compared	 to	wildtype	controls	(Figure	5.16	A).	IC/IT	and	IC	mice	did	not	show	any	significant	neuron	loss	in	the	VPM/VPL	until	7	months,	unlike	IT	mice	and	untreated	Ppt1-/-	mice,	 but	 all	 groups	 showed	 significant	 neuron	 loss	 in	 the	 VPM/	 VPL	 after	 7	months	(Figure	5.16	B).		Lastly	in	the	ventral	horn	of	the	lumbar	spinal	cord,	only	untreated	 Ppt1-/-	 mice	 showed	 significant	 neuron	 loss	 at	 3	 and	 5	 months	compared	 to	 wildtype	 mice,	 with	 all	 treatment	 groups	 showing	 significant	neuron	loss	at	7	months	(Figure	5.16	C).		 	
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 Figure 5.16– Delayed neuron loss in Ppt1-/- mice receiving gene therapy 
Optical fractionator estimates of neuron numbers in brain and spinal cord regions showing a 
delayed loss of neurons in almost all regions between 3 and 7 month time points across 
intracranial (IC), intrathecal (IT) and combination intracranial and intrathecal (IC/IT) treated 
Ppt1-/- mice, as compared to untreated Ppt1-/- mice and wildtype controls. Significance is 
compared to wildtype controls (red stars). ). *p<0.05, **p<0.01, ***p<0.001, one-way ANOVA 
with post-hoc Bonferroni correction. Values shown are mean ± SEM  (n=3 mice/group).	 	
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	Collectively	 these	 data	 reveal	 that	 combination	 IC/IT	 therapy	 has	 a	 greater	neuroprotective	effect	than	either	IC	or	IT	therapy	alone.	Both	IC	and	IT	therapy	show	good	regional	effects,	but	have	significantly	reduced	impact	away	from	the	site	of	delivery.	The	rotarod	testing	and	survival	data	(Figure	5.9),	corroborates	these	 data	 showing	 that	 combination	 therapy	 affords	 the	 best	 therapeutic	efficacy	in	Ppt1-/-	mice,	and	we	can	infer	that	this	protracted	disease	course	is	in	part	due	to	the	delayed	neuron	loss	observed	here	(Figure	5.16).	
5.4	Summary	Having	demonstrated	early	and	profound	spinal	cord	pathology	in	Ppt1-/-	mice,	it	was	 imperative	 to	 test	 whether	 this	 significantly	 contributes	 to	 disease	progression	and	the	appearance	of	sensorimotor	deficits.	Therefore,	we	tested	whether	 targeting	 this	 region	 of	 the	 CNS	 with	 experimental	 therapies	 would	prove	beneficial	in	treating	these	mice.			A	 pilot	 study	 to	 test	 the	 feasibility	 of	 administering	 intrathecal	 human	recombinant	 PPT1	 showed	 a	 significant	 reduction	 in	 glial	 activation	 and	autofluorescent	storage	material	accumulation	in	the	spinal	cords	and	the	cortex	of	 Ppt1-/-	 mice.	 Although	 there	 was	 little	 neuroprotection	 afforded	 by	 this	therapeutic	approach	at	such	a	 late	 time	point	after	receiving	IT	administered	ERT,	the	improvements	in	longevity,	motor	performance	and	some	pathological	features	such	as	gliosis	and	AFSM	accumulation	(Figures	5.1-5.8)	(Lu	et	al,	2015)	showed	 a	 significantly	 protracted	 disease	 progression	 in	 these	mice	 that	was	dose	dependent.	It	also	demonstrated	that	the	spinal	cord	contributes	to	disease	progression	and	 that	 reducing	pathology	 in	 this	 region	of	 the	CNS	 is	not	only	feasible,	 but	 can	 also	 be	 an	 effective	 therapeutic	 approach	 in	 Ppt1-/-	 mice.	Furthermore,	 delivering	 the	 therapy	 to	 the	 CSF	was	 shown	 to	 have	 a	 greater	impact	on	brain	structures,	especially	the	cortex,	than	was	initially	predicted.			Targeting	gene	therapy	to	the	brain	alone	was	shown	not	to	have	any	significant	effect	 on	 spinal	 cord	 pathology,	while	 targeting	 the	 same	 therapy	 only	 to	 the	spinal	cord	only	showed	minor	improvements	in	brain	pathology	(Figures	5.10-
		 173	












The	research	presented	in	this	thesis	represents	the	first	study	to	characterize	the	spinal	cord	as	a	site	of	significant	pathology	in	CLN1	disease,	or	indeed	in	any	major	 form	of	NCL.	We	have	 also	 demonstrated	 gait	 defects	 in	 Ppt1	 deficient	(Ppt1-/-)	mice	that	may	relate	to	this	pathology,	and	have	defined	the	spinal	cord	as	a	novel	therapeutic	target	in	this	disease	that	can	be	treated	effectively.			Characterizing	the	nature	and	progression	of	pathology	in	the	spinal	cord	of	Ppt1-
/-	mice	has	not	only	revealed	widespread	and	profound	changes	in	this	region	of	the	CNS,	but	also	that	these	changes	precede	the	onset	of	similar	events	within	the	brain.	Furthermore,	there	is	evidence	of	a	postnatal	developmental	delay	as	well	as	significant	white	matter	pathology	that	are	not	seen	in	the	forebrains	of	these	mice.	Similar	pathology	to	that	seen	in	Ppt1-/-	mice	was	also	described	in	human	CLN1	post-mortem	spinal	cord	tissue.	Taken	together,	these	data	serve	to	highlight	 the	 spinal	 cord	 as	 a	 novel	 and	 unexpected	 site	 of	 pathology	 that	 is	profoundly	affected	early	in	CLN1	disease	progression	(Chapter	3).	The	presence	of	 similar	 spinal	 cord	 pathology	 in	mouse	models	 of	 CLN2	 and	 CLN3	 disease	suggests	that	this	region	of	the	CNS	may	also	be	a	potential	therapeutic	target	across	various	forms	of	NCL	(Chapter	3.11).		We	demonstrate	a	variety	of	novel	gait	abnormalities	in	Ppt1-/-	mice,	including	an	increased	 reliance	 on	 the	 forelimbs	 for	 support	 and	 altered	 inter-limb	 co-ordination	 that	 begin	 early	 in	 disease	 progression	 (Chapter	 4).	 These	 early	changes	in	gait	may	not	only	relate	to	the	spinal	cord	pathology	demonstrated	at	these	ages	in	Ppt1-/-	mice	(Chapter	3),	but	also	provide	evidence	for	early	motor	deficits	as	seen	in	human	CLN1	disease	(Dolisca	et	al,	2013).	This	gait	analysis	also	corroborated	evidence	 from	previous	studies	 for	a	significant	and	overall	decline	in	motor	function	with	age	in	these	mice	(Dearborn	et	al,	2015;	Gupta	et	al,	2001;	Macauley	et	al,	2009).			Lastly,	we	show	that	therapeutically	targeting	the	Ppt1-/-	mouse	spinal	cord	via	intrathecal	 administration	 of	 either	 ERT	 or	 AAV-mediated	 gene	 therapy	positively	 impacts	 disease	 progression	 and	 that	 the	 later	 approach	 combined	with	 brain-directed	 gene	 therapy	 results	 in	 synergistic	 and	 significant	
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improvements	 in	 lifespan,	 behavior	 and	 pathology	 in	 these	mice	 (Chapter	 5).	These	data	not	only	demonstrate	 the	 spinal	 cord	 to	be	clinically	 significant	 to	disease	progression	in	these	mice,	but	that	targeting	it	in	addition	to	the	brain	will	be	important	for	the	success	of	future	therapies	for	CLN1	disease.	
6.1	Spinal	cord	pathology	in	human	and	murine	CLN1	disease.	The	initial	study	of	human	CLN1	disease	pathology	briefly	described	the	spinal	cord	 to	 be	 atrophied,	 but	 to	 a	 lesser	 extent	 than	 either	 the	 forebrain	 or	 the	cerebellum	and	as	having	“distended”	anterior	horn	cells,	presumably	due	to	the	accumulation	of	 storage	material	 (Haltia	 et	 al,	 1973a;	 Santavuori	 et	 al,	 1974).	However,	 thus	 far,	 the	brain	has	been	considered	 the	main	 locus	of	pathology	(Bible	 et	 al,	 2004;	 Kielar	 et	 al,	 2007;	 Macauley	 et	 al,	 2009)	 in	 CLN1	 disease	possibly	due	to	the	nature	of	clinical	symptoms	(Dolisca	et	al,	2013).			Despite	the	comprehensive	pathological	characterization	of	brain	and	cerebellar	pathology	in	CLN1	disease	(Bible	et	al,	2004;	Kielar	et	al,	2007;	Macauley	et	al,	2009),	 the	 sensorimotor	 deficits	 observed	 in	 both	 human	 cases	 and	 mouse	models	cannot	be	completely	explained	(Dearborn	et	al,	2015;	Dolisca	et	al,	2013;	Schulz	et	al,	2013).	Combined	with	the	limited	success	of	various	brain	directed	therapies	(Chapter	1.6),	we	hypothesized	the	presence	of	significant	pathology	in	CNS	outside	either	the	forebrain	or	cerebellum.	We	initially	focused	our	efforts	on	 the	spinal	 cord	due	 to	 its	 involvement	 in	 the	sensory	and	motor	pathways	connecting	the	brain	and	peripheral	nervous	system	(PNS)	(Chapter	1.7).	
a)	Early	generalized	pathology	in	Ppt1-/-	mice	spinal	cord	Given	the	profound	and	progressive	pathology	that	has	already	been	described	in	 the	 forebrain	and	cerebellum	of	Ppt1-/-	mice	 (Bible	et	 al,	2004;	Kielar	et	 al,	2007;	Macauley	et	al,	2009),	it	is	perhaps	not	entirely	surprising	to	have	found	some	degree	of	pathology	in	the	spinal	cord	of	these	mice.	Indeed,	the	various	pathological	changes	seen	in	the	brain	including	regional	atrophy,	neuron	loss,	accumulation	of	autofluorescent	storage	material	and	glial	activation	are	all	also	observed	 in	 the	 cord.	 However,	 the	 early	 onset	 and	 severity	 of	 spinal	 cord	pathology	 in	 these	 mice	 was	 unexpected.	 Indeed,	 all	 the	 above	 pathological	
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phenotypes	seen	 in	 the	brain	seem	to	have	an	earlier	onset	 in	 the	spinal	cord	(Summarized	in	Fig	6.1).		
	
 
Figure 6.1 – Disease progression in the brain vs. spinal cord in Ppt1-/- mice.  
Figure summarizing the timing of key neuropathological features in brains vs. spinal cords in 
Ppt1-/- mice. The ages shown represent the age of onset of a given pathological phenotype in 
that region of the CNS. All pathological phenotypes were shown to have an earlier onset in 
the spinal cord than in the brain with the exception of white matter (WM) pathology, which was 
present in the spinal cord, but not observed in the brain. 
 Despite	 this	 early	onset	of	pathology,	 the	progression	of	 the	disease	 in	Ppt1-/-	mice	followed	the	same	general	pattern	in	the	spinal	cord	as	in	the	brain,	with	spinal	 cord	neurons	 in	 the	dorsal	and	ventral	horns	of	Ppt1-/-	mice	showing	a	clearly	 visible	 increase	 of	 AFSM	 accumulation	 as	 early	 as	 3	months,	which	 is	earlier	 than	 seen	 in	 the	 forebrain	 (Chapter	3.4).	 Furthermore,	 various	neuron	populations	 have	 hypertrophied	 cell	 bodies	 at	 7	months	 (Chapter	 3.5).	 These	data	indicate	that	not	only	was	there	an	early	onset	in	disease	progression,	but	that	 the	 changes	 observed	 were	 consistent	 with	 those	 seen	 in	 the	 brain	 and	cerebellum,	indicating	the	presence	of	a	similar	disease	process	in	both	regions	(Bible	et	al,	2004;	Kielar	et	al,	2007).		Similarly,	astrocytosis	and	microglial	activation	preceded	significant	neuron	loss	in	the	spinal	cord	(Chapter	3.8),	in	a	similar	fashion	to	in	the	forebrain,	although	CD68	reveals	an	earlier	onset	of	microglial	activation	than	F4/80	that	was	used	
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in	previous	studies	in	the	forebrain	(Bible	et	al,	2004;	Kielar	et	al,	2007).	Despite	this	 early	 onset	 of	 pathology,	 the	 progression	 of	 the	 disease	 in	 Ppt1-/-	mice	essentially	occurs	as	it	does	in	the	brain	(Kielar	et	al,	2007;	Macauley	et	al,	2009).	This	 further	 emphasizes	 the	 role	 that	 glial	 activation	may	 play	 in	 the	 disease	progression	of	CLN1	disease	with	regions	of	glial	activation	“predicting”	where	neuron	loss	occurs	in	the	CNS,	and	studies	to	determine	the	exact	nature	of	this	neuron-glia	 interaction	are	 currently	ongoing.	These	have	 revealed	a	 range	of	functional	deficits	in	Ppt1	deficient	astrocytes	and	microglia,	which	appear	to	be	capable	of	directly	harming	neurons	(Lange,	PhD	thesis).		The	 re-distribution	 of	 AFSM	 from	 within	 neuron	 cell	 bodies	 to	 activated	microglial	cells	that	we	documented	in	the	spinal	cord	(Figure	3.8),	has	also	been	documented	in	the	brains	of	CLN6	sheep	(Oswald	et	al,	2005),	most	likely	due	to	activated	microglia	phagocytizing	dead	or	dying	neurons.	This	suggests	that	the	microglial	activation	seen	in	the	Ppt1-/-	spinal	cord	is	also	similar	in	nature	to	that	occurring	 in	 other	 forms	 of	 NCL.	 Indeed,	 taken	 together,	 the	 glial	 activation	observed	in	Ppt1-/-	mouse	spinal	cords	appears	similar	to	that	occurring	in	the	brains	of	these	mice,	indicating	that	the	same	disease	process	may	be	at	work	at	an	 earlier	 time	 point	 in	 this	 region	 of	 the	 CNS.	 Microglial	 activation	 and	astrocytosis	 in	 the	spinal	cord	have	been	shown	to	be	associated	with	altered	spinal	cord	function	in	spinal	cord	injury	and	diseases	such	as	transverse	myelitis	and	multiple	sclerosis,	with	symptoms	including	increased	pain,	irritability	and	altered	mobility	as	well	as	actual	damage	 to	spinal	 cord	structures	 (Beh	et	al,	2013;	 Hausmann,	 2003).	 Furthermore,	 the	 low-level	 infiltration	 of	 peripheral	lymphocytes	observed	in	the	spinal	cord,	may	also	contribute	to	these	symptoms,	similar	to	the	brain	(Groh	et	al,	2013).	Therefore,	we	may	hypothesize	that	the	progressive	increase	in	spinal	cord	inflammation	observed	in	Ppt1-/-	mice	may	have	a	profound	effect	on	the	sensorimotor	function	in	these	animals,	although	it	would	take	the	generation	of	cell	type-specific	knockout	mice	to	determine	if	this	was	the	case	experimentally.			Recently,	 a	mouse	model	where	Ppt1	 is	 tethered	 to	 the	LAMP1	protein	 in	 the	lysosomal	 membrane	 has	 been	 generated	 (Cooper	 and	 Sands,	 personal	
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communication).	 Such	 a	 mouse	 model	 would	 reduce	 any	 extra-lysosomal	functions	of	Ppt1	(Chapter	1.4	c),	but	would	also	prevent	cross-correction	of	the	enzyme	by	 the	mannose-6-phosphate	 (Chapter	1.6	a)	 receptor	 system	both	 in	
vivo	and	in	vitro.	Therefore,	this	model	could	prove	to	be	a	powerful	tool	to	create	cell-specific	knock	outs	of	Ppt1	to	study	in	vivo	the	contribution	of	glial	cells	to	disease.			As	 discussed	 in	 Chapter	 3.3,	 our	 data	 revealing	 the	 average	 loss	 of	 34.4%	 of	neurons	 in	 the	 dorsal	 horn	 and	 28.61%	 in	 the	 ventral	 horn	 of	 Ppt1-/-	 mice,	compared	to	their	wildtype	counterparts	by	7	months	of	age	(Table	3.1)	reinforce	that	Ppt1-/-	mice	have	a	severe	neurodegenerative	pathology	in	the	spinal	cord.	These	values	are	comparable	to	that	seen	in	Cln8	(Cln8mnd)	(Fujita	et	al,	1998;	Plummer	et	al,	1995)	`(before	it	was	confirmed	as	an	NCL	mouse	model)	as	well	as	to	other	models	of	neurodegenerative	diseases	affecting	the	spinal	cord	such	as	ALS	 (Dal	Canto	&	Gurney,	 1997;	Ravits	 et	 al,	 2007)	 and	SMA(Simone	et	 al,	2016;	Sleigh	et	al,	2011),	Parkinson	disease	(Martin	et	al,	2006;	Vivacqua	et	al,	2011),	 Alzheimer	 disease	 (Seo	 et	 al,	 2010)	 and	 HD	 (Valadao	 et	 al,	 2016).	Interestingly	however,	while	nearly	all	of	these	diseases	show	a	vulnerability	of	motor	neuron	populations	over	interneuron	populations,	our	observations	show	that	interneuron	populations	are	more	vulnerable	than	motor	neurons	early	in	disease	progression	in	the	spinal	cords	of	Ppt1-/-	mice.		The	 loss	 of	 calbindin	 positive	 interneurons,	 before	 either	 calretinin	 positive	interneurons	or	motor	neurons,	which	we	saw	in	the	spinal	cord	of	Ppt1-/-	mice	(Chapter	3.3)	was	also	observed	in	the	brain	(Kielar	et	al,	2007),	which	further	suggests	the	common	pathological	themes	in	both	regions,	but	this	process	starts	at	 an	 earlier	 time	 point	 in	 the	 spinal	 cord.	 This	 initial	 selective	 loss	 of	interneurons	in	the	spinal	cord	may	potentially	lead	to	a	reduction	of	inhibitory	tone	 in	 the	 spinal	 cord	 that	 is	 required	 for	 the	 integration	 of	 central	 motor	commands	 and	 sensory	 feedback	 signals	 in	 the	 spinal	 cord	 (Rossignol	 et	 al,	2006),	and	it	would	be	informative	to	investigate	whether	this	is	the	case.	The	loss	of	inhibitory	interneurons	in	the	dorsal	horn	of	the	spinal	cord	is	associated	with	 the	 development	 of	 pain	 and	 increased	 pruritis	 or	 itching	 (Adams	 et	 al,	
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2010;	Bardoni	et	al,	2013;	Meisner	et	al,	2010;	Ross	et	al,	2010),	while	the	loss	of	interneurons	can	also	affect	motor	function	with	an	initial	“release”	 leading	to	increased	 activity	 of	 motor	 neurons,	 causing	 muscular	 spasticity	 and	 hyper-reflexia	(Florman	et	al,	2013).	These	findings	may	in	part	help	explain	the	early	clinical	 presentation	 of	 human	 CLN1	 disease	 including	 irritability,	 motor	clumsiness,	ataxia,	spasticity	and	hyperkinesias	(Dolisca	et	al,	2013;	Williams	et	al,	2006).	To	further	investigate	this,	testing	Ppt1-/-	mice	for	nociceptive	assays	such	as	von	Frey	testing	(Bradman	et	al,	2015),	tests	for	itch	(Shimada	&	LaMotte,	2008)	or	other	tests	 for	pain	(Wilson	&	Mogil,	2001)	at	early	time	points	may	provide	further	evidence	of	such	sensory	deficits.		Furthermore,	crossing	these	mice	with	other	knockout	mouse	models	used	in	pain	research	such	those	which	have	 genes	 for	 opioid	 receptors,	 cytokines	 or	 neurotrophins	 genetically	inactivated,	may	also	help	to	further	understand	these	mechanisms	(Dierich	&	Kieffer,	2004).	If	such	a	sensory	defect	can	be	established,	similar	non-invasive	tests	for	nociception	can	also	be	used	to	detect	such	early	changes	in	the	clinical	diagnosis	of	CLN1	disease.		The	early	selective	loss	of	interneurons	before	that	of	motor	neurons	suggests	a	similarity	between	pathological	processes	in	the	spinal	cords	and	brains	of	Ppt1-
/-	mice,	where	there	also	is	an	early	loss	of	GABAergic	interneurons	in	the	cortex	and	hippocampus	(Kielar	et	al,	2007).	There	may	also	be	a	similar	process	in	the	spinal	 cords	of	Cln8mnd	mice	where	GABAergic	 interneurons	are	preferentially	lost	 in	 the	 forebrain	 (Cooper	 et	 al,	 1999),	 but	 it	 remains	 to	 be	 seen	 if	 such	interneuron	loss	precedes	motor	neuron	loss	in	the	spinal	cords	of	these	mice	(Plummer	et	al,	1995;	Ranta	et	al,	1999).	This	however,	is	in	contrast	to	models	of	other	LSDs	such	as	gangliosidoses	(Hahn	et	al,	1997;	Jellinger	et	al,	1982)	or	Neimann-Pick	type	A	(Marmiroli	et	al,	2009)	or	type	C	(Dardis	et	al,	2016;	Yan	et	al,	 2011),	which	preferentially	 seem	 to	 affect	motor	neurons.	 The	mechanism	underlying	this	neuronal	selectivity	in	the	spinal	cord,	similar	to	that	in	the	brain	remains	unexplained,	and	will	require	further	work	to	better	understand	disease	pathophysiology	in	Ppt1-/-	mice.		
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The	subsequent	loss	of	motor	neurons	at	5	months,	as	well	as	the	loss	of	primary	sensory	neurons	in	the	DRG	(Chapter	3.3,	3.7),	may	both	contribute	to	the	overall	decline	 in	motor	 function	 seen	 in	 both	Ppt1-/-	mice	 and	human	CLN1	disease,	along	 with	 the	 pathology	 in	 the	 brain	 and	 cerebellum	 (Kielar	 et	 al,	 2007;	Macauley	 et	 al,	 2009).	 Therefore,	 from	our	 preliminary	 description	 of	 lumbar	DRG	pathology	in	7	month	old	Ppt1-/-	mice	(Chapter	3.7)	and	given	the	severity	of	pathology	affecting	spinal	cord	neurons,	it	will	be	of	great	interest	to	study	the	extent	and	nature	and	progression	of	DRG	neuron	loss	and	how	this	relates	to	pathology	within	the	spinal	cord.	It	is	not	clear	whether	an	inflammatory	process	also	 occurs	 within	 DRGs,	 as	 staining	 for	 satellite	 cells	 of	 the	 DRG	with	 GFAP	revealed	no	overt	differences	between	genotypes	(data	not	shown),	and	it	will	require	 the	 use	 of	 other	 markers	 such	 as	 TNF-α,	 IL-6,	 S100	 or	 glutamine	synthetase	 in	 order	 to	 determine	 if	 the	 disease	 cascade	 within	 the	 DRG	 also	involves	 such	 cells	 (Hanani,	 2005).	 Furthermore,	 staining	 DRG	 tissue	 for	peripheral	lymphocytes	with	CD4+CD8	did	not	reveal	any	positive	staining,	and	therefore,	further	investigation	will	be	required	to	see	if	there	is	any	peripheral	lymphocyte	 infiltration	 in	 this	 tissue,	 which	 is	 often	 associated	 with	 the	development	of	pain	(Scholz	&	Woolf,	2007).	Understanding	DRG	pathology	may	provide	us	with	a	better	understanding	of	in	how	sensory	and	motor	pathways	may	be	affected	differentially	in	this	disease,	and	may	help	to	better	explain	the	sensory	symptoms	of	CLN1	disease.		Interestingly,	very	little	change	was	observed	when	staining	for	synaptic	markers	in	Ppt1-/-	spinal	cords,	as	compared	to	the	changes	that	have	been	reported	in	their	brains	(Chapter	3.6)	(Kielar	et	al.,	2009).	With	the	exception	of	changes	seen	in	VAMP2	staining,	which	closely	 resemble	 those	seen	 in	 the	brain,	 staining	7	month	old	tissue	for	pre-	and	post-synaptic	markers	revealed	very	little	change	in	these	markers	in	the	spinal	gray	matter	of	Ppt1-/-mice.	This	discrepancy	may	also	be	a	result	of	the	relatively	thick	(40	microns)	sections	used	to	examine	the	synapse-rich	grey	matter	of	 the	spinal	 cord	 (Chapter	1.7).	Furthermore,	many	synaptic	 markers	 are	 known	 to	 have	 “down-up”	 or	 “up-down”	 temporal	expression	 profiles	 during	 disease	 progression	 (Kielar	 et	 al,	 2009).	 Thus,	analyzing	 7	month	 old	 tissue	may	 not	 reflect	 changes	 seen	 earlier	 in	 disease	
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progression.	Alternatively,	this	may	indicate	that	synaptic	defects,	while	present,	may	be	of	a	different	nature	to	those	seen	in	the	brain.	Regardless	of	the	cause,	further	 work	 will	 be	 required	 to	 determine	 the	 exact	 nature	 and	 temporal	progression	 of	 synaptic	 pathology,	 if	 any,	 in	 the	 Ppt1-/-	 mouse	 spinal	 cord.	Currently,	 we	 plan	 on	 employing	 western	 blotting	 from	 synaptosomal	preparations	 to	 determine	 whether	 the	 expression	 of	 synaptic	 markers	 is	significantly	 altered	 at	 7	 months	 in	 Ppt1-/-	 mouse	 spinal	 cords,	 as	 was	demonstrated	in	their	brains	(Kielar	et	al,	2009).			In	addition	to	the	early	onset	of	disease	in	the	spinal	cords	of	Ppt1-/-	mice,	the	other	unexpected	feature	was	the	simultaneous	onset	of	pathology	at	all	levels	of	the	 cord,	 involving	 both	 the	 dorsal	 and	 ventral	 horn	 (Chapter	 3).	 This	 is	 in	marked	 contrast	 to	 the	 regional	 specificity	 of	 brain	 pathology	where	 there	 is	more	pronounced	pathology	 in	 the	 sensory	 versus	motor	 regions	 (Bible	 et	 al,	2004;	Kielar	et	al,	2007;	Macauley	et	al,	2009).	Differences	in	cellular	architecture	and	function	may	play	a	major	role	in	the	regional	specificity	of	neuron	loss	in	the	brain	of	Ppt1-/-	mice	(Cooper,	2003;	Cooper,	2010).	Why	there	should	be	such	fundamental	 differences	 in	 cellular	 selectivity	 between	 the	 Ppt1-/-	 brain	 and	spinal	cord	is	unclear,	but	the	relatively	similar	regional	architecture	at	all	levels	of	the	spinal	gray	matter	(Chapter	1.7),	as	well	as	the	high	population	of	spinal	interneurons	in	the	dorsal	and	ventral	horns	may	be	determining	factors	in	the	generalized	nature	of	spinal	cord	pathology	in	these	mice.	However,	the	existence	of	region-specific	differences	in	disease	mechanisms	in	the	spinal	cord	of	Ppt1-/-	mice	cannot	be	excluded.	
b)	Novel	pathological	phenotypes	in	Ppt1-/-	mice	spinal	cord.	The	difference	in	the	age	of	onset	as	well	as	the	generalized	nature	of	spinal	cord	pathology	 in	 Ppt1-/-	mice	 makes	 it	 important	 to	 consider	 that	 there	 may	 be	slightly	different	disease	mechanisms	occurring	in	this	region	of	the	CNS	than	in	the	brain.	This	is	corroborated	by	the	presence	of	novel	pathological	phenotypes	in	 the	 spinal	 cord	 that	 are	not	 observed	 in	 the	brain	 including	 evidence	 for	 a	possible	postnatal	developmental	delay,	and	significant	white	matter	pathology.			
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The	volumes	of	both	the	spinal	gray	and	white	matter	has	been	shown	to	increase	in	the	postnatal	period	in	both	mice	and	humans	(Lassek	AM,	1938;	Sakla,	1959;	Sakla,	1969).	Our	analysis	revealed	that	between	1-3	months	of	age,	in	wildtype	(C57BL/6)	mice	 there	 is	an	 increase	 in	whole	cord,	as	well	 as	gray	and	white	matter	volumes	at	all	levels	of	the	cord.	However,	despite	initially	having	similar	postnatal	spinal	cord	volumes	at	1	month	of	age,	Ppt1-/-	mouse	spinal	cords	fail	to	 grow	 in	 size	 to	 the	 same	 extent	 (Figure	 3.1,	 3.2).	 Interestingly,	 this	 lack	 of	spinal	cord	growth	was	seen	at	all	levels	of	the	cord,	and	was	evident	in	both	the	gray	 and	 white	 matter.	 This	 suggests	 that:	 a)	 like	 the	 other	 pathological	phenotypes	 that	 have	 been	 already	mentioned,	 this	 volume	 change	 affects	 all	levels	of	the	cord,	and	b)	that	this	delay	affects	the	postnatal	development	of	both	the	gray	and	white	matter	and	may	result	from	the	loss	of	PPT1	function	during	development,	 as	 it	 has	 been	 implicated	 in	 processes	 such	 as	 axon	 guidance,	synaptic	 pruning	 and	 determining	 cell	 fate	 during	 (Chu-LaGraff	 et	 al,	 2010;	Fabritius	et	al,	2014;	Isosomppi	et	al,	1999;	Minye	et	al,	2016).	This	loss	of	the	developmental	functions	of	PPT1	may	be	more	apparent	in	the	spinal	cord	that	undergoes	significant	postnatal	growth	cord	in	mice	(Sakla,	1969)		as	compared	to	 the	 forebrain.	 Indeed,	 the	 cerebellum,	 which	 also	 undergoes	 significant	postnatal	development,	is	also	severely	affected	in	Ppt1-/-	mice	(Macauley	et	al,	2009).		The	 fact	 that	 the	 spinal	white	matter	 is	 affected	 in	 these	mice	 is	 also	 a	 novel	finding,	as	various	studies	in	the	brain	and	cerebellum	have	failed	to	observe	any	significant	changes	in	the	white	matter	in	these	regions	of	the	CNS	(Bible	et	al,	2004;	Kielar	et	al,	2007;	Macauley	et	al,	2009).		Further	evidence	for	white	matter	involvement	was	observed	by	the	pronounced	microglial	activation	in	the	dorsal	and	ventral	funiculi	of	the	cervical	and	lumbar	cord	(Chapter	3.8).	Investigation	of	the	white	matter	using	other	markers	showed	that	greater	differences	were	observable	in	sections	stained	for	neurofilament-H	(NF)	and	toluidine	blue,	with	the	later	showing	reduced	axon	densities	in	Ppt1-/-	mice,	as	compared	to	those	stained	for	Luxol	fast	blue	or	myelin	basic	protein	(MBP)	(Chapter	3.9).	This	was	further	 supported	 from	 the	 analysis	 of	 Thy1-YFP/Ppt1-/-	 mouse	 spinal	 cords,	which	showed	significant	axonal	degeneration	in	the	spinal	white	matter	in	these	
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mice	 (Figure	 3.17).	 The	 fact	 that	 these	 changes	 are	 seen	 at	 5	 months	 at	 the	earliest	probably	means	that	the	observed	white	matter	pathology	is	likely	due	to	axon	loss	as	a	result	of	neuron	loss	in	the	gray	matter	(Chapter	3.3),	as	opposed	to	a	primarily	demyelinating	pathology.	Further	work	remains	to	be	done	with	regards	 to	 the	 age	 of	 onset	 of	 axon	 degeneration,	 as	 well	 as	 to	 understand	whether	any	individual	white	matter	tracts	may	be	affected	first,	similar	to	the	selectivity	 of	 neuron	 loss	 in	 the	 gray	matter.	 Furthermore,	 given	 the	 changes	observed	with	MBP	staining,	it	will	also	be	of	interest	to	stain	for	oligodendrocyte	markers	to	see	if	they	are	affected	in	the	spinal	cord,	even	though	they	are	not	obviously	 thought	 to	 be	 involved	 in	 CLN1	 disease	 progression	 (Cooper	 et	 al,	2015).		The	early	onset	of	spinal	cord	pathology	in	Ppt1-/-	mice	raises	the	possibility	of	disease	 spreading	 rostrally	 from	 the	 spinal	 cord	 to	 the	 brain.	 This	 is	substantiated	further	by	the	fact	that	one	of	the	earlier	sites	of	pathology	in	the	brain	 is	 the	 ventral	 posterior	 (VPM/VPL)	 nucleus	 of	 the	 thalamus	where	 the	spino-thalamic	pathways	synapse	(Chapter	1.7)	(Kielar	et	al,	2007).	Similar	data	has	also	been	shown	for	the	dorsal	lateral	geniculate	nucleus	(LGnD)	in	the	visual	pathway	following	retinal	degeneration	(Griffey	et	al,	2005;	Kielar	et	al,	2007).	Together,	these	data	suggest	that	the	disease	progresses	from	the	periphery	to	the	CNS	and	raises	the	possibility	of	the	anterograde	(or	retrograde	in	the	case	of	motor	pathways)	progression	of	the	disease.	This	may	be	because	the	death	of	spinal	 cord	 neurons	 may	 lead	 to	 reduced	 afferent	 input	 to	 the	 postsynaptic	thalamic	or	cortical	neurons	that	they	project	to	(or	receive	input	from),	causing	them	 to,	 in	 turn,	 become	 dysfunctional.	 In	 this	 sense	 it	 could	 potentially	 be	considered	 as	 an	 anterogradely	 spreading	 deafferentation	 along	 these	interconnected	pathways.	A	similar	“knock-on	effect“	of	disease	propagation	has	been	 suggested	 in	 a	 variety	 of	 neurodegenerative	 conditions	 (Braak	 &	 Del	Tredici,	 2011;	 Fornito	 et	 al,	 2015;	Raj	 et	 al,	 2012;	 Yates,	 2012),	 and	 our	 data	suggest	 this	may	also	be	 the	case	 in	CLN1	disease.	Our	 findings	also	 raise	 the	possibility	that	there	may	be	significant	pathology	 in	the	PNS	that	may	have	a	role	 in	 initiating	 spinal	 cord	 pathology.	 Therefore,	 in	 addition	 to	 the	 DRG,	studying	the	staging	of	pathology	in	the	dorsal	column	nuclei	in	the	brainstem	
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(Chapter	 1.7),	 as	 well	 as	 peripheral	 nerves	 will	 be	 crucial	 to	 developing	 our	understanding	 of	 disease	 progression.	 Analyzing	 the	 same	 Thy1-YFP/Ppt1-/-	reporter	 mice	 that	 we	 used	 to	 reveal	 the	 loss	 of	 spinal	 axons	 (Chapter	 3.9)	provides	 robust	 preliminary	 data	 that	 the	 sciatic	 nerve	 undergoes	 a	 similar	profound	loss	of	axons	(Cooper	and	Sands,	personal	communication).	It	will	be	important	to	follow	up	these	preliminary	observations	to	define	the	time	course	and	mechanisms	by	which	this	occurs.	Furthermore,	the	brainstem	also	houses	the	centers	for	cardiovascular	and	respiratory	control	(Batten	&	Deuchars,	2009;	Coote,	2007;	Dampney,	1994;	Smith	et	al,	2007;	Wong-Riley	&	Liu,	2005).	With	compromised	 respiratory	 and	 cardiovascular	 function	 a	 major	 clinical	 theme	across	 the	NCLs	(Dolisca	et	al,	2013;	Williams	et	al,	2006),	 it	will	also	be	very	informative	 to	 know	 how	 much	 brainstem	 pathology	 contributes	 to	 these	symptoms	in	CLN1	disease.	
c)	Spinal	cord	pathology	in	human	CLN1	disease	and	mouse	models	of	other	
NCLs.	There	have	been	very	few	descriptions	of	spinal	cord	pathology	in	any	form	of	human	 NCL	 (Anderson	 et	 al,	 2013;	 Bruun	 et	 al,	 1991).	 However,	 there	 was	evidence	of	some	degree	of	pathology	in	human	CLN1	disease	spinal	cords	(Haltia	et	al,	1973a;	Santavuori	et	al,	1974),	and	we	were	fortunate	to	gain	access	to	this	original	post	mortem	sample.		Our	 analysis	 revealed	more	 profound	 pathology	 in	 this	 tissue	 than	 originally	described	 with	 abundant	 accumulation	 of	 AFSM,	 microglial	 activation	 and	changes	 in	 neuron	 morphology	 (Chapter	 3.10).	 This	 closely	 resembled	 the	pathology	 seen	 in	 Ppt1-/-	 mice,	 and	 provides	 evidence	 for	 the	 presence	 of	similarly	profound	pathology	in	human	CLN1	disease.	The	dearth	of	samples	has	precluded	our	ability	to	obtain	quantitative	data	for	human	pathology	and	given	our	findings	in	murine	and	human	CLN1	disease,	the	collection	of	spinal	cords	and	peripheral	nerves	at	autopsy	would	be	recommended.		Furthermore,	given	the	early	onset	of	spinal	cord	pathology	in	Ppt1-/-	mice	and	following	 the	 neuroradiological	 studies	 in	 human	 CLN1	 disease	 brains	
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(Vanhanen	et	al,	2004),	it	would	be	interesting	to	revisit	these	imaging	data	sets	to	 look	 for	any	changes	 in	 the	spinal	cord	volumes	and/or	 intensities	 in	 these	cases.	 This	 may	 prove	 a	 non-invasive	 option	 as	 either	 a	 diagnostic	 tool	 or	 a	prognostic	measure	of	therapeutic	efficacy.		A	brief	study	of	neuronal	morphology	and	glial	activation	in	mouse	models	for	CLN2	and	CLN3	disease	demonstrated	the	existence	of	pathology	in	the	spinal	cords	of	these	mice	as	well	(Chapter	3.11).	Despite	visibly	different	pathological	phenotypes	in	each	of	these	forms	of	NCL,	this	serves	to	highlight	the	spinal	cord	as	 being	 involved	 in	multiple	 forms	of	NCL.	As	 such,	 detailing	 the	nature	 and	progression	of	 spinal	 cord	pathology	will	 be	useful	 in	not	only	understanding	these	 diseases,	 but	 also	 in	 possibly	 uncovering	 any	 common	 pathological	phenotypes	 across	 the	 NCLs.	 This	 will	 likely	 also	 inform	 us	 about	 which	therapeutic	approaches	may	be	best	suited	for	each	form	of	NCL.	
6.2	Changes	in	the	gait	of	Ppt1-/-	mice	Gait	 is	 the	 sequential	 and	 cyclical	 stepping	 pattern	 used	 by	 animals	 for	locomotion	(Biewener,	1990;	Takakusaki,	2013).	The	activity	of	neural	circuits	within	 the	 spinal	 cord	 plays	 a	 vital	 role	 in	 controlling	 gait	 and	 locomotion	 in	mammals,	 acting	 as	 a	 “central	 pattern	 generator”	 that	 receives	 inputs	 from	sensory	afferents	as	well	as	descending	 impulses	 from	supra-spinal	centers	 in	order	 to	 modulate	 motor	 function	 (Dietz,	 1997;	 Dietz,	 2003).	 From	 this	description,	 it	 is	easy	to	see	that	the	gait	 is	more	than	just	the	result	of	motor	function,	 but	 rather	 the	 coordinated	 functioning	 of	 sensorimotor,	 cortical,	cerebellar,	vestibular	and	musculoskeletal	systems	mediated	through	the	spinal	cord	and	PNS	(Takakusaki,	2013).		Gait	abnormalities	are	seen	in	a	variety	of	neurological	disorders	or	as	a	result	of	spinal	cord	or	PNS	injury	(Dietz,	1997;	Enriquez-Algeciras	et	al,	2011;	Hamers	et	al,	2006;	Lin	et	al,	2001;	Starkey	et	al,	2005;	Vrinten	&	Hamers,	2003;	Wooley	et	al,	2005;	Zhou	et	al,	2015).	Indeed	Parkinsonism,	a	clinical	syndrome	that	affects	gait	and	includes	resting	tremors,	bradykinesia,	rigidity	and	postural	instability	is	associated	with	many	LSDs	including	GM1	and	GM2	gangliosidoses,	Gaucher	
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disease,	Fabry-Anderson	disease	and	even	the	major	forms	of	NCLs,	which	may	show	some	or	all	of	these	features	(Shachar	et	al,	2011;	Tuite	&	Krawczewski,	2007)			
Ppt1-/-	mice	show	a	significantly	reduced	ability	to	stay	on	a	rotarod	starting	at	5	months,	as	well	as	other	sensorimotor	and	gait	deficits	that	have	been	previously	described	(Chapter	1.5)	(Dearborn	et	al,	2015;	Griffey	et	al,	2006;	Gupta	et	al,	2001).	 However,	 until	 recently,	 there	 was	 little	 evidence	 of	 any	 significant	sensorimotor	 deficits	 before	 this	 age,	 with	 young	 Ppt1-/-	 mice	 apparently	showing	changes	in	the	walking	initiation	test	as	well	as	their	ability	to	climb	up	a	60°	inclined	plane	(Dearborn	et	al,	2015).	However,	this	reported	phenotype	is	very	different	to	the	clinical	progression	of	human	CLN1	disease,	where	there	is	an	early	onset	of	clumsiness	and	motor	deficits	(Dolisca	et	al,	2013;	Williams	et	al,	2006).	Therefore,	given	our	findings	of	early	and	profound	pathology	in	the	spinal	cords	of	Ppt1-/-	mice	(Chapter	3),	we	decided	to	analyze	the	gait	of	these	mice	at	all	ages	between	1-7	months	using	the	CatWalk	XT	gait	analysis	system	(Noldus,	Wageningen,	Netherlands)	to	further	detail	the	sensorimotor	deficits	in	these	mice.	At	2	months,	Ppt1-/-	mice	demonstrated	a	significantly	altered	gait	with	greater	speed	of	movement,	larger	strides	and	shorter	step	cycles	(Chapter	4.2	–	4.4).	At	this	 time,	 there	 is	 significant	glial	 activation	 in	 the	 spinal	 cords	of	 these	mice,	which	 may	 be	 associated	 with	 pain	 and	 irritation,	 as	 previously	 discussed	(Chapter	6.1).	Furthermore,	it	has	also	been	shown	that	mice	may	go	through	a	phase	of		“galloping”	or	asymmetrical	gait	during	postnatal	development	before	1	month	(Eilam,	1997),	and	while	Ppt1-/-	mice	appear	to	move	in	a	similar	fashion	to	 their	wildtype	 counterparts	 at	1	month,	 their	 apparently	delayed	postnatal	development	of	the	spinal	cord	may	contribute	to	the	re-emergence	of	such	an	asymmetrical	gait	at	this	age.	This	increase	in	asymmetrical	gait	is	evidenced	by	a	 significant	 increase	 in	 single,	 diagonal	 and	 four-limb	 support	 at	 2	 months	(Figure	4.13).			After	5	months	of	age,	there	is	not	only	severe	neurodegeneration	in	the	spinal	cords	 of	 Ppt1-/-	 mice	 (Chapter	 3),	 but	 also	 significant	 neurodegenerative	
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pathology	in	the	brain	and	cerebellum	(Kielar	et	al,	2007;	Macauley	et	al,	2009).	Thus,	 the	 altered	 gait	 observed	 is	 likely	 the	 result	 of	 a	 profoundly	neurodegenerative	disease,	and	shows	a	significant	sensorimotor	decline	across	various	 measures	 including,	 speed	 of	 movement,	 step	 cycle	 measures,	 paw	intensities,	 stride	 length	 and	 step	 sequences	 (Chapter	 4).	 There	 is	 also	 an	increased	 need	 to	 use	 more	 than	 two	 limbs	 for	 support	 during	 a	 step	 cycle	(Chapter	 4.5).	 These	 data	 are	 in	 agreement	 with	 previous	 studies	 that	demonstrate	significant	sensorimotor	deficits	in	these	mice	after	5	months	of	age	(Dearborn	et	al,	2015;	Griffey	et	al,	2006;	Gupta	et	al,	2001).		
Ppt1-/-	mice	also	showed	an	increased	dependence	on	their	forelimbs,	evidenced	by	increased	print	length,	width	and	area	of	the	fore	paws	as	early	as	2	months.	An	increase	in	forepaw	print	width	was	also	seen	from	5	months	of	age,	along	with	a	converse	decrease	of	hind	paw	print	width	(Figure	4.6).	Meanwhile,	these	mice	 tend	 to	 place	 their	 hind	 paws	 closer	 to	 their	 forepaws	during	 each	 step	cycle,	indicating	a	preference	for	support	with	the	fore	limbs,	starting	at	2	months	and	also	seen	consistently	after	4	months	(Figure	4.14).	They	also	demonstrate	an	 increased	 base	 of	 support	 (BOS)	 observed	 in	 the	 forepaws	 with	 age,	presumably	because	of	their	increasing	use	of	the	forelimbs	for	stability,	while	the	hind	paws	only	demonstrated	an	increased	BOS	after	6	months	(Figure	4.12).	The	phase	dispersions	between	each	set	of	 ipsilateral	 limbs	were	significantly	increased	in	Ppt1-/-	mice	after	5	months,	indicating	that	the	forepaws	remained	in	contact	with	the	plate	(or	floor)	longer	when	moving	their	hind	paws	(Figure	4.16).	Ppt1-/-	mice	 also	 showed	 significantly	 higher	 preference	 for	 altered	 AA	pattern	step	sequence,	compared	to	the	AB	pattern	that	is	more	commonly	seen	in	wildtype	mice	(Figure	4.15).	This	change	has	been	shown	to	be	associated	with	spinal	cord	lesions	in	the	ventral	and	lateral	funiculi	of	cats	(Bem	et	al,	1995),	and	indicates	that	there	is	perhaps	a	differential	involvement	of	white	matter	tracts	during	disease	progression.	It	will	require	further	analysis	of	the	white	matter	tracts	to	determine	how	they	are	affected	during	disease	progression,	in	order	to	provide	histological	confirmation	of	this.			
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Therefore	we	see	that	overall,	starting	at	an	early	time	point	of	2	months,	Ppt1-/-	mice	demonstrate	a	greater	dependence	on	their	forelimbs	for	locomotion,	with	reduced	use	of	the	hind	limbs	with	age,	which	closely	resemble	the	changes	in	hind	 limb	 mobility	 that	 were	 first	 observed	 in	 the	 later	 stages	 of	 disease	progression	in	these	mice	(Gupta	et	al,	2001).	This	differential	alteration	in	gait	where	 the	 hind	 limbs	 are	 more	 affected	 is	 commonly	 seen	 in	 spinal	 cord	degeneration	 in	 Parkinson	 and	 Huntington	 diseases	 (Amende	 et	 al,	 2005).	Nonetheless,	this	difference	between	fore	and	hind	limb	coordination	in	Ppt1-/-	mice	 is	 juxtaposed	 to	 the	 generalized	 nature	 of	 their	 spinal	 cord	 pathology	(Chapter	 6.1),	 and	 perhaps	 indicates	 that	 there	 may	 either	 be	 a	 differential	pathological	involvement	of	the	white	matter	tracts	that	we	are	yet	to	uncover	and/or	the	peripheral	nerves.	As	mentioned	before	(Chapter	6.1),	initial	analysis	of	Thy1-YFP/Ppt1-/-	mouse	sciatic	nerves	has	shown	that	this	may	indeed	be	the	case	in	the	PNS	(Cooper	and	Sands,	personal	communication).			This	 study	 has	 therefore	 demonstrated	 the	 existence	 of	 early	 sensorimotor	phenotypes	in	Ppt1-/-	mice	that	had	previously	not	been	known	to	exist	and	are	possibly	caused	by	the	significant	spinal	cord	pathology	at	this	time	point.	It	also	served	 to	 confirm	 the	 significant	 and	 progressive	 decline	 of	 sensorimotor	function	after	5	months	in	these	mice	as	a	combined	result	of	cortical,	cerebellar	and	spinal	cord	pathology.		
6.3	The	spinal	cord	as	a	novel	therapeutic	target	in	CLN1	disease.	As	 previously	 discussed,	 there	 has	 only	 been	 limited	 success	 with	 various	systemic	 and	 brain-directed	 therapeutic	 strategies	 for	 CLN1	 disease	 (Chapter	1.6).		Our	research	has	demonstrated	early	and	profound	pathology	in	the	spinal	cord	 of	 Ppt1-/-	 mice	 (Chapter	 3)	 that	 had	 previously	 not	 been	 described.	We	therefore	 hypothesized	 that	 this	 pathology	 was	 not	 ameliorated	 by	 previous	brain-directed	therapies	approaches,	and	that	targeting	the	spinal	cord	in	Ppt1-/-	mice	would	have	a	beneficial	impact	on	disease	progression.			A	well-established	approach	for	delivering	therapeutic	agents	to	the	spinal	cord	is	 by	 means	 of	 intrathecal	 (IT)	 injections	 into	 the	 cerebrospinal	 fluid	 (CSF)	
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commonly	at	the	level	of	the	lumbar	vertebrae.	This	approach	is	quite	common	in	clinical	practice,	especially	for	the	management	of	cancer-related	and	chronic	pain	(Bruel	&	Burton,	2016;	Pope	et	al,	2016).	IT	delivery	of	therapeutics	has	also	been	demonstrated	to	be	effective	in	delivering	protein	therapeutics	to	the	CNS	in	a	variety	of	disorders	including	stroke,	brain	tumors	and	neurodegenerative	disorders	including	the	LSDs	(Calias	et	al,	2014).	However,	a	disadvantage	of	this	approach	is	that	accurately	measuring	actual	doses	delivered	to	the	CSF	can	be	difficult	(Follett	et	al,	2003).	Also,	IT	drug	delivery	has	been	associated	with	the	development	of	certain	complications	such	as	an	inflammatory	response	along	with	the	development	of	antibodies	against	the	therapeutic	agent	(Follett	et	al,	2003),	 high	 infection	 rates	 (Aprili	 et	 al,	 2009;	 Motta	 &	 Antonello,	 2014)	 and	granuloma	 formation	 (Duarte	 et	 al,	 2012).	 The	 risk	 of	 developing	 these	complications	is	directly	related	to	the	duration	of	intrathecal	catheter	placement	(Fluckiger	et	 al,	2008).	Nevertheless,	 for	 severe	neurodegenerative	 conditions	such	as	the	NCLs,	the	benefits	of	IT	drug	delivery	may	well	outweigh	the	risks,	especially	via	gene	therapy,	which	is	theoretically	a	one-time	treatment.	
a)	IT	Enzyme	replacement	therapy	(ERT)	in	Ppt1-/-	mice	High-dose	IT	ERT	into	the	sub-arachnoid	space	in	the	lumbar	region	was	shown	to	be	effective	in	ameliorating	brain	pathology	in	mouse	model	of	CLN2	disease	(Xu	et	al,	2011).	This	promising	data	led	us	to	revisit	previous	attempts	at	ERT	with	recombinant	human	PPT1	in	CLN1	disease	(Hu	et	al,	2012;	Lu	et	al,	2010).	Delivering	recombinant	PPT1	intrathecally	resulted	in	significant	improvements	in	 the	 lifespan	 and	 motor	 function	 of	 Ppt1-/-	 mice	 (Lu	 et	 al,	 2015).	 Perhaps	surprisingly,	histological	examination	of	mice	sacrificed	6	months	after	receiving	the	 ERT	 revealed	 a	 significant	 reduction	 of	 gliosis,	 especially	 in	 the	 case	 of	microglial	 activation,	 as	well	 as	 a	 significant	 reduction	 of	 AFSM	accumulation	(Chapter	5.2,	Lu	et	al,	2015).	These	findings	were	very	promising	for	two	reasons	–	a)	given	 that	 these	mice	were	sacrificed	nearly	6	months	after	receiving	 the	ERT,	there	was	significantly	prolonged	activity	of	IT	delivered	PPT1	even	at	this	late	time	point,	and	b)	that	delivery	of	the	recombinant	enzyme	at	the	 lumbar	level	of	the	spine	resulted	in	a	good	spread	of	the	enzyme	in	the	CSF,	as	evidenced	by	the	reduction	of	gliosis	and	AFSM	in	the	cerebral	cortex	(Figures	5.2-5.7).		
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	However,	 in	 this	 study	 IT	administration	of	PPT1	did	not	have	any	significant	effect	on	pathology	in	the	deeper	brain	structures	(thalamic	nuclei)	in	these	mice	(Chapter	 5.2)	 which	 may	 be	 due	 to	 the	 lack	 of	 penetration	 of	 the	 brain	parenchyma	by	the	enzyme	from	the	CSF	(Lu	et	al,	2015).	Therefore,	it	is	likely	that	 the	 lifespan	and	 functional	 improvements	observed	 in	 these	mice	 cannot	solely	be	explained	by	the	moderate	improvements	observed	in	brain	pathology.	Indeed,	the	histological	improvements	observed	in	the	spinal	cords	of	these	mice	were	 generally	more	 pronounced	 than	 those	 seen	 in	 the	 brain	 (Chapter	 5.2).	From	 these	 data,	 we	 can	 see	 that	 not	 only	 is	 the	 IT	 administration	 of	 PPT1	effective	in	targeting	the	spinal	cord	in	these	mice,	but	that	ameliorating	spinal	cord	pathology	appears	to	have	a	significant	effect	on	functional	motor	deficits	and	lifespan	in	Ppt1-/-	mice.		The	long-lasting	and	widespread	effects	seen	by	early	IT	delivery	of	recombinant	PPT1	may	be	due	to	a	combination	of	factors	such	as	the	dynamics	of	CSF	flow	and	reabsorption	(Calias	et	al,	2014).	These	factors	allow	for	the	distribution	of	the	enzyme	to	at	least	some	brain	structures,	as	well	as	the	low	enzyme	activity	required	to	restore	normal	cellular	function	in	CLN1	disease	(Griffey	et	al,	2006).	Indeed,	a	 low	level	of	PPT1	activity	was	surprisingly	observed	in	the	brains	of	treated	mice	up	to	240	days	(6	months)	after	IT	administration	(Lu	et	al,	2015).	Such	a	long-lasting	effect	of	early	administration	of	the	therapy	may	be	the	result	of	a	more	protracted	course	of	neurodegeneration,	and	although	there	was	no	significant	neuroprotective	effect	of	IT	ERT	observed	at	6	months,	the	improved	survival	and	motor	performance	of	these	mice	suggest	that	they	may	also	display	delayed	 neurodegeneration.	 Furthermore,	 there	 was	 a	 clear	 dose-dependent	improvement	of	IT-administered	ERT	upon	lifespan	and	motor	performance	(Lu	et	al,	2015).		This	is	also	apparent	in	the	reduction	of	AFSM	and	gliosis	(Figures	5.2-5.7)	(Lu	et	al,	2015),	and	demonstrates	that	further	titration	of	the	dose	could	have	significantly	beneficial	effects.		Therefore,	this	study	clearly	provides	proof	of	principal	that	IT	delivery	of	drugs	can	successfully	target	spinal	cord	pathology	in	Ppt1-/-	mice	and	that	this	route	of	
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administration	 can	 also	 potentially	 help	 ameliorate	 disease	 pathology	 in	 the	brain	by	achieving	a	widespread	distribution	of	the	enzyme.	
b)	Combination	intracranial	(IC)	and	IT	gene	therapy	in	Ppt1-/-	mice.	To	date	the	most	promising	of	the	brain-directed	therapies	in	CLN1	disease	has	been	 the	 intracranial	 administration	 of	 gene	 therapy	 (Griffey	 et	 al,	 2006;	Hawkins-Salsbury	et	al,	2013).	The	efficacy	of	this	strategy	in	Ppt1-/-	mice	has	also	been	 shown	 to	 improve	 when	 combined	 with	 other	 systemic	 therapeutic	approaches	(Macauley	et	al,	2012;	Macauley	et	al,	2014;	Roberts	et	al,	2012).	We	therefore	hypothesized	that	IC	delivery	of	AAV-mediated	gene	therapy	alone	may	not	be	sufficient	to	impact	the	spinal	cord	pathology	in	these	mice	that	we	have	described	 here	 (Chapter	 3).	 Furthermore,	 targeting	 spinal	 cord	 pathology	 in	
Ppt1-/-	mice	by	means	of	IT	injection,	which	was	shown	to	be	a	feasible	route	for	administering	 ERT	 (Lu	 et	 al,	 2015),	with	 similar	 AAV	 vectors	 used	 for	 the	 IC	injections	 could	 have	 an	 additional	 beneficial	 effect	 to	 the	 IC	 therapy.	Furthermore,	we	also	used	a	new	AAV	vector	–	AAV2/9,	which	was	shown	 to	have	widespread	distribution	 throughout	 the	CNS	upon	 IT	delivery	as	well	 as	better	transduction	capability	than	the	AAV2/5	vector	that	was	previously	used	(Dayton	et	al,	2012;	Macauley	et	al,	2014;	Schuster	et	al,	2014;	Swain	et	al,	2014).		All	treatment	groups	showed	improved	measures	of	lifespan	and	motor	function,	with	Ppt1-/-	mice	that	received	a	combination	of	IC	and	IT	therapy	(IC/IT	mice)	performing	 significantly	 better	 than	 mice	 receiving	 either	 treatment	 alone	(Chapter	 5.3).	 The	 fact	 that	 mice	 receiving	 IT	 injections	 only	 preformed	significantly	better	than	untreated	Ppt1-/-	mice	demonstrates	that	targeting	the	spinal	cord	with	AAV-mediated	gene	therapy	had	a	significant	effect	on	disease	progression,	as	we	had	seen	previously	with	ERT	(Lu	et	al,	2015).	Interestingly,	the	 IC/IT	mice	 lived	 for	 an	 average	of	19.3	months,	 an	 increase	of	 around	11	months	 from	the	untreated	Ppt1-/-	mice.	This	 is	 the	 first	study	 to	show	such	a	significant	 improvement	 in	 these	 parameters	 in	 these	 mice,	 and	 further	substantiates	our	data	for	the	spinal	cord	being	crucial	to	disease	progression	in	
Ppt1-/-	mice.		
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Histological	examination	of	the	brains	and	spinal	cords	of	mice	from	the	different	treatment	groups	at	3,	5,	7	 and	9	months	 revealed	 that	 the	 spinal	 cords	of	 IC	treated	 Ppt1-/-	 mice	 showed	 that	 they	 still	 displayed	 significant	 pathology	including	 gliosis,	 AFSM	 accumulation	 and	 neuron	 loss	 similar	 to	 untreated	mutant	mice	(Chapter	5.3).	This	data	confirms	our	hypothesis	that	brain-directed	AAV-mediated	 gene	 therapy	 alone	 did	 not	 impact	 spinal	 cord	 pathology.	 As	expected,	 the	 IT	 only	 treated	 mice	 showed	 significant	 reduction	 in	 all	pathological	parameters	in	the	spinal	cord,	with	some	improvements	also	seen	in	 the	cerebral	cortex,	although	not	 to	 the	same	extent	as	 that	seen	 in	 IC	only	treated	mice.	This	demonstrates	that	IT	injection	of	AAV2/9	vector	resulted	in	its	distribution	to	structures	beyond	the	spinal	cord,	as	seen	before	with	ERT	(Lu	et	al,	2015).	Interestingly,	IC/IT	combination	treated	mice	showed	improvements	in	both	brain	and	spinal	cord	pathology,	but	in	general,	these	were	more	than	the	sum	of	its	parts,	with	spinal	cord	and	cortical	pathology	almost	being	reduced	to	levels	 comparable	 to	 wildtype	 mice.	 This	 was	 particularly	 evident	 in	 the	VPM/VPL	nuclei	of	 the	thalamus,	where	neither	IC	nor	IT	therapy	alone	had	a	greatly	 significant	 impact	 on	 pathology	 in	 these	mice,	 but	 IC/IT	mice	 showed	significant	improvements	in	almost	all	pathological	parameters.			Despite	the	therapies	administered,	all	treatment	groups	still	show	a	progression	of	pathology	in	the	brain	and	spinal	cord	across	the	time	points	measured,	with	IC/IT	mice	 again	 faring	much	 better	 than	mice	 receiving	 either	 IC	 or	 IT	 gene	therapy	 alone.	This	 data	 suggests	 that	 despite	 the	 exciting	data,	 the	mice	 still	demonstrated	progressive	pathology	elsewhere	in	the	body	that	still	needs	to	be	treated	to	improve	efficacy	still	further.	Despite	this,	our	data	from	this	study	is	the	 first	 to	demonstrate	such	significant	synergistic	 improvements	 in	 lifespan,	behavior	and	pathology	and	has	further	demonstrated	the	clinical	significance	of	targeting	the	spinal	cord	in	CLN1	disease.	It	will	therefore	be	very	important	for	future	 therapies	 to	 target	 spinal	 cord	 pathology	 to	 ensure	 better	 treatment	outcomes	for	patients.		
	Taken	together,	both	studies	of	IT	ERT	as	well	as	combination	IC/IT	gene	therapy	have	 served	 to	 demonstrate	 the	 clinical	 significance	 of	 targeting	 spinal	 cord	
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pathology	in	Ppt1-/-	mice,	showing	that	early	intervention	is	key	to	dealing	with	the	early	onset	of	this	pathology	in	this	region	of	the	CNS.	With	growing	evidence	of	systemic	pathology	in	Ppt1-/-	mice	(Galvin	et	al,	2008)	as	well	as	the	increasing	number	 of	 systemic	 therapies	 that	 are	 available	 (Chapter	 1.6),	 it	 is	 becoming	more	evident	that	the	treatment	of	CLN1	disease	will	be	better	facilitated	by	early	intervention	 and	 the	 use	 of	 combined	 therapeutic	 approaches	 that	 can	successfully	target	the	various	loci	of	pathology.	
6.4	Future	directions		From	the	data	presented	in	this	thesis,	it	is	evident	that	despite	having	shown	the	spinal	cord	to	be	severely	affected	in	murine	and	human	CLN1	disease,	as	well	as	it	 being	 an	 effective	 therapeutic	 target,	 there	 still	 is	 much	 work	 to	 be	 done	towards	the	complete	understanding	of	CLN1	disease	pathology	and	to	optimize	therapies	for	clinical	application.		
	
a)	Further	analysis	of	the	CLN1	spinal	cord	Our	data	 from	 the	analysis	of	Ppt1-/-	mouse	 spinal	 cords	has	 revealed	a	novel	phenotype	of	spinal	white	matter	pathology	(Chapter	3.9).	 It	will	 therefore	be	important	to	understand	the	exact	nature	of	this	pathology.	The	development	of	the	 Thy1-YFP/Ppt1-/-	 mouse	 has	 been	 shown	 to	 be	 of	 great	 use	 in	 studying	axonopathies,	(Castelvetri	et	al,	2011;	Feng	et	al,	2000)	(Chapter	3.9)	and	further	analysis	 of	 the	 progression	 of	 this	 pathology	 in	 these	 mice	 will	 be	 very	informative	regarding	white	matter	pathology.	Electron	microscopy	can	also	help	study	the	 thickness	of	 the	myelin	sheath	and	axon	density	and	morphology	at	various	levels	of	the	cord.	It	will	also	be	helpful	to	track	the	progression	of	axon	density	loss	in	the	different	white	matter	tracts	of	the	spinal	cord,	and	see	how	this	may	relate	to	the	onset	of	sensorimotor	deficits	(Chapter	4).	It	will	also	be	important	 to	detail	 the	progression	of	pathology	 in	 the	DRGs	at	various	 levels	(Chapter	3.7),	to	study	not	only	neuron	loss,	but	also	the	possible	involvement	of	satellite	glial	cells	and	the	infiltration	of	peripheral	lymphocytes	in	this	region.			Our	initial	histological	survey	of	synaptic	markers	did	not	reveal	any	significant	synaptic	changes	in	the	spinal	cord	(Chapter	3.6),	but	the	exact	nature	and	cause	
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of	any	potential	synaptic	pathology	as	well	as	its	temporal	progression	is	yet	to	be	 detailed.	 We	 shall	 do	 this	 by	 means	 of	 western	 blotting	 of	 synaptosomal	preparations	at	various	time	points,	as	was	performed	on	the	brain	tissue	of	Ppt1-
/-	mice	(Kielar	et	al,	2009).		Neuron-glial	interactions	have	been	shown	to	be	vital	to	maintaining	the	normal	functioning	of	the	CNS	(Belin	&	Hardin,	1991;	Burda	&	Sofroniew,	2014;	Fields	&	Stevens-Graham,	2002;	Sofroniew	&	Vinters,	2010).	The	presence	of	significant	glial	 activation	 that	 precedes	 neurodegeneration	 in	 Ppt1-/-	 mice	 in	 the	 brain	(Kielar	et	al,	2007;	Macauley	et	al,	2009)	and	spinal	cord	(Chapter	3.8)	has	been	well	established.	However,	the	exact	nature	of	this	neuron-glia	interaction	and	whether	it	may	be	detrimental	to	neuron	function	is	poorly	understood.	In-vitro	studies	 of	 neuron-glia	 interactions	 with	 cortical	 tissue	 from	 Ppt1-/-	 mice	 are	currently	 ongoing	 (Lange,	 PhD	 thesis),	 and	 it	will	 now	 be	 important	 to	 study	whether	similar	effects	exist	in	spinal	cord	tissue.		The	presence	of	early,	widespread	pathology	spinal	cord	pathology	with	novel	phenotypes	of	postnatal	developmental	delay	and	white	matter	pathology	raises	the	 possibility	 of	 region-specific	 mechanisms	 at	 work	 in	 the	 spinal	 cord	compared	to	the	brain.	We	therefore	propose	proteomic	profiling	of	brain	and	spinal	cord	tissue	at	early	(3	months)	and	late	(7	months)	time	points.	This	will	allow	us	 to	 compare	 and	 contrast	 the	 effects	 of	 Ppt1	deficiency	 at	 both	 these	regions	over	the	course	of	the	disease,	and	will	help	to	shed	light	on	any	region-specific	 functions	 of	 Ppt1	 and	 possibly	 help	 us	 understand	 the	 greater	vulnerability	of	the	spinal	cord	in	CLN1	disease.	
b)	Analysis	of	other	possible	pathological	loci	in	Ppt1-/-	mice.	Given	the	early	onset	and	unexpected	severity	of	disease	detailed	in	the	spinal	cords	 of	 Ppt1-/-	 mice,	 we	 must	 now	 additionally	 characterize	 pathological	changes	 in	 other	 regions	 that	 would	 have	 otherwise	 not	 have	 thought	 to	 be	involved	in	disease	progression.	The	early	onset	of	disease	in	the	spinal	cord	and	the	subsequent	pathology	seen	 in	 the	 thalamic	nuclei	of	 the	brain	(Chapter	3)	(Kielar	et	al,	2007)	has	made	us	consider	the	antero-	or	retrograde	transmission	
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of	disease	in	a	caudo-rostral	fashion	(Chapter	6.1).	Therefore,	the	analysis	of	the	brainstem	and	peripheral	nerves	in	Ppt1-/-	mice	will	be	informative	of	the	overall	progression	of	disease	in	these	mice.	The	Thy1-YFP	mice	(Castelvetri	et	al,	2011;	Feng	 et	 al,	 2000)	 will	 also	 prove	 a	 useful	 tool	 for	 studying	 the	 integrity	 of	peripheral	 nervous	 tissue	 in	 greater	 detail.	 The	 brainstem	 acts	 as	 the	 “relay-station”	for	the	dorsal	column	(Chapter	1.7)	as	well	as	housing	the	centers	for	CNS	 control	 of	 cardiovascular	 and	 respiratory	 function	 (Batten	 &	 Deuchars,	2009;	Smith	et	al,	2007),	which	are	affected	in	CLN1	disease	(Dolisca	et	al,	2013;	Williams	et	al,	2006).	As	such	analysis	of	the	brainstem	will	also	provide	great	insight	into	whether	these	defects	are	caused	by	PNS	or	CNS	pathology.			In	addition	 to	 studying	 the	central	 control	 centers	 for	 cardiac	and	respiratory	function,	describing	any	pathology	that	may	be	present	in	the	heart	and	lungs	of	these	mice	will	tell	us	whether	the	clinical	symptoms	are	due	to	a	combination	of	factors,	or	either	central	or	peripheral	pathology	alone.	Similarly,	studying	the	autonomic	nervous	system	may	also	help	to	explain	the	autonomic	disturbances	seen	in	human	CLN1	disease	(Williams	et	al,	2006;	Wisniewski	et	al,	2001).			Therefore,	 the	characterization	of	pathology	 in	various	 loci	 in	Ppt1-/-	mice	will	help	to	provide	a	more	comprehensive	understanding	of	disease	progression	in	CLN1	disease.		




d)	Therapeutic	implications	of	spinal	cord	pathology	in	CLN1	disease.	Targeting	the	spinal	cord	in	Ppt1-/-	mice	has	not	only	shown	it	to	be	an	effective	therapeutic	 target	 in	CLN1	disease	 (Chapter	5),	but	 that	when	combined	with	brain-directed	 therapies,	 there	 is	a	significantly	greater	synergistic	effect	 than	would	be	anticipated	(Chapter	5.3).	Therefore,	to	build	on	this	exciting	and	novel	data,	it	is	likely	that	therapies	must	now	be	optimized	in	order	to	target	multiple	foci	of	pathology.			There	is	also	increasing	evidence	for	pathology	outside	the	CNS	in	Ppt1-/-	mice	(Galvin	et	al,	2008)	and	that	targeting	this	pathology	in	combination	with	brain	directed	therapies	can	have	a	positive	impact	on	disease	progression	(Macauley	et	 al,	 2012;	 Macauley	 et	 al,	 2014;	 Roberts	 et	 al,	 2012).	 Therefore	 future	therapeutic	 approaches	 may	 have	 to	 additionally	 target	 systemic	 pathology.	While	these	separate	routes	of	drug	administration	may	be	impractical	as	well	as	increase	 the	 risk	 for	 infections,	 the	 severity	 and	 rate	 of	 progression	 of	 CLN1	disease	may	allow	for	such	clinical	intervention.			A	 different	 approach	 to	 reduce	 the	 number	 of	 injections	may	 be	 through	 the	delivery	 of	 either	 ERT	 or	 AAV-mediated	 gene	 therapy	 via	 the	 ventricles	 as	 a	
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repeated	dosing	using	a	cannula	(Katz	et	al,	2014),	for	ERT	or	a	one-time	injection	for	gene	therapy	by	transducing	the	ependyma	(Katz	et	al,	2015),	an	approach	that	has	been	shown	to	be	useful	in	a	canine	model	of	CLN2	disease.	Intravenous	delivery	of	gene	therapy	has	also	been	attempted	in	non-human	primates,	and	while	 this	 approach	 showed	 a	 higher	 level	 of	 glial	 transduction	 as	 a	 result	 of	having	to	cross	the	blood-brain	barrier,	it	led	to	accumulation	of	large	amounts	of	the	vector	in	the	liver	(Gray	et	al,	2011).	This	may	have	toxic	effects,	and	as	it	stands	this	approach	will	need	much	more	work	before	being	viable	for	therapy.			Despite	 the	 success	 in	 treating	 disease	 progression	 in	 Ppt1-/-	 mice,	 it	 will	 be	important	to	test	these	therapeutic	approaches	in	larger	species	(Chapter	6.4	c).	As	a	virtue	of	the	size	and	complexity	of	the	CNS	in	these	larger	animals,	there	will	very	likely	be	differences	in	drug	distribution	and	efficacy.	Recent	attempts	at	 gene	 therapy	 in	 a	 sheep	model	of	CLN5	disease	have	 shown	great	promise	(Palmer	and	Mitchell,	personal	communication)	and	these	models	will	therefore	serve	as	 a	 crucial	 intermediate	 step	before	 therapies	 for	CLN1	disease	 can	be	clinically	tested.		
6.5	Conclusion	The	research	presented	in	this	thesis	serves	to	highlight	the	early	and	profound	involvement	of	the	spinal	cord	in	CLN1	disease	progression	that	adversely	affects	sensorimotor	 function,	 as	 well	 as	 revealing	 the	 spinal	 cord	 as	 a	 novel	 and	effective	 therapeutic	 target	 in	 this	 disease.	 We	 have	 shown	 significant	 and	widespread	 pathology	 in	 the	 spinal	 cords	 of	 Ppt1-/-	 mice,	 describing	 similar	changes	to	that	seen	in	the	brains	of	these	mice,	but	with	an	earlier	onset	(Figure	6.1),	 as	 well	 as	 novel	 disease	 phenotypes	 including	 postnatal	 developmental	delay	and	significant	white	matter	pathology.	Similar	pathological	changes	were	also	observed	in	a	human	CLN1	disease	post-mortem	sample,	indicating	that	this	pathology	is	not	confined	to	the	murine	disease,	and	were	also	present	in	other	mouse	models	of	NCL,	 implying	 that	 spinal	 cord	pathology	may	be	a	 common	feature	in	various	forms	of	NCL	(Chapter	3).			
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Automated	gait	analysis	has	revealed	novel	phenotypes	of	gait	abnormalities	at	early	 time	points	 in	Ppt1-/-	mice	 and	 along	with	 the	 documented	pathological	changes	in	the	spinal	cords,	has	helped	to	better	understand	the	sensorimotor	deficits	seen	in	these	mice	as	well	as	to	reconcile	those	observed	in	human	CLN1	disease	(Chapter	4).			We	have	also	shown	 that	 therapeutically	 targeting	 the	spinal	 cord	with	either	enzyme	 replacement	 therapy	or	AAV-mediated	gene	 therapy	 significantly	 and	synergistically	 improves	 the	 lifespan,	motor	 function	 and	 pathology	 in	Ppt1-/-	mice.	 Furthermore,	 the	 combination	 of	 intracranial	 (IC)	 and	 intrathecal	 (IT)	administration	 of	 AAV-mediated	 gene	 therapy	 has	 shown	 the	 most	improvements	in	these	parameters	of	any	experimental	therapy	for	CLN1	disease	to	 date	 (Chapter	 5).	 These	 data	 serve	 not	 only	 to	 emphasize	 the	 clinical	significance	 of	 targeting	 spinal	 cord	 pathology,	 but	 also	 that	 combination	approaches	that	target	the	various	pathological	foci	in	the	CNS	may	be	the	most	effective	approach	for	future	CLN1	disease	therapies.		Despite	the	success	of	 this	CNS-directed	combination	therapeutic	strategy,	 the	evidence	for	significant	pathology	outside	the	CNS	in	CLN1	disease	(Galvin	et	al,	2008)	and	the	fact	that	combination	treated	mice	still	do	not	live	as	long	as	their	wildtype	 counterparts	 (Chapter	 5.3)	 means	 that	 further	 work	 is	 required	 to	elucidate	the	exact	nature,	as	well	as	the	temporal	and	anatomical	progression	of	disease	outside	the	CNS	in		Ppt1-/-	mice.	Moreover,	therapeutically	targeting	only	the	 CNS	 could	 lead	 to	 non-neuronal	 symptoms,	 which	 would	 have	 otherwise	been	 ‘masked’	by	 the	 severity	 and	 rapid	onset	of	neurological	 symptoms,	 and	may	still	significantly	contribute	to	disease	progression.			In	light	of	this	study	highlighting	the	spinal	cord	as	a	novel	site	of	pathology	as	well	as	the	growing	body	of	evidence	for	other	possible	regions	of	pathology	in	these	mice,	a	holistic	therapeutic	approach	should	be	encouraged	so	as	to	allow	for	the	greatest	therapeutic	effect.	Therefore,	there	is	still	much	work	to	be	done	in	murine,	as	well	as	 larger	animal	models	(as	 these	become	available)	before	moving	towards	human	clinical	studies	for	CLN1	disease.	Furthermore,	despite	
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the	 success	 of	 recent	 clinical	 trials	 for	 CLN2	 disease	 using	 ERT	(https://clinicaltrials.gov/show/NCT02678689),	 the	 finding	 of	 spinal	 cord	pathology	in	other	forms	of	NCL	(Chapter	3.11)	could	have	similar	implications	for	therapeutic	strategies	in	these	and	possibly	other	forms	of	NCL	as	well.					This	 study	 therefore	 represents	 a	 significant	 departure	 from	 the	 forebrain-centric	 view	of	 the	NCLs,	 showing	 that	 CLN1	disease	 affects	 the	CNS	 at	 large.	Along	with	 the	evidence	of	 other	 systems	also	being	affected,	 this	means	 that	future	therapeutic	approaches	must	now	be	designed	to	target	all	these	sites	of	pathology	so	as	to	be	able	to	provide	effective	means	of	treating	these	diseases	in	humans.		
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